',6&/2685(
5('$&7('35272&2/$0(1'0(17
$&(0'6
$3+$6('28%/(%/,1'5$1'20,=('678'<72&203$5(7+(
()),&$&<$1'6$)(7<2)/863$7(5&(37$&(9(56863/$&(%2)2 5
7+(75($70(172)$1(0,$'8(72,36659(5</2:/2:25
,17(50(',$7(5,6.0<(/2'<63/$67,&6<1'520(6,168%-(&76:,7+
5,1*6,'(52%/$676:+25(48,5(5('%/22'&(//75$16)86,216
7KHÂ³0('$/,67Â´7ULDO

7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1(35235,(7$5<,1)250$7,21255
:,7+:,7+
86,21686,216
XOGQRWEHVXOGQRWEH
VHDUFKHUVDQHDUFKHUVD
QGUHJXODWLRGUHJXODWL
HOHJDORUFROHJDO
DWHGWRFHUWDDWHGWRFHU
FHFHUWDLQLQIRUWDLQL
RWHFW&HOJHQRWHFW&HOJH
ZLQJSULQFLSLQJSULQFL
\JUH\VSDF\JUH\VSDF
GHQWLILFDWLRQHQWLILFDWLR
RQWDLQFRQILGRQWDLQFRQ
FRQWDLQLGHFRQWDLQLGH
KH\DOVRPD\KH\DOVRPD\
RWKHVLVJHQHKHVLVJHQH
KHVHDWWDFKPKHVHDWWDFKP
ERG\RIWKHRG\RIWKH
DODO
DERXW&HOJHDERXW&HO
HRIWKDWLQIRHRIWKDWLQI
DWLRQDERXWLRQDERXW
PDWLRQDERXPDWLRQDER
IRXQGDWKWIRXQGDWKW
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 1 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017TITLE PAGE
A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY
TO COMPARE THE EFFICACY AND SAFETY OF 
LUSPATERCEPT (ACE-536) VERSUS PLACEBO FOR
THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY 
LOW, LOW, OR INTERMEDIATE RISK
MYELODYSPLASTIC SYNDROMES IN SUBJECTS 
WITH RING SIDEROBLASTS WHO REQUIRE RED 
BLOOD CELL TRANSFUSIONS
The â€œMEDALISTâ€ Trial
PROTOCOL NUMBER: ACE-536-MDS-001 
ORIGINAL PROTOCOL FINAL: 25 Sep 2015
AMENDMENT 1.0 DATE: 21 Sep 2016
AMENDMENT 2.0 DATE: 09 May 2017
EudraCT NUMBER: 2015-003454-41
IND NUMBER: 112,562
SPONSOR NAME/ ADDRESS: Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for 
review by you, your staff, and ethics committee/institutional review board.  The information 
contained in this document is regarded as confidential and, except to the extent necessary to 
obtain informed consent, may not be disclosed to another party unless such disclosure is 
required by law or regulations.  Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further disclosed by them.
CCIrovided to yovided to 
your staff, your staff, 
 this documthis docu
nformed conformed c
uired by lauired by la
nformed thnformed t35235,(7$5<,1)250$7,21TS TS
RED RED 
MDSMDS -001-001
p 2015p 2015
1Sep 2016Sep 2016
09 May09 May
201201
353
&((/
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 2 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:  
Address:   Route de Perreux 1 - 2017 Boudry â€“ Switzerland
Phone:
E-mail:   
Note: The back-up 24-hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for emergency calls. 
Back-up 24-hour Global Emergency Contact Call Center: 
CCIPPD
PPD
PPD
PPD
PPD
&(/*(1(35235,(7$5<,1)250$7,21$$$00$0
nly be usedly be use
nitor or denitor or d
1)
<,<, 1
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.  
CCIPPD
&(/*(1(35235,(7$5<,1)250$7,210$0$5
d its contend its conten
<<
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from
Celgene representatives, the Declarat ion of Helsinki, International Council for
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations governing the conduct of clinical studies.
CCI&(/*(1(35235,(7$7$7$5<,1)250$7,210$0$5000
s studys study at matyy
, informed nformed
ocedures, iedures, i
rnational rnational C
nes, and locs, and lo
7$
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 5 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017PROTOCOL SUMMARY
Study Title
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of 
Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, 
Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions
Indication
Treatment of anemia due to very low, low, or  intermediate risk myelodysplastic syndromes 
(MDS) according to the revised International Prognostic Scoring System (IPSS-R) in subjects 
with ring sideroblasts who requi re red blood cell (RBC) transfusions
Objectives
The primary objective is:
!To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with 
placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring sideroblasts who require RBC transfusions
The secondary objectives are:
!To assess the safety and tolerability of luspatercept compared with placebo
!To evaluate the effect of luspatercept on re duction in RBC transfusions, increase in 
hemoglobin, duration of RBC-TI, improvement in h ealth-r elated quality of life (HRQoL)
(ie, European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire [EORTC QLQ-C30]), increase in neutrophils, increase in platelets, 
decrease in serum ferritin, decrease in iron chelation therapy use, and time to RBC-TI 
compared with placebo
!To evaluate population pharmacokinetics and exposure-response relationships for 
luspatercept in MDS subjects
Study Design
This is a Phase 3, double-blind, randomized, pl acebo-controlled, multicenter study to determine 
the efficacy and safety of luspatercept (ACE-536) versus placebo for the treatment of anemia due 
to IPSS-R very low, low, or intermediate risk  MDS in subjects with ring sideroblasts who require 
RBC transfusions. 
The study is divided into the Screening Period, a double-blind Treatment Period (Primary Phase 
and Extension Phase) and a Posttreatment Follow-up Period.  
The study design is described in detail in Section 3.
The study will be conducted in compliance wi th International Council for Harmonisation (ICH) 
Good Clinical Practices (GCPs).
Study TreatmentsEligible subjects will be rando mized at a 2:1 ratio to either:
CCI&(/*(1(35235,(7$5<,1)250$7,21ubjects ubjects 
rcept compept co
ow, or inteow, or inte
ransfusioansfusio nn
t comt com paredparedmmm
tion in RBtion in RB
ment in ment in heahea
h and Treatmand Trea
increase inincrease in
e in iron che in iron ch
armacokinemacokine
bjectsbjects
ee--blind, ranblind, r
ty y ofof llffuspauspa
w, lw, low, or ow, or 
nsns. 
is divided is divided 
ensioensio n Phan Pha
e studystudy desidesy
The studyThe study
Good CGood C
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 6 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!Experimental Arm - Luspatercept (ACE-536): Starting dose of 1.0 mg/kg subcutaneous 
injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle) 
OR 
!Control Arm: Placebo (volume equivalent to experimental arm) subcutaneous injection 
every 3 weeks (administered on Day 1 of each 21-day treatment cycle). 
After randomization, no crossover between the tr eatment arms will be permitted at any point 
during the study.
Best supportive care may be used in combinatio n with study treatment in both arms when 
clinically indicated per investig ator discretion. See Section 8for more details.  
Stratification will be based on the following factors:
1. RBC Transfusion burden at baseline 
!â‰¥ 6 RBC units/8 weeks (mean of the two consecutive 8-week periods immediately 
prior to randomization)
!< 6 RBC units/8 weeks (mean of the two consecutive 8-week periods immediately 
prior to randomization)
2. IPSS-R at baseline 
!Very low, low
!Intermediate
Primary Phase of the Treatm ent Period: Weeks 1-24
Subjects should receive investig ational product (IP) through at least the first 24 calendar weeks 
unless the subject experiences unacceptable toxicities, withdraws consent, or meets any other
discontinuation criteria (Section 11).
Refer to Section 6.2.1 for additional details related to st udy procedures and assessments during 
the Primary Phase of the Treatment Period.
MDS Disease Assessment: Week 25 Visit 
The Week 25 Visit should be completed 24 calendar weeks after the date of first dose, regardless 
of dose delays.  Because central laboratory results from bone marrow and peripheral blood 
samples are required as part of the MDS Disease Assessment, a 14-day window is allowed for 
the Week 25 Visit.  Please refer to Section 6.2.2 for details.  
In order for subjects to remain on double-blind treatment beyond the first 24 calendar weeks, the 
following criteria must be confirmed upon the completion of the MDS Disease Assessment by 
the investigator at the Week 25 Visit:
!Evidence of clinical benefit (eg, decrease in  RBC transfusion re quirement compared 
to baseline requirement or hemoglobin increase compared to baseline)
AND
!Absence of disease progression per IWG criteria for altering natural history of MDS 
(Cheson, 2006 ; Appendix E ).
CCI&(/*(1(35235,(7$5<,1)250$7,21eririods immeods imm
week perieek peri odd
-2424,(ductuct((IPIP))ththhh
ble toxicitble toxicit iei
aladetails rdetailsl
ment Periodment Period
Week 25 VWeek 25 3 ould be comuld be com
auseusecentracentr
ired as partired as part
Visitisit.  Pl.  Pleasea
or subjects subjects 
ing criteria ing criteria 
nvestnvest igatoigato
!!
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 7 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Based on the outcome of the Week 25 Visit MDS Disease Assessment, subjects will either be 
discontinued from treatment with IP and enter the Posttreatment Follow-up Period or continue 
double-blind treatment with IP  in the Extension Phase of the Treatment Period. 
Refer to Section 6.2.2 for additional details related to procedures/assessments.
Extension Phase of the Treatment Period:  After Week 25 Visit
Subjects who meet the criteria for r emaining on double-b lind treatment with IP in the Extension 
Phase may continue dosing on Day 1 of each 21-day treatment cycle until the subject 
experiences unacceptable toxicities, disease progression per IWG criteria for altering natural 
history of MDS ( Cheson, 2006 ; Appendix E ) or withdrawsconsent, or meets any other
discontinuation criteria (Section 11).  
MDS Disease Assessment will be repeated by the investigator at Extension Cycle 8, Day 1 and 
Day 1 of every eighth Extension cycle thereaf ter (ie, Extension Cycle 8, 16, 24+, or every 24 
weeks in the event of dose delays) until the subject is discontinued from IP.
Refer to Section 6.2.3 for additional details related to procedures/assessments.
Posttreatment Follow-up Period:
All subjects discontinued from protocol-prescribed therapy for any reason will be followed for
adverse event (AE)/serious adverse event (SAE) reporting for a period of 42 days after the last 
dose of IP, as well as for SAEs made known to the Investigator at any time thereafter that are 
suspected of being related to IP, as described in Section 10.
For subjects who do not complete the Primary Treatment Phase or do not participate in the 
Extension Phase or subjects who terminate the Extension Phase with less than 1-year of ADA 
monitoring, ADA and PK samples will be collected at End of Treatment (EOT) and then every 12 weeks for up to 1 year from the first dose in the Primary Treatment Phase (please refer to 
Section 6.4and Section 6.5).
Transfusion data collection will continue up until 16 weeks from the date of last dose of IP or the 
EOT Visit (whichever is later).  
Continuation of monitoring for progression to AML and other malignancies/pre-malignancies
(please refer to Section 10.5 for details) will occur in the Posttreatment Follow-up Period along 
with collection of information related to subsequent MDS therapies, and overall survival for at 
least 3 years from the date of last dose of IP un less the subject withdraws consent from the study, 
dies, or is lost to follow-up.  
Refer to Section 6.8for additional details.
Study Population
The study will enroll approximately 210 subjects with IPSS-R ( Greenberg, 2012; Appendix D ) 
very low, low, or intermediate MDS with ring siderobl asts who require RBC transfusions.
Length of Study
The expected duration of the study is a pproximately 5 years which consists of a pproximately 2
years of enrollment, approximately 1 additional year of blinded luspatercept or placebo treatment 
CCI88, Day, Day  1 an1 ayy
+,+,or everyor ever
ments.ents.
anynyreason wreason w
a period oa period 
gator at anygator at an
1010..
tmtment Phasent Pha
ExtensioExtensio n Pn P
lected at lected at EE
se in the Prse in the Pr
inuenuup unup un
or or progressprogre
0.50fofor detar d
rmmatatioion reln rel
he date of ldate of l
fofollollow-w-upup
tiontion6.86.8fofo
PopulationPopulation
studystudy willwilly
veryeryllyyow, low, l oo
LengthLength
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 8 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017after the last subject is randomized, and at least an additional3 years to complete the 
posttreatment follow-up period.
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is required for primary, secondary  analysis, as prespecified in the protocol
and/or SAP, whichever is the later date.  
The Sponsor may end the trial when all key endpoints and objectives of the study have been 
analyzed and the availab ility of a roll-over protocol exists into which any subjects remaining on 
study may be consented and continue to receive access to luspatercept and/or complete long-term 
follow-up. Such a protocol would be written for a compound that would not  yet be commercially 
available.  
Overview of Key Efficacy Assessments
Efficacy assessments include:
!Transfusions (eg, RBC);
!Hematology (eg, hemoglobin, platelet count, neutrophils);
!Bone marrow aspirate (or biopsy) for a ssessment of MDS diseas e (eg, cytomorphology, 
cytogenetics)
Refer to Section 6for full list.  
Overview of Key Safety Assessments
Safety assessments will include:
!Adverse event reporting;
!Concomitant medication/procedures;
!MDS disease assessment (eg, cytomorphology, cytogenetics) via bone marrow aspirate 
(or biopsy)
!Hematology (eg, hemoglobin, hematocrit, complete blood count [ CBC] with differential); 
!Serum Chemistry; 
!Urinalysis;
!Electrocardiogram (ECG);
!Vital signs and body weight;
!Physical examinations; 
!Eastern Cooperative Oncology Group (ECOG) performance status;
Refer to Section 6for full list. 
Statistical Methods
A total sample size of 210 (140 in experimental arm [lusp atercept (ACE-536)], 70 in control arm 
[placebo]) will have 90% power to detect the difference between a response rate of 0.30 in the 
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21on n
gg-termterm
merciallyrcially
DS disease (S disease (
dures;ures;
g, cytomorpcytomo
mmogloglobin, hobin
ry; y; 
cardiogramcardiogra
all signs and signs anll
Physical ePhysical e
!!EasteEaste
Refer to Refer to 
ti
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 9 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017experimental arm (luspatercept [ACE-536]) and a res ponse rate of 0.10 in the control arm 
(placebo).  The sample size calculation is based on one-sided alpha of 0.025, test s tatistics on 
difference of proportions using pool ed estimate of variance and 10% dropout rate. 
The primary efficacy analysis will be the comparison of the response rates in the two treatment 
arms in the intent-to-treat (ITT) population. The primary efficacy endpoint of transfusion 
independent response is defined as the absence of any RBC transfusion during any consecutive 
56 day period during the Primary Phase of the Treatment Period.
The Cochranâ€“Mantelâ€“Haenszel (CMH) test will be used to compare the response rates from 
treatment group and control group with randomization factors as strata. Ka planâ€“Meier methods 
will be used to characterize the duration of response and survival.
The primary efficacy endpoint will be tested fi rst at the one-sided 0.025 significance level. If 
superiority of luspatercept is demonstrated for the primary efficacy endpoint, then the key 
secondary endpoint will be tested at a one-sided 0.025 significance level. The key secondary endpoint, proportion of subjects achieving RBC-TI with duration â‰¥ 12 weeks, will be tested in 
the same manner as primary efficacy endpoint using the CMH test.
The analyses for the key secondary endpoint will be based on the ITT population. In order to 
perform hypothesis testing on multiple endpoints while controlling the overall Type I error rate, 
a sequential testing approach will be employed where the order of the endpoints to be tested are 
prespecified.
An interim analysis to assess futility w ill be performed when approximately 105 subjects have 
completed the Primary Phase of the Treatment Period (first 24 weeks of double-blind treatment) 
or discontinued before reaching 24 weeks of double-blind treatment (50% information for primary endpoint). 
Conditional power for the primary endpoint will be calculated assuming the observed trend 
continues for the rest of the data. If it is 10% or less, with confirmative data for secondary and 
other efficacy endpoints, the Data Monitoring Committee (DMC) may recommend stopping the 
study for futility.
There is no plan to claim luspatercept superiority based on interim analysis efficacy results, thus
the type one error rate remains at 0.025 one-sided for the final analysis.
The final analysis will be performed when all 210 subjects have completed 48 weeks of 
treatment or discontinued before 48 weeks. 
Additional follow-up analysis for efficacy and safety will be performed when all subjects have 
been followed for at least 3 years from the last dose of IP.
Refer to Section 9for additional details.
CCI&(/*(1(35235,(7$5<,1)250$7,21thods ods 
e level. If e level. If 
n the keyn the key
key secondkey secon
ks, will be ks, will be 
TT populatpopulat ii
ng the overthe ove
er of the ener of the 
when apprwhen appr
d d (fir(first 24 24
bleble-blind trblind t
ntnt will be c will be c
s 10% or l10% or l
Monitoring Conitoring
patercept patercept su
ains at 0.0ns at 0.0
l be performl be perfo
tinued befoued bef
owow-up analup an
ed ed fofor rat at lele
Sectionction 99
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 10 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017TABLE OF CONTENTS
TITLE PAGE ..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................5
1. INTRODUCTION ..................................................................................................17
1.1. Disease Background ...............................................................................................17
1.1.1. Staging and P rognostic Fact ors...............................................................................17
1.1.1.1. Revised International Prognostic Scoring System (IPSS-R) for MDS ......................17
1.1.1.2. Ring Side roblasts ....................................................................................................18
1.1.2. Current Treatment Options for Lower Risk MDS ....................................................19
1.1.2.1. Revlimid .................................................................................................................19
1.1.2.2. Eryth ropoiesis Stimulating Agents (E SAs) Therapy ................................................19
1.1.2.3. Red Blood Cell Transfusions ..................................................................................19
1.1.2.4. Hypomethylati ng Agents ........................................................................................20
1.2. Compound B ackground ..........................................................................................21
1.2.1. Summary of Nonclinical Stud ies with Lu spatercep t ................................................22
1.2.2. Summary of Clin ical Exper ience ............................................................................ 23
1.2.2.1. Potential Risks of Hu man Use ................................................................................23
1.2.2.2. Overall Benefit Risk Assessment ............................................................................24
1.3. Ration ale ................................................................................................................25
1.3.1. Study  Rationale a nd Purpos e ..................................................................................25
1.3.2. Rationale for the Study De sign ...............................................................................26
1.3.3. Rationale for Dose, Schedule and Regimen Selectio n .............................................27
1.3.4. Rationale for Choice of Placebo Compa rator ..........................................................28
2. STUDY OBJECTIVES AND ENDPOINTS ...........................................................30
3. OVERALL STUDY DESIGN ................................................................................34
3.1. Study De sign..........................................................................................................34
3.2. Study Duration for Subj ects....................................................................................39
3.3. End of Trial ............................................................................................................39
4. STUDY POPULATION .........................................................................................40
CCICCI
CCI
CCI
&(/*(STUDYSTUD
OVOV
.1..1.
.2..2.(1(35235,(7$5<,1)250$7,2177
.......1717
..................... 181
.........................
..........................
.........................
..........................
...........................
......................
rceptrcept ......
..........................
...........................
entent............
......................
PurposePurpose ....
StudyStudy  Desi Desyy
Dose, ScheDose, S
for Choifor Choi ce7$5
(1(*(1
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 11 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20174.1. Number of Subjects ................................................................................................40
4.2. Inclusion Criteri a ....................................................................................................40
4.3. Exclusion Criteri a...................................................................................................42
5. TABLE OF EVENTS.............................................................................................45
6. PROCEDURES......................................................................................................53
6.1. Screening Period.....................................................................................................53
6.2. Treatment Pe riod....................................................................................................59
6.2.1. Primary Phase of the Treatment Period: Weeks 1-24 ...............................................60
6.2.2. MDS Disease Assessment: Week 25 Visit ..............................................................61
6.2.3. Extension Phase of the Treatment Period:  After Week 25 Visit ..............................63
6.3. Dose Delays ...........................................................................................................63
6.4. Pharmacoki netics....................................................................................................64
6.5. Anti-Drug Antibody (ADA) ....................................................................................64
6.6. Unscheduled Visits.................................................................................................65
6.7. End of Treatment Visit ...........................................................................................65
6.8. Posttreatment Fo llow-up Pe riod..............................................................................66
6.8.1. Safety Fo llow-up ....................................................................................................66
6.8.2. Long-Term Fo llow-u p ............................................................................................66
6.9. Efficacy Assessments .............................................................................................67
6.10. Safety Assessments .................................................................................................67
6.12. Subject Reported Outcomes or Quality of Life Measurements ................................68
6.14. Screen F ailures ....................................................................................................... 69
7. DESCRIPTION OF ST UDY TREATM ENTS........................................................70
7.1. Description of Investigational Products ...................................................................70
7.2. Treatment Administration and Schedule .................................................................70
7.2.1. Dose Modifications: Dose Titration, Dose Reduction, and Dose Delay ...................71
7.2.1.1. Dose Titrati on Increase...........................................................................................71
7.2.1.2. Dose Delay and Dose Reduc tion.............................................................................72
7.2.1.3. Overdose ................................................................................................................73
7.3. Method of Treatment Assignment ...........................................................................74
7.4. Packaging and Labeling ..........................................................................................74
CCICCI
CCI
&(/*(1(3ilureslures ......
CRIPTIONCRIPTION
Descriptescript ioonn
TreatmeTreatme
DosDo
.2.1.1..2.1.1.
7.2.1.2..2.1.2352Outcomes Outcomes235,(7$5<,1)250$7,2133
.......595
..............606
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
.......................
.................
523
(3 5
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 12 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20177.4.1. Bli nding................................................................................................................. .74
7.5. Investigational Product Accountability and Disposal ..............................................75
7.6. Investigational Product Compliance ........................................................................75
8. CONCOMITANT MEDICATI ONS AND PROC EDURES ....................................76
8.1. Permitted Concomitant Med ications and P rocedure s...............................................76
8.1.1. Iron Chelation Therapy ...........................................................................................76
8.1.2. RBC Transfusions ..................................................................................................76
8.2. Prohibited Concomitant Medications and Procedures ..............................................77
8.3. Required Concomitant Medications and Procedures ................................................77
9. STATISTICAL CONSIDERATIONS ....................................................................78
9.1. Overvi ew................................................................................................................78
9.2. Study Population Definitions ..................................................................................78
9.3. Sample Size and Po wer Consider ations ...................................................................78
9.4. Randomization and Stratification ............................................................................78
9.5. Background and Demographic Characteristics ........................................................79
9.6. Subject Disposition .................................................................................................79
9.7. Efficacy Analysis ....................................................................................................79
9.7.1. Primary Efficacy  Analysi s ......................................................................................79
9.7.2. Secondary Eff icacy Analyse s..................................................................................80
9.7.2.1. Key Secondary E fficacy Analy ses..........................................................................80
9.7.2.2. Additional Secondary  Efficacy An alyses ................................................................80
9.8. Safety An alysis.......................................................................................................81
9.9. Other An alysis........................................................................................................82
9.10. Timing of Analyses ................................................................................................82
9.10.1. Interim An alysis ..................................................................................................... 82
9.10.2. Final An alysis.........................................................................................................8 3
9.11. Other T opics ...........................................................................................................83
9.11.2. Data Monit oring Co mmittee ...................................................................................83
9.11.3. Steering Committee ................................................................................................84
9.11.5. Subgroup Analysis ..................................................................................................84
10. ADVERSE EV ENTS ..............................................................................................85
CCICCI
CCI&(/*(1(35235,(7$5<,1)250$7,2166
.......767
..............777
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
.......................
AnalysesAnalyse .
EfficacyEfficacy A
.....................
is...............
f Analysesf Analyse
m Analysism Analysis
inal Analysinal Analy
Other TOther T
.11.2..11.2.
9.11.3..11.3.(/*
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 13 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201710.1. Monitoring, Recording and Re porting of Advers e Even ts .......................................85
10.2. Evaluation of A dverse Events.................................................................................85
10.2.1. Se riousness............................................................................................................. 85
10.2.2. Severity/I ntensi ty....................................................................................................87
10.2.3. Caus ality ................................................................................................................87
10.2.4. Dur ation ................................................................................................................ .88
10.2.5. Action Taken .......................................................................................................... 88
10.2.6. Outco me................................................................................................................. 88
10.3. Abnormal Laborat ory Valu es..................................................................................88
10.4. Pregna ncy...............................................................................................................88
10.4.1. Females of Childbear ing Poten tial:......................................................................... 89
10.4.2. Male Subjects .........................................................................................................89
10.5. Other Malignancies/P re-malignancies.....................................................................89
10.6. Reporting of Serious Adverse Ev ents...................................................................... 90
10.6.1. Safety  Querie s ........................................................................................................ 90
10.7. Expedited Reporting of Adverse Events ..................................................................91
11. DISCONTINUATIONS .........................................................................................92
11.1. Treatment Disc ontinuation......................................................................................92
11.2. Study Discont inuation ............................................................................................92
12. EMERGENCY PROCEDURES .............................................................................94
12.1. Emergency Contact .................................................................................................94
12.2. Emergency Identification of Investigational Products .............................................94
13. REGULATORY CONSIDERATIONS ...................................................................95
13.1. Good Clinical Practice ............................................................................................95
13.2. Inve stigator Responsibilities ...................................................................................95
13.3. Subject Information and Informed Consent .............................................................96
13.4. Confidentiality ........................................................................................................96
13.5. Protocol A mendments.............................................................................................96
13.6. Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................ 96
13.7. Ongoing Information for Institutional Review Board/ Ethics Co mmittee ................97
13.8. Termination of the St udy........................................................................................97
14. DATA HANDLING AND RECORDKEEPING .....................................................99
CCI88
.......888
..............888
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
.......................
URESRES ....
.......................
ficatificati on ofon off
RY CONSIY CONS
nical Practcal Pra i
igator Resigator Res
ubject Infoubject Info
ConfideConfide
ProtPro
33.6..6.
7
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 14 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201714.1. Data/Docu ments .....................................................................................................99
14.2. Data Management ...................................................................................................99
14.3. Record Retention ....................................................................................................99
15. QUALITY CONTROL AND QUALITY ASSURANCE ......................................101
15.1. Study Monitoring and S ource Data Veri ficatio n....................................................101
15.2. Audits and Inspections..........................................................................................101
16. PUBLICATIONS .................................................................................................102
17. REFERENCES.....................................................................................................103
18. APPENDICES ......................................................................................................107
APPENDIX A: Table of Abbreviations ................................................................................107
APPENDIX B: Myelodysplastic Syndromes World HealthOrganization Classification
System (2016) ......................................................................................................111
APPENDIX C: French-American-British (FA B) Myelodysplastic Syndromes (MDS) 
Classificatio n Sys tem............................................................................................113
APPENDIX D: International Prognostic Scoring System Score - Revised ............................114
APPENDIX E: International Working Group Response Criteria for Myelodysplastic
Syndromes ............................................................................................................116
APPENDIX F: European Organization for Research and Treatment of Cancer Quality-
of-Life Questionnair e (Version  3.0) ...................................................................... 119
APPENDIX G: Eastern Cooperative Oncology Group (ECOG) Performance Status .............121
CCICCI
&(/*(1(35235,(7$5<,1)250$7,2111
..102.10
............10310
......................... 1
..........................
ClassificatClassificat i
.....................
Syndromesyndromes
.........................
ore -ore RevisRev
Criteria foCriteria fo
.......................
arch and Trarch and Tr
)..........................
ologylogy GrouGroyy
235
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 15 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017LIST OF TABLES
Table 1: Revised International Prognostic Scoring System for Myelodysplastic 
Syndromes (IPSS-R): Prognostic Score Values .......................................................18
Table 2: Study Objectives .....................................................................................................30
Table 3: Study Endpoints .....................................................................................................31
Table 4: Table of Events.......................................................................................................45
Table 5: Starting Dose Level with Dose  Reductions and Dose Titr ation ................................71
Table 6: Dose Modification: Dose Delay, Dose Reduction, and Discontinuation 
Guidelin es ..............................................................................................................72
Table 7: Abbreviations and Specialist Terms ......................................................................107
CCI&(/*(1(35235,(7$5<,1)250$7,2155
......71
.................... 77
.................
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 16 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017LIST OF FIGURES
Figure 1: Luspatercept Schematic Representation and Mechanism of Action .........................22
Figure 2: Overall Study Design ..............................................................................................38
CCI&(/*(1(35235,(7$5<,1)250$7,21
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 17 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20171. INTRODUCTION 
1.1. Disease Background 
Anemia is the predominant cytopenia observed in adult myelodysplastic syndrome (MDS) and is 
present in approximately 85% of MDS patien ts at the time of diagnosis ( Noel, 1992 ). Anemia in 
MDS can range in severity from mild (asy mptomatic) to severe, requiring re gular RBC 
transfusion support. Of the approximately 80%  to 90% of patients with MDS who develop 
anemia, 40% become transfusion dependent (TD) ( Zeidan, 2013 ).
Lower hemoglobin (Hgb) le vels and red blood cell ( RBC) transfusion-dependence have been 
associated with inferior cardiovascular outcomes and increased mortality in patients with MDS, 
representing a strong rationale for aggressive management of anemia in MDS ( Zeidan, 2013 ). In 
addition, long-term RBC transfusion dependence has other clinical and economic consequences, 
including a potentially negative imp act on health-related qu ality of life  (HRQoL), iron overload, 
and its associated complications, immune-related disorders, and increased risk of infections 
(Hellstrom-Lindberg, 2003; Jansen, 2003; Thomas, 2007 ). Therefore, a therapeutic option that 
would achieve transfusion independence in patients with International Prognostic Scoring System-Revised (IPSS-R) lower-risk MDS for a sustained period of time is an important unmet 
medical need.
Myelodysplastic syndromes are a heterogeneous group of clonal disorders of hematopoietic stem 
cells characterized by ineffective hematopoiesis that manifest clinically as anemia, neutropenia, 
and/or thrombocytopenia of variable severity; these often result in RBC- transfusion dependent 
(TD) anemia, increased risk of infection, and/ or hemorrhage, as well as a potential to progress to 
acute myeloid leukemia (AML) ( AdÃ¨s, 2014; Visconte, 2014; Zeidan, 2013; Brunning, 2008; 
Fenaux, 2009; Steensma, 2013; Catenacci, 2005 ).
For most patients with MDS, anemia and associated transfusion dependency are the most 
prominent clinical problems and the main d eterminants of quality-of-life (QoL) ( Balducci, 2010; 
Chan, 2014; Kao, 2008; Malcovati, 2005; Platzbecker, 2012; HellstrÃ¶m-Lindberg, 2013 ).
1.1.1. Staging and Prognostic Factors 1.1.1.1. Revised International Prognostic Scoring System (IPSS-R) for MDS
Patients with MDS can be categorized into 1 of 4 risk groups according to the IPSS (low,
intermediate [Int]-1, Int-2, and high) based on cytogenetics, number of peripheral blood cell 
lineages affected by cytopenia, and bone marrow (BM) blast percentages obtained at diagnosis. 
The 4 risk groups showed significantly different risk of progression to AML and overall survival (OS) ( Greenberg, 1997 ). The median survival rate is 5.7 years for patients with low risk MDS is
as short as 0.4 years for high-risk MDS.
While p roviding insight into the prognostic significance of baseline variables such as percent 
bone marrow blasts and cytogenetics, one of the limitations of the International Prognostic 
Scoring System (IPSS) ( Greenberg, 1997 ) is that it underestimates the impact of cytopenias on 
prognosis for patients with lower-risk disease. The IPSS also underestimates the impact that RBC transfusion dependency has on overall survival and does not adequately assess the impact 
of cytogenetic changes ( Germing, 2012 ).
CCIeen ee
h MDS, MDS, h
an, 2013n, 2013 ). I). I
consequenonsequen
oL), iron ovL), iron o
isk of infecsk of infe
herapeutierapeu c
l Prognostic Prognosti
f time is anf time is 
loonal disordnal disord
nifest clinicfest clin
ten resulten resulf t itill
mmorrhage, orrhage, 
sconte, 20sconte, 20
005005).).
associatedassociated
main determmain determ
200520 ; ;PlPlata
nostic Facnostic Fac
rnational rnationa
can be categan be cate
1, 1, IIntnt--2, a2, a
ed byed by  cycyyytoptoyyy
grouroups showps showuu
reenberg, 1nberg, 
rt as 0.4 rt as 0.4 y
While pWhile p rovirovid
bone marbone mar
corincorin
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 18 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017A recent revision of the IPSS (the IPSS-R) provides more discriminatory risk factor assessment 
than the original IPSS for evaluating clinical outcomes (survival duration and time to AML 
evolution) for MDS patients ( Greenberg, 2012 ). Bone marrow cytogenetics, bone marrow blast 
percentage, and cytopenias remain the basis of the IPSS-R, but with further refinement of these 
categories ( Table 1 ). Cytogenetic prognostic subgroups were split into 5 rather than 3 categories 
with the addition of new and specific classif ications of a number of less common cytogenetic 
subsets. Low bone marrow blast percentage was split into 2 categories (ie, â‰¤ 2% versus > 2% to 
< 5%), and the depth of cytopenias was defined using precise cutpoints. The application of 
additional refinements and prognostic variables in IPSS-R were intended to provide more 
meaningful classifications upon which to assess clinical outcome in MDS patients.
Table 1: Revised International Prognostic Scoring System for Myelodysplastic 
Syndromes (IPSS-R): Prognostic Score Values
Prognostic
Variable0 0.5 1 1.5 2 3 4
Cytogenetics Very good -- Good -- Intermediate Poor Very poor
BM blast % â‰¤ 2 -- > 2% to < 5% -- 5% to 10% > 10% --
Hemoglobin â‰¥10 -- 8 to <10 <8 -- -- --
Platelets â‰¥100 50 to <100 <50 -- -- -- --
ANC â‰¥0.8 <0.8 -- -- -- -- --
Source: Greenberg, 2012 .
1.1.1.2. Ring Sideroblasts
Early investigators defined ring sideroblasts as having iron granules in a perinuclear distribution 
surrounding the entire nucleus. The definition of a ring sideroblast proposed by the International 
Working Group on Morphology of Myelodysplas tic Syndromes (IWGMDS) (a n erythroblast 
with at least 5 siderotic granules covering at least a third of the circumference of the nucleus) has been incorporated into the 2008 World Health Organization (WHO) classification of Tumors of 
Hematopoietic and Lymphoid Ti ssues and for the definition of refractory anemia with ring 
sideroblasts (RARS), the required number of ring sideroblasts is â‰¥15% ( Mufti, 2008 ).  The 2016 
update to the WHO criteria further expanded on this definition of ring sideroblastic disease by 
also including cases with ring sideroblasts â‰¥ 5% if SF3B1 mutation is present ( Arber, 2016 ).
It is estimated that approximately 30% of all MDS patients have > 15% of bone marrow 
erythroid precursors being ring sideroblasts. Recently, spliceosome mutations were shown to be 
prevalent in MDS with ring sideroblasts, particul arly mutations involving splicing factor 3B 
subunit 1 (SF3B1). RNA splicing is the most commonly mutated pathway in MDS, and there is strong evidence that mutations in splicing factors occur early in disease evolution. These 
mutations play a major role in determining the clinical features of the disease, with differences in 
morphological features seen on bone marrow biopsy and in leukemia-free survival 
(Papaemmanuil, 2013 ).
Subjects with RS with splicing factor mutations have been shown to have ineffective 
erythropoiesis, possibly related to  defects in iron utilization ( Conte, 2015; del Rey, 2015; 
Dolatshad, 2015 ). Recently, a heterozygous conditional knock-in mouse model has been 
developed with the most frequent K700E mutation of SF3B1 ( Obeng, 2014 ). Ineffective 
CCI&(/*(1(35235,(7$5<,1)250$7,21stic ic 
4425252525 PoorPoor)21>>10%10%111),1-,1,1,1,1< ----5<$$$$5
s having iros having iro
oon of a ringn of a ring
odysplasticodysplas
ring at leasring at 
orlld Heald Heal ththll
issues andissues and
uired numbuired numb
ia further exfurther e
ith ring sideth ring sid
approximaapproxima
rsorsrsors being being
MDS witMDS wit h h
(SF3B1F3B1 ). R). R
evidence thvidence th
atiations playons play
momorpholrphol ogiogi
(PapaPa emmemm
bje
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 19 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017erythropoiesis developed in these mice, with a block in the maturation of late-stage erythroid 
precursors.
1.1.2. Current Treatment Options for Lower Risk MDS
In lower risk MDS, the risk of AML progression is less and survival is longer, with 
approximately one-half of these elderly patients dying from a cause other than the consequences 
of MDS or AML ( Greenberg, 2012 ). In those patients, the main priority is generally the 
treatment of cytopenias, primarily anemia (usually the predominant cytopenia), and the improvement in quality of life ( Fenaux, 2013 ). A clinically prominent challenge in patients with 
lower-risk MDS is the management of preexisti ng conditions aggravated by anemia, such as 
cardiovascular diseases.
The standard of care for cytopenias remains s upportive treatment with er ythropoiesis-stimulating 
agents (ESAs) such as epoetin alfa or darbepoetin, administration of RBC and/or platelet 
transfusions, infection prophylaxis and/or treatment and use of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and nutritional supplements when needed 
(Greenberg, 1997; Casadevall, 2004 ). 
1.1.2.1. Revlimid
Revlimid
Â®(lenalidomide) is approved in the United States (US) for the treatment of patients with 
transfusion-dependent anemia due to low- or Int-1-risk MDS associated with a del (5q) abnormality with or without additional cytogenetic abnormalities. This is the standard of care (in 
those countries where it is approved) for the small proportion of patients with lower risk del-5q 
MDS. In this population, lenalidomide led to transfusion independence for 67% of the patient population and a median duration of transfusion independence of 44 weeks. 
1.1.2.2. Erythropoiesis Stimulating Agents (ESAs) Therapy
Erythropoiesis s timulating agents (ie, recombinant eryt hropoietin [EPO] or darbepoetin [DAR]), 
although not currently approved in most countrie s, are commonly used for the treatment of 
anemia in lower-risk MDS without del(5q) cytogenetic abnormality. Major favorable prognostic 
factors for response to ESAs are low or no RBC transfusion requirement (< 2 U per month) and baseline serum EPO level < 500 U/L. ( Fenaux, 2013 ) Responses to ESAs are best in subjects 
with low endogenous levels (eg < 500 U/L) of eryth ropoi etin (EPO), normal blast counts and 
lower IPSS/WHO Prognostic Scoring System (WPSS) scores ( HellstrÃ¶m-Lindberg, 2003; 
Santini, 2011 ).
More recently, the European ESA Scoring System was developed, using a serum EPO level of 
â‰¤200 U/L as a prognostic factor for ESA responsiveness ( Santini, 2013 ). Approximately 70% of 
the relapses of anemia after initial response to ESAs are not associated with progression to 
higher-risk MDS but simply to loss of sensitiv ity of erythroid progenitors to ESAs. Second-line 
treatments in those patients may be different from those required in patients showing concomitant progression to higher-risk MDS ( Fenaux, 2013 ).
1.1.2.3. Red Blood Cell Transfusions 
In many patients with lower-risk MDS, anemia will eventually become resistant to all available 
drug treatments, even in the absence of evolution to higher-risk MDS, and will require repeated 
CCI&(/*(1(35235,(7$5<,1)250$7,21wiwiththii
as as 
sisis-ststimulaimula
or platelet r platele
c growth fac growth 
pplements wpplements w
US) for US) for ththete
DS associatDS associa
ormormalialititiiiies. es
roportion oroportion
sfusion indsfusion in
niinndependndepend
AgeAgents (ESnts (ES
, recombinarecomb
momost couo
outoutdel(5qdel(5q
s are low or are low 
<500 U/L500 
evels (eg <evels (eg <
Prognostic Sognostic 
ly, the Euroly, the Eur
L as a prognas a prog
apses of anapses of an
herher-ririsk MDsk MD
reatmreatm ents ients i
concomioncomi
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 20 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017RBC transfusions. Frequent RBC transfusions ar e associated with chronic anemia (ie, average 
hemoglobin levels < 10g/dL) which can lead to increased morbidity, especially as a result of 
cardiac failure, falls, fatigue and lower quality of life ( Fenaux, 2013 ). The development of 
transfusion dependency significantly worsens the survival of patients with MDS ( Malcovati, 
2005 ). Long-term RBC transfusion dependence has several detrimental clinical effects including 
iron overload, economic consequences, and a negative impact on patientsâ€™ QoL (HellstrÃ¶m-
Lindberg, 2003 ; Jansen, 2003 ; Thomas, 2007 ).
1.1.2.3.1. Iron Chelation Therapy (ICT)
Clinically significant iron overload associated with decreased cardiac function is often observed 
in patients who have received 100 or more RBC units ( AdÃ¨s, 2014 ). Therefore, iron chelation 
may be required in patients receiving frequent transfusions in order to avoid iron-related cardiac, 
hepatic and endocrine toxicities. Deferoxamine (intramuscular/subcutaneous/intravenous) or 
deferasirox (oral) have been used in MDS patients as a treatment for iron overload ( Messa, 
2010 ). However, deferasirox is fre quently associated with  gastrointestinal side effects and cannot 
be used in patients with renal function impairment ( Fenaux, 2013 ). 
Retrospective studies suggest that when serum ferritin levels exceed 1000 Î¼g/L, in the absence of 
inflammatory or other causes for ferritin elevation, transfusion burden often exceeds the bodyâ€™s 
capacity to maintain iron bound to transferrin ( Dreyfus, 2008 ). Patients with lower-risk World 
Health Organization (WHO) morphologic categories of refractory anemia (RA) or refractory anemia and with ringed sideroblasts (RARS) who had ferritin levels above 1,000 Î¼g/L 
experienced more cardi ac complications a nd had a reduced overall survival (hazard ratio [HR] = 
1.51; p < 0.001) ( List, 2010 ). 
Sanz, et al reported that transfusion dependence and iron overload are independent risk factors 
for overall survival and leukemic progression ( Sanz, 2008 ). In their review of 2241 patients 
whose complete transfusion history was available, 835 were transfusion dependent at the time of diagnosis, 526 became transfusion dependent during follow-up, and 880 remained transfusion 
independent ( Sanz, 2008 ). Median survival was significantly shorter in patients who were 
transfusion dependent at diagnosis (19 months) compared with 60 months for those who later became transfusion dependent and 96 months for those who remained transfusion free 
(p < 0.0001). Independent prognostic factors associated with OS in a multivariate analysis 
included iron overload (HR = 52.4; p < 0.0001) and transfusion dependency (HR = 8.8; p < 0.0001) ( Sanz, 2008 ).
Hence, therapeutic options that would achieve transfusion independence (TI) or reduce 
transfusion intensity in patients with lower-risk MDS for a significant amount of time would be highly desirable in terms of reduced requirements for iron chelation therapy.
1.1.2.4. Hypomethylating Agents
There are 2 hypomethylating agents currently approved for the treatment of various subtypes of 
MDS, azacitidine and decitabine.
VidazaÂ® (azacitidine for injection) is indicated for treatment of patients with the following 
French-American-British (FAB) classification subtypes of MDS ( Appendix C ) in the US:  RA or 
RARS (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), 
refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in 
CCI&(/*(1(35235,(7$5<,1)250$7,21served erved 
elatelatioion n 
ated cardiated cardi
avenousavenous ) o)o
load (oad ( MessMes
side effectside effects
d 1000 Î¼g/L 000 Î¼g/L
urden oftenden ofte
. Pati. Pati ents went
ractoryactory  aneanyy
erritin levelritin lev
duced overduced over
ce and iron ce and iron
on (n (Sanz, 2Sanz, 
available, available
pendent dupenden
survival wsurvival w
osis (19 mosis (19 mo
nt and 96 mnt and 96 m
t prognostict prognosti
(HR = 52.4(HR = 52.
200808).).
utic optionsutic options
ntntensiensitytyiii iiyn n
irable in teable in tei
(/*.4..4. Hy
There are 2There are 2
MDSMDS , , az
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 21 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML), but it is not 
routinely utilized in the lower risk disease setting.  
Azacitidine is approved in the European Union (EU) for the treatment of adult patients who are 
not eligible for hematopoietic stem cell transplan tation with IPSS Int-2 or High risk MDS, 
CMML with 10% to 29% marrow blasts without myeloproliferative disorder and AML with 20% 
to 30% blasts and multi-lineage dysplasia, according to WHO classification. In addition to the 
US and EU, azacitidine is currently approved in 30 other countries, including Canada, Switzerla nd, Australia and Japan, for the treatment of MDS (approvals for specific subtypes vary 
by country).
Dacogen
Â®(decitabine for injection), another hypomethylating agent, is approved in the US for 
treatment of patients with MDS, including previously treated and untreated, de novo and 
secondary MDS of all FAB subtypes (RA, RARS, RAEB, RAEB-T, and CMML) and Int-1, 
Int-2, and high-risk IPSS groups.
While azacitidine and decitabine are approved for treatment of various subtypes of MDS 
including Int-1 risk MDS in some countries, these agents are not uniformly administered as 
standard of care. This is partly because clinicians are reluctant to treat asymptomatic or minimally symptomatic lower-risk MDS patients, especially those who are not yet transfusion-
dependent. In addition, extensive data for these agents in the lower-risk MDS patient population 
are not currently available.
1.2. Compound Background 
Luspatercept (ACE-536) is a recombinant fusio n protein consisting of a modified form of the 
extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the 
human IgG1 Fc domain. The ActRIIB receptor and its ligands are members of the transforming growth factor (TGF)- Î² superfamily, a group of proteins involved in the development, 
differentiation, and/or maturation of various organ systems. No species differences have been 
described in the ligand-receptor interactions among members of the TGF- Î² family as the ligands 
and receptors are highly conserved across species ( MassaguÃ©, 1998 ).  Thus, observations from 
pharmacology studies of luspatercept or its murine analog RAP-536 in animal models provide 
significant insight into the potential of luspatercept to treat human disease. 
Members of the TGF- Î² family have been shown to play a role as negative regulators of red bl ood 
cell (RBC) development (e rythropoiesis). In nonclinical experiments, luspatercept has been 
shown to bind with high affinity to some TGF- Î² ligands (eg, growth differentiation factor 
[GDF]8, GDF11, bone morphogenetic protein [BMP]6 and activin B)  
. The emerging body of evidence on 
luspatercept suggests that its mechanism of action is completely independent from that of EPO, and involves stimulation of the later, maturation phase of erythroblast differentiation and 
maturation in the bone marrow ( Figure 1 ).
Across the Phase 2 program, responses to luspatercept treatment were observed in the majority 
of subjects at expected pharmacologic dos e levels of approximately 0.75 up to 1.75 mg/kg, 
administered once every 3 weeks. In particular, as described in more detail in the following 
sections, luspatercept treatment led to hematologic improvement in erythroid response (HI-E) in a substantial proportion of MDS subjects within the initial 3 months of treatment. 
CCICCI
&(/*cept suggescept sugge
nvonvolves stlves st im
aturauratition inon in
Across thAcross th*(1(35235,(7$5<,1)250$7,21ary ry 
US for S for 
and and 
and and IIntnt-1, 1,
ypes of Mypes of M
mly adminiy adm
at asymptomasympto
e who are nwho are n
werwer--ririsk M
protein consprotein con
in receptorn recepto
tor and its ltor and its 
up of proteup of prote
arious ious orgaorga
eractions amactions a
ed across sped across s
atercept or atercept or
potential ootential o
Î² fÎ² familyamifff haha
ment (eryent (ery ththyyy
tth high affh high aff
11, 1, bone mbone m
subsb*(
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 22 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017The preliminary Phase 2 data suggest luspatercept is likely to attenuate ineffective erythropoiesis 
and correct the anemia that characterizes MDS and could provide significant clinical benefit to 
patients by improving hemoglobin levels and reducing the need for regular RBC transfusions. 
The impact on these endpoints, as supported by the preliminary clinical evidence presented here, suggest that luspatercept may provide a sustained clinical benefit (eg, RBC transfusion 
independence) for the treatment of anemia in  patients with IPSS lower risk MDS with â‰¥15% ring 
sideroblasts.
Figure 1: Luspatercept Schematic Representation and Mechanism of Action
A B
Please refer to the Investigatorâ€™s Brochure for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the 
investigational product (IP).
1.2.1. Summary of Nonclinical Studies with Luspatercept
A brief summary of key findings from pharmacology and toxicology studies is provided below. 
Please refer to the Investigatorâ€™s Brochure (IB) for detailed information concerning the available pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the 
investigational product (IP). The most recent version of the luspatercept IB should be reviewed 
prior to initiating the study.
 
 
 
 
 
 
  
 
 
 
 
CCICCI
(/*(1(35235,(7$5<,1)250$7,21$7$7
5<$7
nformation formatio
studies, anstudies, an
th Luspateth Luspate
harmacoharmaco log
hure (IB) fohure (IB) f
taboablism, ism, 
e most recee most rece
(31((1(*(1*(/*(/*&(/&(&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 23 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2. Summary of Clinical Experience 
One Phase 1 trial with healthy postmenopausal women has been completed. Two Phase 2 studies 
with MDS patients are ongoing:
!Study A536-03: A Phase 2, Open-label, Ascending Dose Study of ACE-536 for the 
Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic 
Syndromes (MDS)
!Study A536-05: An Open-label Extension Study to Evaluate the Long-Term Effects of 
ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk 
Myelodysplastic Syndromes (MDS)
Preliminary results from ongoing Phase 2 studies of luspatercept in patients with MDS indicate 
that the dose levels up to 1.75 mg/kg have been generally safe and well-tolerated to date, with no dose-limiting toxicities observed as of 07 July 2015 in either study.  Efficacy parameters are still 
under evaluation.
Additional information regarding clinical experience with luspatercept is summarized in the
current version of the luspatercept IB.
1.2.2.1. Potential Risks of Human Use 
Increases in hematologic parameters (RBC, hemoglobin, hematocrit, reticulocytes) are expected 
pharmacologic effects of luspatercept treatment. Increases in systolic and diastolic blood 
pressures may occur in concert with increases in hemoglobin values. Excessive or rapid increases 
in hemoglobin or blood pressure may occur and w ill be monitored. Dose modification rules for 
CCICCI
&(/*(1(35235,(7$l women hl women h
enn-l-labelabe, AA
entnts wis withthiiiLh
OpenOpen -l-labelabel
reatmatment oent o
c Syndromc Syndrom
s frofrom m ongoongo
vels up to 1vels up to 1
g toxicig toxici titiiies es 
uatatioon.n.
oonal nalinformnform$5<,1)250$7,21
rrent versioent versio
1.2.2.1..2.2.1$0$50$50250)25)21),1)<, 15<
7$5
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 24 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017individual subjects, including dose delay and/or dose reduction, will be utilized to minimize risks 
associated with increased RBC parameters. 
Adverse events considered probably or possibly related to study drug that were reported in at 
least 5% of subjects in the Phase 1 study in h ealthy volun teers included injection site hemorrhage 
and injection site macule.  Adverse events reported in at least 10% of patients regardless of 
causality in the ongoing Phase 2 studies in MDS and Î²-thalassemia included bone pain, 
headache, asthenia, myalgia, arthralgia, py rexia, musculoskeletal  pain, oropharyngeal pain, 
diarrhea, nasopharyngitis, and cough. As with all biologics, there is the potential for antidrug 
antibodies (ADA) that can be associated with increased drug clearance and hypersensitivity 
reactions.  
 
Luspatercept has exhibited maternal and developmental toxicity in reproductive toxicity studies 
in preclinical species and therefore luspatercept should not be administered to pregnant or nursing women. Male and female subjects of childbearing potential participating in studies of 
luspatercept must be willing to use effect ive methods of contraception during the Treatment 
Period and up to 12 weeks from the last dose of IP. Females of childbearing potential (FCBP)must agree to pregnancy testing prior to enrollment and prior to each treatment cycle for the 
duration of the Treatment Period. 
 The occurrence of new malignancies, pre-malignant 
or precancerous lesions will be monitored as events  of interest and will be included as part of the
assessment of adverse events regardless of cau sality, throughout the course of the study. In 
addition, participating subjects should be follow ed long term as specified in the protocol for 
evidence of tumor formation.  
Safety effects will be 
monitored closely through adverse event (AE) reporting, clinical laboratory tests, vital signs, 
physical examinations, and ongoing review of unblinded data by an external Data Monitoring 
Committee (DMC).  
Please refer to the most current version of the Investigatorâ€™s Brochure and subsequent safety 
correspondence for additional information regarding findings from toxicology and clinical
studies.
The most recent version of the luspatercept IB should be reviewed prior to initiating the study.
1.2.2.2. Overall Benefit Risk Assessment
Current available information continues to support an acceptable benefit-risk profile for 
luspatercept when used in accordance with the precautions, dosing, and safety monitoring 
outlined in the study protocol and the routine pharmacovigilance practices.
CCICCI
CCI
CCI
&(/*(1(35235,(7$5<,1)250$7,21oxicitxicity study stu
pregnant orregnant 
ating in stuating in st
uring the ring the Tr
earing poteearing pot
ch treatmenh treatme
e of nee of ne w m
f interest aninterest an
y,y, througho through
d lod long termng ter
nt (AE) repot (AE) re
review of ureview o
nt version ont version 
nal al informainform
sion ofon of  the theff
erall Beneerall Ben
ailable infoilable info
rcept whencept when
ined in the ned in the$5<
5,(35,(
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 25 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20171.3. Rationale
1.3.1. Study Rationale and Purpose
IPSS-R classification of MDS (very low, low, or intermediate risk) 
The IPSS-R classification has been chosen to define the Phase 3 patient population because as 
discussed in Section 1.1.1.1 , the IPSS-R classificatio n provides a more discriminatory risk factor 
assessment than the original IPSS ( Greenberg, 1997 ) for evaluating clinical outcomes (survival 
duration and time to progression of AML) for MDS subjects ( Greenberg, 2012 ). The Phase 3 
patient population has been defined as having IPSS -R very low, low or, intermediate risk MDS. 
This patient population represents a subset of subjects with IPSS-R lower-risk MDS who have 
anemia and have limited treatment options in managing the anemia. Subjects in the lower risk groups often become dependent on frequent RBC transfusions, which leads to decreased health-
related quality of life (HRQoL) and increased morbidity and mortality ( HellstrÃ¶m-Lindberg, 
2003; Malcovati, 2005 ). Therefore, the clinically prominent challenge in subjects with lower risk 
MDS is the management and treatment of cy topenias, mainly anemia (the predominant 
cytopenia), and the improvement in QoL. The recent IPSS-R classified 39% of subjects with 
RARS as very low risk, 56% as low risk, and 5% as intermediate risk. The IPSS-R assigns 34% 
of subjects with refractory cytopenia with multilineage dysplasia with ringed sideroblasts 
(RCMD-RS) to the very low risk, 50% to the low, and 16% to the intermediate risk groups 
respectively ( Malcovati, 2013 ). 
Ring sideroblasts â‰¥ 15% of erythroid precursors in bone marrow (or â‰¥ 5%, if SF3B1 
mutation is present)
According to WHO criteria, refractory anemia with ring sideroblasts (RARS) is characterized by 
isolated anemia, erythroid dysplasia only, less than 5% blasts and â‰¥ 15% ring sideroblasts in the 
bone marrow. The 2016 update to the WHO criteria further expanded on this definition of ring 
sideroblastic di sease by also including cases with ring sideroblasts â‰¥ 5% if SF3B1 mutation is 
present ( Arber, 2016 ). Anemia is macrocytic in the large majority of these subjects, while 
reticulocyte count is in the normal range , reflecting an inappropriately low RBC production 
leading to anemia. The natural history of RARS is characterized by an initial phase of erythroid hyperplasia and ineffect ive erythropoiesis ( Malcovati, 2013 ).
Two recent phase 3 randomized controlled st udies evaluated the us e of erythropoiesis-
stimulating agents (ESAs) versus placebo. In these studies, subjects with lower-risk MDS without ring sideroblasts had a higher probability of response, compared to those with ring 
sideroblasts. In subjects wi th RARS, responses were less frequent and not significantly different 
between ESAs and placebo ( HellstrÃ¶m-Lindberg, 2013 ). The mode of action of ESAs on early 
erythroid progenitors would not be expected to bene fit subjects with defects in the later stages of 
erythropoiesis when erythropoietin r eceptors are absent ( Hattangadi, 2011; Broudy, 1991 ).
Study A536-03 is a Phase 2, open-label, ascending dose study of luspatercept for the treatment of 
anemia in patients with low or intermediate-1 risk MDS.  
In patients (n = 49) receiving 0.75 to 1.75 mg/kg, 51% of patients responded per International 
Working Group (IWG) hematologic improvement, erythroid response (HI-E) hemoglobin increase â‰¥1.5 g/dL for low transfusion burden patients or reduction of â‰¥ 4 RBC units or â‰¥50% 
CCI&(/*(1(35235,(7$5<,1)250$7,21MDS. DS. 
ho have ho have 
lower risk lower risk
creased hecreased he
rÃ¶m-mLindbLindb
ubjects wibjects wi ththiii
he predomipredo
ed 39% of sd 39% of
isk. The IPsk. The I
ia with ringa with
to the interto the inter
n bone man bone ma
wiwiththiiiriring ng 
ess than 5%ss than 5
WHO criteriWHO crit
g casg cas es wies ti
macrocytmacrocyt ic 
malmalrange, rrange, r
ral historyal histor oy
e eryryththyyropohh
andomized andomize
(ESAs) (ESAs) veve
deroblasts heroblasts h
In subjectsIn subjects
SAsAand pand p
id progenid progeni ii
hhropoiropoihhh esis esis 
StudyStudy A53A53yy
anemia nemia
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 26 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017of units of RBCs transfused/8 weeks for high transfusion burden patients).  Higher response rates 
were observed in ring sideroblast positive patients.  Patients with splicing factor mutations 
present (primarily SF3B1) had a 58% response rate.  Of the patients in the higher-dose group 
who received RBC transfusions pri or to luspatercept treatment (ra nge 2 to 18 units/8 weeks), 14
out of 40 (35%) patients were transfusion-free for â‰¥8 weeks during the 12-week treatment 
period. Add itional information is summarized in the current version of the luspatercept IB.
Refractory, intolerant, or ineligible (endogenous serum erythropoietin level >200 U/L) for 
ESAs.
Erythropoiesis-stimulating agents (ESAs) are often used in many newly diagnosed IPSS-R lower
to intermediate (very low, low, intermediate) risk MDS subjects with early onset anemia, as many subjects respond well to ESAs. To be eligible for the ACE-536-MDS-001 Phase 3 study, 
subjects must be refractory to, intolerant, or ineligible for ESAs.
Treatment guidelines vary in regards to defining an adequate course of ESA treatment.  The 
National Comprehensive Cancer Network (NCCN) guidelines ( NCCN 2015 guidelines )
recommends dose levels starting at 40,000 IU administered 1-3 times weekly for a duration 6-8 
weeks prior to assessment of hematological improvement. The European Society for Medical Oncology (ESMO) guidelines recommend dose levels starting at 30,000 IU weekly ( Fenaux, 
2014 ).  However, a significant proportion of these subjects will be resistant to ESAs as 
monotherapy or experience short-lasting responses. ( HellstrÃ¶m-Lindberg, 2013 ). Studies have 
shown that elevated endogenous serum erythropoietin levels and RBC transfusion requirements 
are negatively correlated with response to ESAs. ( HellstrÃ¶m-Lindberg, 2013 ).
Meta-analyses of clinical trials with thousands of treated subjects have led to the following 
conclusions: 
!RARS subjects with or without a need for transfusion but with a serum EPO level > 200 
U/L had a response rate of 0% to ESAs ( HellstrÃ¶m-Lindberg, 1995; Santini, 2011 ).
!MDS subjects without a need for transfusion, with a serum EPO level < 200 U/L, and a 
diagnosis other than RCMD-RS have a higher response rate to ESAs ( Santini, 2011 ). 
In study A536-03, high response rates were also seen in subjects in the higher-dose group with 
EPO levels < 200U/L (68%) and 200-500 U/L (36%).
1.3.2. Rationale for the Study Design
ACE-536-MDS-001 is a phase-3 multicenter randomized double-blind placebo controlled study.
The primary objective is to evaluate RBC tran sfusion independence (RBC-TI) in 2 treatment
arms (luspatercept versus placebo) for treatment of anemia due to very low, low, or intermediate
risk (IPSS-R) MDS in subjects with ring sideroblasts who require RBC transfusions. Secondary 
objectives include evaluation of efficacy (eg, h ematological improvement, HRQoL, changes in 
serum ferritin and iron chelation therapy use) as well as safety and tolerability.
The multicenter nature of the study provides assurance that the results are likely to have general 
applicability.  The design of this study (ie, randomized, double-blinded, placebo-controlled, and 
parallel-group) will eliminate bias in assignment of the IP or in data interpretation.
A 2:1 randomization w ill be used as this is an orphan disease with a limited number of subjects 
available. Subjects will be randomized to receive luspatercept or placebo at a 2:1 ratio. A 2:1 
CCI&(/*(1(35235,(7$5<,1)250$7,21lowerower
a, as as 
se 3 studyse 3 study
eatment.  Tatment.  
5 guideline5 guideline
eeklyklyffyor a offf
pean Societean Socie
30,000 IU0,000 IU w
be resistanbe re
Ã¶m-m-LindberLindbe
elelssand andRBRB
strstrÃ¶m-m-LindLind
treated subjreated subj
ed for traned for tran
ESAs ESAs ((HeH
d for transffor trans
MDMD--RSRShavhav
onse rates wonse rates w
%) and 200%) and 200
e for the Sfor the S
001 i001 i s a phs a ph
objectobject ive ive isi
atercept vetercept ve
SSSS-R)R)MDMD
cttiveivessincluincl
rumrum f fmmerrierrifftitiiii
The mThe m ulummm
plic
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 27 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017randomization scheme would enrich the number of participants e xposed to the active treatment 
group ( Dumville, 2006 ).
In order to mitigate the potential bias should subjects in the control arm drop out early due to the
lack of a quick response, the primary efficacy analysis will be the proportion of subjectsachieving RBC-TI with a duration â‰¥8 weeks measured at 24 weeks.
After completion of the MDS Disease Assessment by the investigator at the Week 25 Visit, 
subjects who exhibit clinical benefit with no evidence of disease progression per IWG criteria for altering natural history of MDS ( Cheson, 2006 ; Appendix E ) will continue double-blind
treatment. The proportion of subjects achieving RBC-TI with a duration â‰¥8 weeks at 48 weeks
will be assessed as a secondary endpoint to capture potential late responders. In addition, the proportion of subjects achieving RBC-TI with a duration â‰¥ 12 weeks will be assessed as a 
secondary endpoint, representing extended duration of benefit achieved with therapy.
The study will be stratified by RBC transfusion burden and IPSS-R risk category ( Greenberg, 
2012 ) at baseline. These factors are discussed below.
RBC transfusion burden at baseline
The primary endpoint for the study is the proportion of subjects who are RBC transfusion free 
over any consecutive 56-day period. In the phase 2 studies, achieving transfusion independence 
(TI) was shown to be dependent on baseline transfusion burden, Subjects who receive an average 
of â‰¥ 6 RBC units during each of two consecutive 8-week periods prior to randomization will be 
less likely to become transfusion independent than those subjects who receive < 6 RBC units/8 
weeks. Thus, stratification by RBC transfusion burden is considered useful due to its likely effect 
on the primary endpoint.
IPSS-R classification at baseline: Very low and low versus intermediate
Among the lower risk categories for IPSS-R, m ortality risk is distinctively worse for 
intermediate risk than for very low and low ri sk. The intermediate classification may also be 
indicative of higher risk of progression to AML ( Greenberg, 2012 ). Thus in consideration of the 
long-term safety analyses, stratification for IPSS-R will be used.
1.3.3. Rationale for Dose, Schedule and Regimen Selection
The starting dose level of 1.0 mg/kg and the maximum dose level of 1.75 mg/kg are based on 
clinical data from the ongoing Phase 2 A536-03 and A536-05 studies in MDS. Preliminary 
results indicate that the dose levels up to 1.75 mg/kg have been generally safe and well-tolerated to date. A higher response rate, including HI-E  and RBC-TI, was observe d in the higher dose 
groups (0.75-to 1.75 mg/kg subcutaneous every 3 w eeks [Q3W]) compared to the lower dose 
groups (0.125-0.5 mg/kg subcutaneous Q3W).
Selection of the dosing schedule (every 3 weeks, Q3W) was based on the duration of the 
luspatercept responses as well as pharmacokinetic parameters for luspatercept in MDS patients.  
The transfusion-reducing effect of luspatercept relies  on its ability to increase hemoglobin; in the 
Phase 2 studies, the increase in hemoglobin was well maintained with the Q3W dosing schedule.
Additional information regarding these clinical studies is summarized in the current version of 
the luspatercept IB.
CCI&(/*(1(35235,(7$5<,1)250$7,21r r 
eksks
n, the he 
as a as a 
apypy..
oryory(yGreenGreen
ho are RBCo are RB
ieving transeving trans
den, Subjecden, Subje
periods priperiods pri
se subjects se subjects 
en is consien is con
and and llow ow 
SS--R, mR, m ortaorta
d ld low riow r sk.
sion to AMon to AM
ficatficatioion nfofo
Dose, Scheose, Sche
l oof f1.0 m1.0 g/m
he ongoiongoi ngngiii
hat the doshat the do
her responser respon
755--toto1.75 m1.75 m
(0.125(0.125 --0.5 0.5 
ctctioion ofn ofthth
uspatercepuspatercep
TThe tranhe tra
ase
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 28 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20171.3.4. Rationale for Choice of Placebo Comparator
Treatment algorithms such as those issued by NCCN ( NCCN 2015 guidelines ) suggest that 
lower risk MDS patients with symptomatic anemia be treated with ESAs Â± G-CSF if the serum 
EPO level is â‰¤500 U/L. Those without a response or who have a higher EPO level and either 
have a poor probability to respond to immune suppressive therapy, or who are intolerant to or 
fail immune suppressive therapy, have three op tions proposed: hypomethylating agents (HMAs), 
lenalidomide, or entry on a clinical trial. 
Entry into a clinical trial of luspatercept rather than use of HMAs or lenalidomide may be 
preferred in order to avoid the risk of Grade 3-4 cytopenias, which occur with both azacitidine 
and decitabine. Since lower risk MDS patients wi th ring sideroblasts a nd low blast counts (< 5%) 
are unlikely to progress to AML, the predominant therapeutic objective is the management of 
anemia and the prevention of trans fusion related complications. Since this might mean 5 or more 
years of primarily chronic anemia management before disease progression, the benefit/risk of early intervention with HMAs is questionable. Subjects who fail to benefit from study drug in 
this clinical trial may subsequently receive HMAs or lenalidomide.
The primary endpoint for this study , RBC-TI, is b etter assessed against the natural history of the 
disease (ie, in subjects previously untreated with disease modifying agents). Based on these 
considerations, placebo is the appropriate comparator for the proposed Phase 3 study. Standard 
of care for the management of acute anemia (ie, RBC transfusions) will be applied to both treatment groups.
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
CCICCI
1(35235,(7$5<,1)250$7,21ine ne 
nts (<(<5%) 5%
ement of ement of 
mean 5 or mean 5 or 
benefit/riskbenefit/r
rorom mstudystudy dy
nst the natust the natu
g agents). g agents). B
roposeopose d Pha
usiousions) willns) wil
,(75,(35,2352352352(31((1(*(1*(/*(/*&(/&(&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 29 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017SF3B1 and other genes involved in RNA splicing such as SRSF2, U2AF1 and ZRSR2 have been 
observed in MDS patients ( Pellagatti, 2015 ).  SF3B1 mutations were found in greater than 70% 
of RS+ patients ( Papaemmanuil, 2011; Malcovati, 2011 ) and thought to be causally related to 
chromosome stability, DNA repair and gene regulation that may result in anemia and 
thrombocytopenia ( Visconte, 2014 ; and Pellagatti, 2015 ).  
 
  
 
 
 
CCICCI
CCI
&(/*(1(35235,(7$5<,1)250$7,21  
$0$70$50$
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 30 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20172. STUDY OBJECTIVES AND ENDPOINTS
Table 2: Study Objectives
Primary Objective
The primary objective of the study is to evaluate RBC transfusion independence (RBC-TI) of 
luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or 
intermediate risk MDS in subjects with ring sideroblasts who require red blood cell (RBC) 
transfusions.
Secondary Objectives
The secondary objectives are:
!To assess the safety and tolerability of luspatercept compared with placebo
!To evaluate the effect of luspatercept on reduction in RBC transfusions, increase in 
hemoglobin, duration of RBC-TI, improvement in h ealth-r elated quality of life (HRQoL)
(ie, European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire [EORTC QLQ-C30]), increase in neutrophils, increase in platelets, decrease in serum ferritin, decrease in iron chelation therapy use, and time to RBC-TI 
compared with placebo
!To evaluate population pharmacokinetics and exposure-response relationships for 
luspatercept in MDS subjects
 
 
 
CCICCI
&(/*(1(35235,(7$5<,1)250$bobo
oons, increans, increa
qualituality of ly
ncer Qualitncer Qualit
s, increase s, increase
rapyrapy use, an use, anyy
posureosure --respre0$7,21$7$7$7$70$
(7$,(
1(352355235
1(3
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 31 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 3: Study Endpoints
Endpoint Name Description Timeframe
Primary Red Blood Cell 
Transfusion 
Independence (RBC-TI)â‰¥ 8 weeks Proportion of subjects who 
are RBC transfusion free over 
any consecutive 56-day periodWeek 1 through Week 24
Secondary RBC-TI â‰¥ 12 weeks Proportion of subjects who 
are RBC transfusion free over 
any consecutive 84-day periodWeek 1 through Week 
24;
Week 1 through Week 48
RBC-TI â‰¥ 8 weeks Proportion of subjects who 
are RBC transfusion free over 
any consecutive 56-day periodWeek 1 through Week 48
Reduction in RBC units 
transfused over 16 
weeksMean change in total RBC 
units transfused over a fixed 
16-week periodWeek 9 through 24;
Week 33 through 48 
Modified hematologic 
improvement - erythroid 
(mHI-E) per IWG 
(Cheson, 2006 )Proportion of subjects 
achieving modified HI-E over 
any consecutive 56-day 
periodWeek 1 through Week 
24;
Week 1 through Week 48
Mean hemoglobin 
increaseâ‰¥ 1.0 g/dLProportion of subjects 
achieving hemoglobin (Hgb) 
increase from baseline â‰¥ 1.0 
g/dL over any consecutive 56-day period in absence of RBC 
transfusions Week 1 through Week 24;
Week 1 through Week 48
Duration of RBC-TI Maximum duration of RBC 
transfusion independence for 
subjects who achieve RBC TI 
â‰¥ 8 weeksWeek 1 through Week 24;
Week 1 through end of 
treatment
Health-related quality of 
life (HRQoL)Change in EORTC QLQ-C30 
scoreWeek 1 through Week 48; 
baseline through end of treatment
Hematologic improvement -
neutrophils (HI-N) per 
IWG ( Cheson, 2006 )Proportion of subjects 
achieving HI-N over any 
consecutive 56-day periodWeek 1 through Week 24;
Week 1 through Week 48
Hematologic improvement - platelets 
(HI-P) per IWG 
(Cheson, 2006 )Proportion of subjects 
achieving HI-P over any 
consecutive 56-day periodWeek 1 through Week 24;
Week 1 through Week 48
Mean decrease in serum ferritinChange in serum ferritin. Week 9 through 24;
Week 33 through 48 
CCI&(/*(1(35235,(7$5<,1)250$7,21eek 48ek 48$7
gh Week 4gh Week 40$
Week 9 throWeek 9 th
Week Week 3333)2
< --E over E ov
day dayWe<<<,<
of subjects of subject
gghemoglobhemoglo
se se from basfrom bas
L over any over any 
day period iday period
transfusiotransf7$
2MaxMa
tr222352
rerelated qualated qu
(HRQoL)(HRQoL)(3
HematolHematol
improimpro
neuneu(1
/*
&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 32 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 3: Study Endpoints (Continued)
Endpoint Name Description Timeframe
Mean decrease in iron 
chelation therapy (ICT) 
useChange in mean daily dose 
of ICTWeek 9 through 24;
Week 33 through 48
Time to RBC-TI Time from first dose to first 
onset of transfusion independence â‰¥ 8 weeksWeek 1 through Week 24;
Week 1 through Week 48
Progression to AML Number and percentage of 
subjects progressing to 
AML; time to AML 
progression Randomization through at 
least 3 years post last dose; 
Week 1 through Week 48
Overall survival Time from date of 
randomization to death due 
to any causeRandomization through at 
least 3 years post last dose; 
Week 1 through Week 48
Safety Type, frequency, severity of 
AEs and relationship of AEs 
to luspatercept/placeboScreening through 42 days 
post last dose; 
Week 1 through Week 48
A population PK model.
Exposure-response 
relationship. A Population PK model that 
describes the PK exposure 
data of luspatercept and associated variability.
Exposure-response 
relationship for the primary 
efficacy endpoint, AEs of 
interest, and selected secondary endpoints.Randomization through 1-
year post first dose.
Anti-drug antibodies (ADA) Frequency of anti-drug 
antibodies and effects on 
efficacy, or safety, or PKRandomization through 1-
year post first dose.
CCI&(/*(1(35235,(7$5<,1)250$7,21$7ugh at ugh at 
t last dose; last dose; 
gh Week 48gh Week 4$7$7$7
mization thrmization thr
t 33years poyears po
Week 1 throueek 1 th25
f 
AEs Es
oScreeninScreenin
post lost l
W1
<model that odel that
PK exposureK exposur
atercept andatercept and
d variabilityd variability
sureure--reresponpo
lationship foationship fo
efficacy enefficacy en
interest, interest
seconsec5<<<
23<
dies dies FF222
32
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 33 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 3: Study Endpoints (Continued)
Endpoint Name Description Timeframe
 
 
  
 
 
 
 
  
 
 
  
 
 
 
 
  
  
 
 
  
  
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21$7
50
<<<<,<
(75,250
5<<<
$5<7$5(7$,(7
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 34 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20173. OVERALL STUDY DESIGN
3.1. Study Design
The study will be conducted in compliance w ith the International Council on Harmonisation 
(ICH) of Technical Requirements for Registrati on of Pharmaceut icals for Human Use/Good 
Clinical Practice (GCP) and applicable regulatory requirements.
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine 
the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to 
IPSS-R very low, low, or intermediate MDS with ring sideroblasts who require RBC 
transfusions. 
The study is divided into the Screening Pe riod, a double-blind Treatment Period (Primary Phase 
and Extension Phase), and a Posttreatment Follow-up Period. See Figure 2 for more details and 
refer to Section 6for full list of study procedures/assessments. 
Screening Period 
Upon giving written informed consent, subjects enter the Screening Period to determine 
eligibility. Subject screening procedures are to ta ke place within 5 weeks prior to randomization. 
During the Screening Period, the subject will undergo safety and other assessments to determine 
eligibility for the randomized study.
Central review of bone marrow aspirate smear and biopsy, peripheral bl ood smear, cytogenetics,
will be used to confirm MDS dia gnosis and WHO classification ( Appendix B ) and/or FAB
classification ( Appendix C ) and to determine the baseline IPSS-R riskclassification ( Greenberg, 
2012; Appendix D ).
Transfusion history must be available for at least the 16 weeks immediately preceding and 
including the date of rando mization. Transfusion d ata should include the type of transfusion (eg, 
RBC, pl atelets), number of units, and d ate of transfusion.  Red bloo d cell (RBC) cell transfusion 
data should include the hemoglobin (Hgb) value for which the transfusion was administered (ie, 
pretransfusion Hgb value).
Refer to Section 6for full list of study procedures/assessments.  
Randomization
Randomization will occur bya central rando mization procedure using integr ated re sponse 
technology (IRT). Eligible subjects will be  randomized at a 2 :1 ratio to either:
oExperimental Arm: Luspatercept (ACE-536): Starting dose of 1.0 mg/kg subcutaneous 
injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
OR 
oControl Arm: Placebo (Volume equivalent to experimental arm) subcutaneous injection 
every 3 weeks (administered on Day 1 of each 21-day tr eatment cycle)
After randomization, no crossover between the tr eatment arms will be permitted at any point 
during the study.
CCI&(/*(1(35235,(7$5<,1)250$7,21e to e to 
rimaryrimary PhaPhayy
ore detailsore details
Period to deeriod to d
weeks weeks priprioo
d other assd othe
sy, peripher, periph
ssificatssificat ioion
aseline IPSaseline IPS
t least the 1least the 
nsfusionsfusio n dn
date of tradate of
n (Hgb) van (Hgb) va
ist of studyst of stud
ll occur byl occur by
T). T). Eligible Eligible
erimental Aerimental A*(njectctioin evn ev
ooConCon&(e
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 35 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Stratification will be based on the following factors:
!RBC Transfusion burden at baseline
âˆ€â‰¥ 6 RBC units/8 weeks (mean of the two consecutive 8 weeks periods 
immediately prior to randomization)
âˆ€< 6 RBC units/8 weeks (mean of the two consecutive 8 weeks periods 
immediately prior to randomization)
!IPSS-R at baseline
âˆ€Very low, low
âˆ€Intermediate
Refer to Section 6for additional details.
Primary Phase of the Treatment Period: Weeks 1-24 
The first dose of investigational product (IP) should be administered after, but within 3 days of 
randomizatio n and can be on the same day as randomization. Refer to the IRT manual for 
additional information on randomization utilizing IRT.  
Subjects will receive IP (either luspatercept or matching placebo) on Day 1 of each 21-day 
treatment cycle.
In both treatment arms, best supportive care (BSC) may be used in combination with study 
treatment when clinically indicated per investigat or. Best supportive care includes, but is not 
limited to, treatment with transfusions, antibiotic, antiviral and/or antifungal therapy, and 
nutritional support as needed.  Best supportive care forthis study excludes the use of ESAs.  Refer to Section 8for additional details.
Subjects should receive IP through at least the first 24 calendar weeks after the date of first dose
unless the subject experiences unacceptable toxicities, withdrawsconsent, or meets any other treatment discontinuation criteria (Section 11.1).
Week 25 Visit:  MDS Disease Assessment 
The Week 25 Visit should be completed 24 calendar weeks after the date of first dose, regardless 
of dose delays.  As central laboratory results from bone marrow and peripheral blood samples are 
required as part of the MDS Disease Assessment, a 14 day window is allowed for the Week 25 
Visit.  Please refer to Section 6.2.2 for more details related to assessments/procedures. 
In order for subjects to remain on double-blind treatment beyond the first 24 calendar weeks, the 
following criteria must be confirmed upon the completion of the MDS Disease Assessment by 
the investigator at the Week 25 Visit:
!Evidence of clinical benefit (eg, decrease in RBC transfusion requirement compared to 
baseline requirement or hemoglobin increase compared to baseline)
AND
!Absence of disease progression per IWG criteria for altering natural history of MDS 
(Cheson, 2006 ; Appendix E ).
CCI&(/*(1(35235,(7$5<,1)250$7,21er, but  but witwh
the IRT mthe IRT m
bo) on Daybo) on D
yybbye used ine used i
Best suppoBest sup
antantiviral aiviral 
care forcare for thith
east the ast the firsfir
eptable toxeptable t
((SectiSect onn1
e Assessme Assessm
d be compld be com
ntral labtral lab ora
he MDS Dhe MDS D
er to er to SectioSecti
subjects to subjects to
g criteria muriteria m
eststigator aigator a
!!EEvidvid
baba
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 36 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Based on the outcome of the Week 25 Visit MDS Disease Assessment, subjects will either be 
discontinued from treatment with IP and enter the Posttreatment Follow-up Period or continue 
double-blind treatment with IP in the Extension Phase of the Treatment Period. 
Extension Phase of the Treatment Period:  After Week 25 Visit
Subjects who meet criteria to remain on double-blind treatment after completion of the Week 25 
Visit MDS Disease Assessment may continue dosing on Day 1 of each 21-day treatment cy cle in 
the Extension Phase of the Treatment Period until the subject experiences unacceptable toxicities, disease progression per IWG criteria for altering natural history of MDS ( Cheson,
2006 ; Appendix E) , withdrawsconsent, or meets any othe r discontinuation criteria (Section 11). 
MDS Disease Assessment will be repeated by the investigator at Extension Cycle 8, Day 1 and 
Day 1 of every eighth Extension Cycle thereafter (ie, Extension Cycle 8, 16, 24+, etc. or every 
24 weeks in the event of dose delays) until th e subject is disconti nued from treatment.  
For subjects to continue double-blind treatment in the Extension Phase of the Treatment Period, 
each MDS Disease Assessment (criteria detailed in Section 6.2.2 ) should confirm continued 
clinical benefit and absence of disease progression per IWG criteria for altering natural history of 
MDS ( Cheson, 2006 ; Appendix E ).
Serial measurements of safety and efficacy will continue on scheduled study visits (Day 1 of 
every treatment cycle) in the Exten sion Phase of the Treatment Peri od.  Refer to Section 6for 
full list of study procedures/assessments.
Best supportive care (BSC) may continue to be used in combination with study treatment when 
clinically indicated per investigator. See Section 8for more information on best supportive
care/concomitant medications.
The same dose titration, delay and/or reduction, and treatment discontinuation criteria will st ill 
apply in the Extension Phase of the Treatment Period.  See Section 7.2.1 for dose modification 
rules and Section 11.2 for discontinuation criteria.
All subjects who have received at least one dose of study treatment should undergo end of
treatment (EOT) evaluations when IP is discontinued.  The reason for discontinuation will be 
recorded in the electronic case report form (eCRF) pages and in the source document.
Posttreatment Follow-up Period
All AEs will be recorded by the Investigator from the time the subject signs informed consent 
until 42 days after the last dose of IP as well as those serious adverse events (SAEs) made known to the Investigator at any time thereafter that are suspected of being related to IP. 
Transfusion data collection will continue up until 16 weeks from the date of last dose of IP or the 
End of Treatment Visit (whichever is later).  
Females of childbearing potential (FCBPs) will be  advised to avoid becoming pregnant during 
study and for 12 weeks after the last dose of IP.  Males will be advised to use a latex condom 
during any sexual contact with FCBP prior to starting investigational product and continue for 12 weeks following the last dose of IP, even if he has undergone a successful vasectomy.  Refer 
to Section 10.
CCI&(/*(1(3uu( 35235,(7$5<,1)250$7,21111). ). 
ayay 1 and 1 and yy
tc.tc.or everyor every
mment.  ent.  
e Treatmene Treatme
confirm coconfirm co
alaltering ntering ll
heduled studeduled stu
nt Perint Pe od. od
n con combinatmbina
fofor mrore inore in
tion, and treion, and tr
tment Periotment Perio
ttioion crin criterii
t least one dleast one
when IP hen IP is dis d
ase report fse report
p Periodp Period
orded byorded by ththyy
er the lr the l ast dast
gator at anygator at an
on data colldata col
Treatment Treatment 
emales of chmales of ch
studytudy and and y
uring uring 
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 37 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017For subjects who do not complete the Primary Treatment Phase or do not participate in the 
Extension Phase or subjects who terminate the Extension Phase with less than 1-year of ADA 
monitoring, ADA and PK samples will be collected at EOT and then every 12 weeks for up to 
one year from the first dose in the Primary Treatment Phase (please refer to Section 6.4and 
Section 6.5).
Long-Term Follow-up: Progression to AML, Other Malignancies/Pre-malignancies, 
Subsequent MDS Therapies, Overall Survival
For all subjects who receive at least one dose of IP, continuation of monitoring for progression to 
AML and other malignancies/pre-malignancies (please refer to Section 10.5 for details) will 
occur in the Posttreatment Follow-up Period along with data collection of subsequent MDS therapies, and overall survival for at least 3 years from the date of last dose of IP unless the 
subject withdraws consent from the study, dies or is lost to follow-up.  Refer to Section 6.1for 
additional details.
Data Monitoring Committee (DMC)
An external, independent DMC will be comprised of experts in MDS not involved in the 
ACE-536-MDS-001 study, an independent Geriatrician/Hypertension Expert, and an independent Statistician, and may include additi onal ad hoc members. Representatives of the 
Sponsor may attend the blinded part of the DMC meetings. The Sponsor will not have access to 
unblinded data during DMC meetings. 
Operational details for the DMC will be detailed in the DMC charter.  Refer to Section 9.11.2 for 
additional details.
Steering Committee
A Steering Committee (SC) will be established by charter for this study.  The Steering 
Committee will be comprised of Study Investigators and Sponsor representatives, and may 
include additional ad hoc members.  The S teering Committee will review blinded data. The SC 
will serve in an advisory capacity to the Sponsor.  
Operational details for the SC will be detailed in a separate SC charter. Refer to Section 9.11.3
for additional details.  
Note: The SC is separate from the DMC.
CCI&(/*(1(35235,(7$5<,1)250$7,21n to to
l 
MDS MDS 
ess the ess the 
ctictionon6.16.1f
not involvedot involv
on Expert,Expert,
mbers. Reprers. Rep
he Sponsorhe Spons
DMC charDMC cha
hed by chahed by cha
nvestnvest igatorigator
he he SteerinStee
o the Sponthe Spon
will be detawill be det
te froe fro m ththe
EDMS Doc. NumberLuspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 38 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Figure 2: Overall Study Design
SCREENING PERIODPosttreatment 
FOLLOW-UP 
PERIOD           STUDY DISCON
aHistorical documentation of RBC transfusion dependence should be available (RBC units transfused and pre-transfusion Hgb values ) for at least 16 weeks prior to 
randomization.  Refer to Section 6for additional details.
bDose may be titrated up to a maximum of 1.75 mg/kg.  Refer to Section 7.2.1.1 for additional details.
cAfter completion of the Week 25 Visit MDS Disease Assessment by the investigator, subjects experiencing clinical benefit and ha ve not experienced disease progression per 
IWG criteria for altering natural history of MDS ( Cheson, 2006 ; Appendix E ), may continue double-blind treatment with IP beyond the Week 25 Visit in the Extension Phase of 
the Treatment Period until meeting protocol discontinuation criteria.  Refer to Section 6and Section 11for additional details.
dMDS Disease Assessment will be repeated by the investigator at Extension Cycle 8, Day 1 and Day 1 of every eighth Extension Cyc le thereafter (ie, Extension Cycle 8, 16, 24+, 
etc. or every 24 weeks in the event of dose delays) until the subject is discontinued from treatment.  For subjects to continue  double-blind treatment in the Extension Phase of the 
Treatment Period, each MDS Disease Assessment (criteria detailed in Section 6.2.2 ) should confirm continued clinical benefit and absence of disease progression per IWG 
criteria for altering natural history of MDS ( Cheson, 2006 ; Appendix E ). Refer to Section 6for additional details.ORLuspaterceptb
starting dose  
1.0mg/kgb
OR
Placebob
Subcutaneous 
injection on D1 of 
each 21-day 
Treatment CycleR
an
d
om
i
z
a
t
i
o
nSubjects 
who 
provide 
signed 
informed 
consent 
and meet 
eligibility 
criteria End of Treatment
AE Reporting 
Window until 42 days 
after last dose of IPContinue double-
blind treatmentb, d 
MDS Disease Status 
Assessment every 
eighth Extension 
Cycle (24 weeks)MDS Disease 
Assessment c  
Week 25 Visit
24 calendar 
weeks after first 
dose, regardless 
of dose delays2:1 randomization
210 sub jectsCollection of 
transfusion data for 
at least 16 weeks afterlast dose of IP or until 
End of Treatment 
visit (whichever is 
later)
Monitor for Other 
Malignancies/Pre-
malignancies, 
progression to AML, 
OS, and subsequent 
MDS therapies for at 
least 3 years from last 
dose of IP unless the 
subject withdraws 
consent from the 
study, dies or is lost to 
follow-upDouble-Blind TREATMENT PERIOD
Primary Phase
(24 weeks)Extension Phase
(After Week 25 Visit until Treatment Discon)
Study
Discontinuation 5 weeksa
No Crossover
CCI&(/*(1(35235,(priprietet5uld be availabuld be availab
Refer to SectiRefer to Sec
Assessment bAssessment b
Chesonheson ,,2006006
scontinuation scontinuation 
by the investigby the investig
se delays) untidelays) unti
Assessment Assessment (c(
of MDS MD ((5,(7$5<,1)2
ChesCh5,(7$55,(7$5nd of Tre
AE Re
Window
after5<5< ,eeks)
5$
5,($550$7,21e Corporae Corpora
21
t t $W--UP UP 
0$RIODRIOD               07,2
0
)250)250Coll
nsfusi
at least
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 39 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20173.2. Study Duration for Subjects 
After a Screening Period of up to 5 weeks, eligible subjects who are randomized to receive IP 
(either placebo or luspatercept) should continue double-blind treatment through at least the first 
24 calendar weeks of the study unless the sub ject experiences unacceptable toxicities, disease 
progression per IWG criteria for altering natural history of MDS ( Cheson, 2006 ; Appendix E ),
withdraws consent, or meets any other discontinu ation criteria (Section 11).
Subjects who experience clinical benefit as determined by the Week 25 Visit MDS Disease 
Status Assessment (Section 6.2.2 ) may continue double-blind treatment beyond the Week 25 
Visit (ie, in the Extension Phase of the Treatment Period) until the subject experiences 
unacceptable toxicities, disease progression per IWG criteria for altering natural history of MDS 
(Cheson, 2006 ; Appendix E ), withdraws consent, or meets any other discontinuation criteria 
(Section 11).
For all subjects who receive at least one dose of IP, continuation of monitoring for progression to 
AML and other malignancies/pre-malignancies (please refer to Section 10.5 for details) will 
occur in the Posttreatment Follo w-up Period, along with subse quent MDS therapies, and overall 
survival for at least 3 years from the date of last dose of IP unless the subject withdraws consent 
from the study, dies or is lost to follow-up.
3.3. End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary  analysis, as prespecified in the protocoland/or SAP, whichever is the later date.
The Sponsor may end the trial when all key endpoi nts and objectives of the study have been 
analyzed, and the availability of a roll-over protocol exists into which any subjects remaining on 
study may be consented and continue to receive access to luspatercept and/or complete post-
treatment follow-up.  Such a protocol would be  written for a compound that would not yet be 
commercially available.
CCICCI
&(/*(1(35235,(7$5<,1)250$7,215 5 
ryyofofyy MDS  MDSff
n criteria n criteria 
ng for ng for progrprog
0.5.5fofor detar
MDS therapiMDS therap
e subject we subject
t visit of tht visit of th
he last datahe last dat
 analysis analysis
eyeyenenyydpoindpoin
over protocover proto
ue to receive to recei
tocol woultocol woul d,(
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 40 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20174. STUDY POPULATION
4.1. Number of Subjects 
Approximately 210 subjects with anemia due to IPSS-R very low, low, or intermediate MDS 
with ring sideroblasts who require RBC transfusions will be randomized worldwide.
4.2. Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Subject is â‰¥ 18 years of age the time of signing the informed consent form (ICF). 
2. Subject must understand and voluntarily sign an ICF prior to any study-related 
assessments/procedures being conducted. 
3. Documented diagnosis of MDS according to WHO/FAB classification that meets IPSS-R 
classification ( Greenberg, 2012; Appendix D ) of very low, low, or intermediate risk 
disease, and:
!Ring sideroblast â‰¥ 15% of erythroid precursors in bone marrow or â‰¥5% (but < 15%) 
if SF3B1 mutation is present.
!< 5% blasts in bone marrow
!Peripheral blood W BC count < 13,000/ Î¼L 
4. Refractory or intolerant to, or ineligible for, prior ESA treatment, as defined by any one 
of the following:
!Refractory to prior ESA treatment - docu mentation of non-response or response that 
is no longer maintained to prior ESA-containing regimen, either as single agent or 
combination (eg, with G-CSF); ESA regimen must have been either:
âˆ€recombinant human erythropoietin (rHu EPO) â‰¥ 40,000 IU/wk for at least 8 doses 
or equivalent; 
OR
âˆ€darbepoetin alpha â‰¥ 500 Î¼g Q3W for at least 4 doses or equivalent; 
!Intolerant to prior ESA treatment - docu mentation of discontinuation of prior ESA-
containing regimen, either as single agent or combination (eg, with G-CSF), at any 
time after introduction due to intolerance or an adverse event
!ESA ineligible - Low chance of response to ESA based on endogenous serum 
erythropoietin level > 200 U/L for subjects not previously treated with ESAs 
5. If previously treated with ESAs or granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), both agents must have 
been discontinued â‰¥ 4 weeks prior to date of randomization.
6. Requires RBC transfusions, as documented by the following criteria:
CCI&(/*(1(35235,(7$5<,1)250$7,21d d 
thhat meetsat meet
ntermnterm ediatediat
marrowmarrow oro
priprior ESAor ESA
t--documedocume5or ESAor ESA -coconn
SF); ESA reF); ESA r
n eryerythyropoopoh
etin alpha etin alpha â‰¥
ant to print to pri or or 1(aining regimaining regi
me after intme after in
ESA ineESA in//*eryryththyy
5.5.If preIf pre
grgr
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 41 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!average transfusion requirement of â‰¥ 2 units/8 weeks of pRBCs confirmed for a 
minimum of 16 weeks immediately preceding randomization.
!Hemoglobin levels at the time of or within 7 days prior to ad ministrati on of a RBC 
transfusion must have been â‰¤ 10.0 g/dL in order for the transfusion to be counted 
towards meeting eligibility criteria. Red blood cell transfusions administered when Hgb levels were > 10.0 g/dL and/or RBC transfusions administered for elective 
surgery will not qualify as a required tran sfusion for the purpose of meeting eligibility 
criteria.   Refer to Section 8.1.2 for guidance on transfusions during the course of the 
study.  
!no consecutive 56-day period that was RBC transfusion-free during the 16 weeks 
immediately preceding randomization
7. Eastern Cooperative Oncology Group (ECOG) score  of 0, 1, or 2 ( Appendix G )
8. Females of childbearing potential (FCBP), defi ned as a sexually mature woman who: 1) 
has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally
postmenopausal (amenorrhea following cancer therapy does not rule out childbearingpotential) for at least 24 consecutive months (ie, has had menses at any time in the
preceding 24 consecutive months), must:
!Have two negative pregnancy tests as verified by the Investigator prior to starting 
study therapy (unless the screening pre gnancy test was done within 72 hours of 
C1D1). Refer to Section 6.1for additional details.  She must agree to ongoing 
pregnancy testing during the course of the study, and after end of study treatment. 
!If sexually active, agree to use, and be  able to comply with, highly effective 
contraception** without interruption, 5 weeks prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks
after discontinuation of study therapy. 
** Highly effective contraception is defined in this protocol as the following (information 
will also appear in the ICF): Hormonal contraception (for example, birth control pills, 
injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal 
ligation (tying your tubes); or a partner with a vasectomy 
9. Male subjects must:
!Agree to use a condom, defined as a male latex condom or nonlatex condom NOT 
made out of natural (animal) membrane (for example, polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while 
participating in the study, during dose interruptions and for at least 12 weeks
following investigational product discontinuation, even if he has undergone a successful vasectomy. 
10. Subject is willing and able to adhere to the study visit schedule and other protocol 
requirements.
CCIce235,(7$5<,1)250$7,21e e 
weeks weeks 
ndix ndix GG))
ure womure wom ana
) has not behas no
trulruleeoutoutc
nsessatatanyan
y the Investthe Invest
y test was dtest was d
details.details.   ShSh
he studyhe study , ana
be able to cbe able to
tition, on, 5 wee5 wee
apyapy (includ (includyy
dydy therapy therapyyy
ption is dption is de
ICF)CF): : HHormormHH
ansdermal ansderm
ur tubes); our tubes
must:must:
gree to use gree to use
made out made out
sexual sexual 
partpar
fo
10.0.SuS
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 42 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20174.3. Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Prior therapy with disease modifying ag ents for underlying MDS disease (eg, immune-
modulatory drug [IMiDs such as lenalidomide], hypomethylating agents, or 
immunosuppressive therapy [IST]).
!subjects who previously received hypomethylating agents (HMA) or lenalidomide 
may be enrolled at the investigatorâ€™s discr etion contingent that the subject received no 
more than 2 doses of HMA or no more than 1 calendar week of treatment with 
lenalidomide.  The last dose must be â‰¥ 5 weeks from the date of rando mization.  
2. Previously treated with either lu spatercept (ACE-536) or sotatercept (ACE-011)
3. MDS associated with del 5q cytogenetic abnorm ality
4. Secondary MDS, ie, MDS that is  known to have arisen as the result of chemical injury or 
treatment with chemotherapy and/or radiation for other diseases.
5. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or 
autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding
!iron deficiency to be determined by serum ferritin â‰¤ 15 Î¼g/L and additional testing if 
clinically indicated (eg, calculated transferrin saturation [iron/total iron binding 
capacity â‰¤ 20%] or bone marrow aspirate stain for iron). 
6. Prior allogeneic or autologous stem cell transplant
7. Known history of diagnosis of AML 
8. Use of any of the following within 5 weeks prior to randomization:
!anticancer cytotoxic chemotherapeutic agent or treatment 
!corticosteroid, except for subjects on a stable or decreasing dose for â‰¥ 1 week prior to 
randomization for me dical conditions other than MDS
!iron-chelating agents, except for subjects on a stable or decreasing dose for at least 8 
weeks prior to randomization
!other RBC hematopoietic growth factors (eg, Interleukin-3)
!investigational drug or device, or approved therapy for investigational use.  If the 
half-life of the previous investigational product is known, use within 5 times the half-
life prior to randomization or within 5 weeks, whichever is longer is excluded.
9. Uncontrolled hypertension, defined as repeated elevations of diastolic blood pressure 
(DBP) â‰¥ 100 mmHg despite adequate treatment.  
10. Absolute neutrophil count (ANC) < 500/ Î¼L (0.5 x 109/L)
11. Platelet count < 50,000/Î¼L (50 x 109/L) 
12. Estimated glomerular filtration rate (eGFR) or creatinine clearance < 40 mL/min.
CCI&(/*(1(35235,(7$5<,1)250$7,21no no 
n.  .  
11)11)
of chemicalof chemic
 ororfofolate dlate d
stinal bleedtinal blee
â‰¤ 15 Î¼g/L aâ‰¤ 15 Î¼g/
aturation [iruration [
in for iron)for iron
splantsplant
weeksweeks pripri
herapeutherapeut ic i
or subjects osubjects 
edical conddical cond
gents, excepents, exc
o randomizo random
C hematopC hematop
tigattigatioional dnal
lf-flife of thlife of th
life prior tife prior t
UncontroUncontro
(DBP) (DBP)
10.0.AbAb
1111
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 43 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201713. Serum aspartate aminotransferase/serum  glutamic oxaloacetic transaminase (AST/SGOT)
or alanine aminotransferase/serum gl utamic pyruvic transaminase (ALT/SGPT) â‰¥ 3.0 x 
upper limit of normal (ULN)
14. Total bilirubin â‰¥ 2.0 x ULN. 
!higher levels are acceptable if these can be attributed to active red blood cell 
precursor destruction within the bone marrow (ie, ineffective erythropoiesis) or in the 
presence of known history of Gilbert Syndrome. 
!subjects are excluded if there is evidence of autoimmune hemolytic anemia 
manifested as a corrected reticulocyte count of > 2% with either a positive Coombsâ€™ 
test or over 50% indirect bilirubin
15. Prior history of malignancies, other than MDS, unless the subject has been free of the 
disease (including completion of any active or adjuvant treatment for prior malignancy) 
for â‰¥ 5 years. However, subjects with the following history/concurrent conditions are 
allowed:
!Basal or squamous cell carcinoma of the skin
!Carcinoma in situ of the cervix
!Carcinoma in situ of the breast
!Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, 
metastasis [TNM] clinical staging system)
16. Major surgery within 8 weeks prior to  randomization. Subjects must have comp letely 
recovered from any previous surgery prior to randomization
17. History of stroke, deep venous thrombosis (DVT), pulmonary or arterial embolism within 
6 months prior to randomization
18. Pregnant or breastfeeding females
19. Myocardial infarction, uncontrolled angina, uncontrolled heart failure, or uncontrolled 
cardiac arrhythmia as determined by the inve stigator within 6 months prior to 
randomization.  Subjects with a known ejection fraction Ë‚35%, confirmed by a local 
ECHO or MUGA performed within 6 months prior to randomization are excluded.
20. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing 
signs/symptoms related to the infectio n without improvement despite appropriate 
antibiotics, antiviral therapy, and/or other treatment), known Human Immunodeficiency 
Virus (HIV), known evidence of active infectious Hepatitis B, and/or known evidence of active Hepatitis C.  Local testing confirming HI V, Hepatitis B, and Hepatitis C status 
should not have been performed earlier than 4 weeks from the date of ICF signature.
21. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (see Investigator Brochure).
22. Subject has any significant me dical condition, laboratory a bnormality, psychiatric illness, 
or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study.
CCI&(/*(1(35235,(7$5<,1)250$7,21ombsâ€™mbsâ€™
free of thefree of th
rior malignaior malig
nt condint condi titiiio
er (T1a orer (T1a o T
)
domizatdomiz ionio
rior to randor to rand
ombosis (Dombosis (D
n
emalesmales
uncontrollencontroll
as determins determi
Subjects Subjects wii
GA performGA perfo
led systemiled system
ymptomymptom s s re
iotiotics, antics, ant ii
irus (HIV)us (HIV)i
active act HeHe
shoulshoul dd
21.1.HiHi
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 44 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201723. Subject has any condition including the presence of laboratory abnormalities , which 
places the subject at unacceptable risk if he/she were to participate in the study.
24. Subject has any condition or conco mitant medication that confounds the ability to 
interpret data from the study.
CCI&(/*(1(35235,(7$5<,1)250$7,21
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 45 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20175. TABLE OF EVENTS
Table 4: Table of Events
ScreeningTreatment Period1 Posttreatment Follow-up
!42 Day Follow-up = Occurs 42 days 
after last dose of IP
!12 Week Follow-up = Occurs 12 
Weeks after last dose of IP
!Long Term Follow-up = Occurs 
every 3 months after 12 Week 
Follow-Up until at least 3 years post last dose of IPPrimary Phase
First 24 weeks of double-blind 
treatment
Up to maximum of 8 Treatment 
Cycles 
(if no dose delays)Week 251,2
Visit
24 calendar 
weeks after 
first dose 
regardless of 
dose delays.Extension Phase
Continuation of double-
blind treatment beyond 
Week 25 VisitEOT
Visit2
Day -35Every 
Cycle
(ie,1,2,3
+ up to 
max 8 
cyclesEvery 
Other 
Cycle
Only)
(ie, 1, 3,
5, 7)Cycles
1a n d5
OnlyCycle 1
OnlyEvery 
Ext 
Cycle
12,2,3
+Ext 
Cycle 4, 
8, 12+Ext 
Cycle 8, 
16, 24+42 Day 
Follow-
up212, 24, 
48
Week 
Follow-
upLong Term 
Follow-upEnd of 
Study 
to -1 Day 1 Day 1 Day 8 Day 15 Day 1 Day 1 Day 1
STUDY ENTRY AND GENERAL ASSESSMENTS
Informed Consent X -- -- -- -- -- -- -- -- -- -- -- -- --
Inclusion/ExclusionevaluationsX - - - -- -- - - - - -- - - - - - - - - - - - - -
Physical Examination X X X X X
Randomization3X - - - -- -- - - - - -- - - - - - - - - - - - - -
Demographics X -- -- -- -- -- -- -- -- -- -- -- -- --
Medical History X -- -- -- -- -- -- -- -- -- -- -- -- --
Prior ESA Therapies X -- -- -- -- -- -- -- -- -- -- -- -- --
Prior RBC and Platelet 
Transfusions4X - - - -- -- - - - - -- - - - - - - - - - - - - -
INVESTIGATIONAL PRODUCT (IP)
IP Administration and 
Accountability15 -- X3-- -- -- -- X -- -- -- -- -- -- --
CCI&(/*(1(opriopriee1(35235,(7$5<,1)250$7,21orporatiorporati onon
21
Posttosttreatmrea
42 Day Follo42 Day Foll
afterafter lastla
!!12 We12 W
WeW
!!0$
ond nd 
tEOTEO
VisVi12
2,3,3
+Ext Ext 
Cycle 4, Cycl
8, 128, 12,111
7$5<1
Day 1 DaDay 177$777$7$$
--(7(7(7(
----5,(333323----22252
-- ---555253---3555
(35
----(3(3(3(3----1(((
(1(
(IP)(IP)(1(1(1
XX33***((
(//*//
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 46 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 4: Table of Events (Continued)
ScreeningTreatment Period1 Posttreatment Follow-up
!42 Day Follow-up = Occurs 42 days 
after last dose of IP
!12 Week Follow-up = Occurs 12 
Weeks after last dose of IP
!Long Term Follow-up = Occurs 
every 3 months after 12 Week 
Follow-Up until at least 3 years post last dose of IPPrimary Phase
First 24 weeks of double-blind 
treatment
Up to maximum of 8 Treatment 
Cycles 
(if no dose delays)Week 251,2
Visit
24 calendar 
weeks after 
first dose 
regardless of 
dose delays.Extension Phase
Continuation of double-
blind treatment beyond 
Week 25 VisitEOT
Visit2
Day -35Every 
Cycle
(ie,1,2,3
+ up to 
max 8 
cyclesEvery 
Other 
Cycle
Only)
(ie, 1, 3,
5, 7)Cycles
1 and 5
OnlyCycle 1
OnlyEvery 
Ext 
Cycle
12,2,3
+Ext 
Cycle 4, 
8, 12+Ext 
Cycle 8, 
16, 24+42 Day 
Follow-
up212, 24, 
48 
Week 
Follow-
upLong Term 
Follow-upEnd of 
Study 
to -1 Day 1 Day 1 Day 8 Day 15 Day 1 Day 1 Day 1
SAFETY ASSESSMENTS
ECOG Performance Status X X -- -- -- X X -- -- X -- -- -- --
Urinalysis5X C1D1 and D1 of every fourth cycle in 
Primary Phase (eg, C1, C4, C8)X Ext C1D1, then D1 of 
every fourth Extension 
cycle until treatment 
discontinuationX- -- - - - - -
Coombsâ€™ test6X - - - -- -- - - - - -- - - - - - - - - - - - - -
Assessment of 
HIV/HepB/HepC status6X - - - -- -- - - - - -- - - - - - - - - - - - - -
ECG (12-lead) X -- -- C5D8 
only-- -- -- -- -- X -- -- -- --
Pregnancy Test and 
Counseling7X X -- -- -- X X -- -- X -- -- -- --
Adverse events Continuous, after signing informed consent until 42 days after last IP administration-- -- --
Prior and Concomitant 
medications/procedures X Continuous, until 42 days after last IP administration or until the EOT visit, whichever occurs later-- -- --
CCI&(/*(opriopriee(1(35235,(7$5<,1)250$7,21orporatiorporati onon
21
eatment Follatment Foll
Followollow -u-up =p =
rlast dose of last dose of 
2 Week2 Week FolloFoll
Weeks Weeks afteaft
!!Long TLong T
everyeve
Fo7,2
OTT
VisitVisit22
12
cle 4, e 4, 
8, 12+8, 12+Ext t
Cycle 8C
16, 216,111)
5<1
Day 1 DDay 1
$5<$$$5XX7$7$7$(7$Ext CExt 
eve(((777
3,(
-- -333523----232323523
C5D8 C5D8 
onlyonly-555235 -- ---- --3
1(Continuous, Continuous, afa111(((
ContinuoContinuo(1
/*/*/*/*
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 47 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 4: Table of Events (Continued)
ScreeningTreatment Period1Posttreatment Follow-up
!42 Day Follow-up = Occurs 42 days 
after last dose of IP
!12 Week Follow-up = Occurs 12 
Weeks after last dose of IP
!Long Term Follow-up = Occurs 
every 3 months after 12 Week 
Follow-Up until at least 3 years post last dose of IPPrimary Phase
First 24 weeks of double-blind 
treatment
Up to maximum of 8 Treatment 
Cycles 
(if no dose delays)Week 251,2
Visit
24 calendar 
weeks after 
first dose 
regardless 
of dose 
delays.Extension Phase
Continuation of double-
blind treatment beyond 
Week 25 VisitEOT
Visit2
Day -35Every 
Cycle
(ie,1,2,3
+ up to 
max 8 
cyclesEvery 
Other 
Cycle
Only)
(ie, 1, 3,
5, 7)Cycles
1 and 5
OnlyCycle 1
OnlyEvery 
Ext 
Cycle
12,2,3+Ext 
Cycle 4, 
8, 12+Ext 
Cycle 8, 
16, 24+42 Day 
Follow-
up212, 24, 
48 
Week 
Follow-
upLong Term 
Follow-upEnd of 
Study 
to -1 Day 1 Day 1 Day 8 Day 15 Day 1 Day 1 Day 1
Vital Signs (Height to be measured only at screening; 
Weight to be measured only at screening and prior to each 
IP administration)X X -- X X X X -- -- X -- -- -- --
Serum Chemistry8X X -- -- -- X X -- -- X -- -- -- --
EFFICACY ASSESSMENTS
Hematology9, 15X X -- X X X X -- -- X -- -- -- --
Serum EPO X10-- X -- -- X -- -- -- X -- -- -- --
Serum Ferritin
X11X11-- -- -- X -- X -- X -- -- -- --
Transfusion Data Collection 
and AssessmentAssess and record on ongoing basis (prior to each dose of IP) until 16 weeks after last dose of IP or the End of Treatment Visit, 
whichever occurs later. Clinical site staff should confirm if any transfusions were received by the subject (including any at ou tside local 
institutions in between study visits) prior to each IP administration via use of patient diary or other local procedure in plac e at the 
investigational site.--
MDS Disease Assessment12-- -- -- -- -- X -- -- X X -- -- -- --
CCI&(/*(opriopriee*(1(35235,(7$5<,1)250$7,21orporatiorporati onon
21
eatment Folatment Fol
y Followy Follow -u-up =p
rlast dose oflast dose
12 Week Foll2 Week Foll
Weeks Weeks afteaft
!!Long TLong T
evereve
F7,2
OTOT
VisitVisit22
12
le 4, e4 ,
8, 12+8, 12+Ext 
Cycle 8C
16, 16,111)
5<1
Day 1Day 1
$5<
XX$$$$5
,(7$
XX5,(,(,(,(
35XX232323235----22252
----5552
(35ongoing basisongoing ba
ater.er.Clinical Clinical 
etween study vetween study v
al site.al site.(((3
----(1(1(1****((1
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 48 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 4: Table of Events (Continued)
ScreeningTreatment Period1 Posttreatment Follow-up
!42 Day Follow-up = Occurs 42 days 
after last dose of IP
!12 Week Follow-up = Occurs 12 
Weeks after last dose of IP
!Long Term Follow-up = Occurs 
every 3 months after 12 Week 
Follow-Up until at least 3 years post last dose of IPPrimary Phase
First 24 weeks of double-blind 
treatment
Up to maximum of 8 Treatment 
Cycles 
(if no dose delays)Week 251,2
Visit
24 calendar 
weeks after 
first dose 
regardless of 
dose delays.Extension Phase
Continuation of double-
blind treatment beyond 
Week 25 VisitEOT
Visit2
Day -35Every 
Cycle
(ie,1,2,3
+ up to 
max 8 cyclesEvery 
Other 
Cycle
Only)
(ie, 1, 3,
5, 7)Cycles
1 and 5
OnlyCycle 1
OnlyEvery 
Ext 
Cycle
1
2,2,3
+Ext 
Cycle 4, 
8, 12+Ext 
Cycle 8, 
16, 24+42 Day 
Follow-
up212, 24, 
48 
Week 
Follow-
upLong Term 
Follow-upEnd of 
Study 
to -1 Day 1 Day 1 Day 8 Day 15 Day 1 Day 1 Day 1
Bone Marrow Aspirate(BMA) and Peripheral Blood for cytomorphology and cytogenetic testing
13BM 
Biopsy 
and
Aspirate 
Required-- -- -- -- X -- -- X X -- -- -- --
CCICCI
&(/*(1(opriopriee,(7$---
5,(7$5<,1)250$7,21orporatiorporati onon
21
eatment Follatment Foll
Followollow -u-up =p =
last dose of ast dose of 
2 Week Follo2 Week Foll
Weeks Weeks afteaft
!!Long TLong T
everyeve
FoF7,2
OTT
VisitVisit22
12
cle 4, e 4, 
8, 12+8, 12+Ext t
Cycle 8C
16, 216,111)
5<1
Day 1 DDay 1
$5<$$$$555
,(7$5
1(35235,(
EDMS Doc. NumberLuspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 49 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 4: Table of Events (Continued)
ScreeningTreatment Period1 Posttreatment Follow-up
!42 Day Follow-up = Occurs 42 days 
after last dose of IP
!12 Week Follow-up = Occurs 12 
Weeks after last dose of IP
!Long Term Follow-up = Occurs 
every 3 months after 12 Week 
Follow-Up until at least 3 years post last dose of IPPrimary Phase
First 24 weeks of double-blind 
treatment
Up to maximum of 8 Treatment 
Cycles 
(if no dose delays)Week 251,2
Visit
24 calendar 
weeks after 
first dose 
regardless of 
dose delays.Extension Phase
Continuation of double-
blind treatment beyond 
Week 25 VisitEOT
Visit2
Day -35Every 
Cycle
(ie,1,2,3
+ up to 
max 8 cyclesEvery 
Other 
Cycle
Only)
(ie, 1, 3,
5, 7)Cycles
1 and 5
OnlyCycle 1
OnlyEvery 
Ext 
Cycle
1
2,2,3
+Ext 
Cycle 4, 
8, 12+Ext 
Cycle 8, 
16, 24+42 Day 
Follow-
up212, 24, 
48
Week 
Follow-
upLong Term 
Follow-up End of 
Study 
to -1 Day 1 Day 1 Day 8 Day 15 Day 1 Day 1 Day 1
PK and ADA
PK Sample Collection 
Refer to Section 6.4-- C1,2,4,
6,8 
Only-- X X X Extension C4D1 and D1 
of every 4th Extension 
Cycle thereafter (eg, Ext. 
C4, C8, etc.) for up to one 
year from the first dose in 
the Primary Treatment 
Phase.X18-- X18-- --
ADA Sample Collection
Refer to Section 6.5-- C1,2,4,
6,8 
Only-- -- -- X Extension C4D1 and D1 
of every 4thExtension 
Cycle thereafter (eg, Ext. 
C4, C8, C12 C16+, etc.) 
for up to one year from 
the first dose in the 
Primary Treatment Phase.X18-- X18
QUALITY OF LIFE 
EORTC QLQ-C30 
 Questionnaire CompletionX- - X16-- -- XDay 1 of Every Other Ext. 
Cycle 
(Ext. C1,C3, C5+, etc.)X- -- - - - - -
CCICCI
CCI
&(/opriopriee((((//*(1(35(35235,(7$5<,1)250$7,21orporatiorporati onon
21
eatment Follatment Foll
y Followollow -u-up =p =
rlast dose of last dose of 
2 Week Follo2 Week Foll
Weeks Weeks afteaft
!!Long TLong T
everyeve
Fo7,2
OTT
VisitVisit22
12
cle 4, e 4, 
8, 12+8, 12+Ext t
Cycle 8C
16, 216111)
5<1
Day 1 DDay 1
$5<$$$5ExtensionExtensio
of eveof ev
CyCycly
C4C47$
23(7
--232323
3523
(((
----111
/*(1
/*/*/*(/*
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 50 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 4: Table of Events (Continued)
ScreeningTreatment Period1 Posttreatment Follow-up
!42 Day Follow-up = Occurs 42 days 
after last dose of IP
!12 Week Follow-up = Occurs 12 
Weeks after last dose of IP
!Long Term Follow-up = Occurs 
every 3 months after 12 Week 
Follow-Up until at least 3 years post last dose of IPPrimary Phase
First 24 weeks of double-blind 
treatment
Up to maximum of 8 Treatment 
Cycles 
(if no dose delays)Week 251,2
Visit
24 calendar 
weeks after 
first dose 
regardless of 
dose delays.Extension Phase
Continuation of double-
blind treatment beyond 
Week 25 VisitEOT
Visit2
Day -35Every 
Cycle
(ie,1,2,3
+ up to 
max 8 cyclesEvery 
Other 
Cycle
Only)
(ie, 1, 3,
5, 7)Cycles
1 and 5
OnlyCycle 1
OnlyEvery 
Ext 
Cycle
1
2,2,3
+Ext 
Cycle 4, 
8, 12+Ext 
Cycle 8, 
16, 24+42 Day 
Follow-
up212, 24, 
48 
Week 
Follow-
upLong Term 
Follow-upEnd of 
Study 
to -1 Day 1 Day 1 Day 8 Day 15 Day 1 Day 1 Day 1
FOLLOW UP 
Monitoring for progression to AML and other 
malignancies/pre-
malignancies
17
(Refer to Section 10.5 for 
details)After signing ICF and until at least 3 years post last dose of IP or until death, lost to follow-up, withdrawal of consent for fu rther data collection.
Posttreatment MDS 
therapies17 -- -- -- -- -- -- -- -- -- -- X X X X
Survival Follow-up17-- -- -- -- -- -- -- -- -- -- X X X X
1Window of +/- 3 days is allowed during Treatment Period.  A window  of +/- 14 days is allowed for the Week 25 Visit (Section 6.2.2 ).  A window of +/- 14 days is allowed for 
Posttreatment Long-term Follow-up Assessments (ie, OS, Progression to AML, other malignancies/pre-malignancies (please refer to Section 10.5 for details), subsequent MDS 
therapies).
2Week 25 Visit and Extension Cycle 1 Visit procedures/assessments may not need to be repeated if previously performed within +/- 7 days of the scheduled visit.  End of 
Treatment (EOT) Visit procedures/assessments may not need to be repeated if previously performed within +/-7 days of EOT visit.  If a subject is discontinued during a regular 
scheduled visit, all EOT procedures should be completed at that visit. End of Treatment (EOT) Visit procedures/assessments may o ccur at 42 Day Follow-up assessment if 
subject is discontinued within +/- 7 days of 42 Day Follow-up assessment.
3Randomization via IRT.  The first dose of IP should be administered after, but within 3 days of randomization and can be on the same day as randomization. Refer to the IRT 
manual for additional information on randomization utilizing IRT.  Documentation must be complete to confirm an average RBC tra nsfusion requirement of at least 2 units of 
packed red blood cells (pRBCs) per 8 weeks during the 16 weeks immediately preceding randomization. Hemoglobin levels at the ti me of or within 7 days prior to 
administration of a RBC transfusion must have been â‰¤ 10.0 g/dL in order for the transfusion to be counted towards meeting eligibility criteria. Red blood cell transfusions 
administered when Hgb levels were > 10.0 g/dL and/or RBC transfusions administered for elective surgery will not qualify as a re quired transfusion for the purpose of meeting 
CCI&(/opriopriee(/*(1(35235,(7$5<,1)250$7,21orporatiorporati onon
21
eatment Follatment Foll
y Followollow -u-up =p =
rlast dose of last dose of 
2 Week Follo2 Week Foll
Weeks Weeks afteaft
!!Long TLong T
everyeve
Fo7,2
OTT
VisitVisit22
12
cle 4, e 4, 
8, 12+8, 12+Ext t
Cycle 8C
16, 216111)
5<1
Day 1 DDay 1
$5<$$$5
se of IP or une of IP or un7$
----333523--5222
353535352
window of +window 
Progression toogression to
es/assessments/asses
ay not need toy not need to
completed at tompleted at t
42 Day Follow42 Day Follow
fIPPshould beshould be
andomizationandomization
r 8 weeks duriweeks du
ion must haveion must have
s were > 10.0 s were > 10.0
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 51 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017eligibility criteria.  There must also not be any consecutive 56-day period that was RBC transfusion free during the 16 weeks i mmediately preceding randomization.  Refer to 
Section 4.2.
4Subjects must have at least 16 weeks documented transfusion history prior to randomization. This transfusion data includes hemo globin measured prior to transfusion 
(pretransfusion Hgb).  Refer to Section 6.1.
5Urinalysis assessed centrally and to include microscopic, quantitative analysis of urine. (eg, microalbumin/albumin, protein, cr eatinine, microalbumin/creatinine ratio).
6A local Coombâ€™s test is only performed if total bilirubin > 2 x ULN (see Section 4.3).  If positive, a local reticulocyte count may be requested.  Local test results confirming 
known Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C status should not have been performed earlier than 4 weeks from  the date of ICF signature.  If beyond 
this window, additional local testing may be requested (see Section 4.3).
7Pregnancy test is required for all female subjects of childbearing potential.  Serum beta human chorionic gonadotropin ( Î²-hCG) will be performed at screening.  A urine (or 
serum) pregnancy test will be repeated prior to the first administration of IP on C1D1, unless the screening pregnancy test was done within 72 hours of C1D1. During the 
Treatment Period, urine or serum pregnancy test is allowed. For males and FCBP, counseling about pregnancy precautions and the p otential risks of fetal exposure must be 
conducted prior to each IP administration or on a monthly basis (eg, in the event of dose delays). Refer to Section 6.1for additional details.
8Serum chemistry (eg, sodium, potassium, chloride, bicarbonate [if available], calcium, magnesium, phosphorus, blood urea nitrog en [BUN], creatinine, creatinine clearance 
and/or estimated glomerular filtration rate, glucose, albumin, total protein, alkaline phosphatase, direct/indirect total bilir ubin, AST/SGOT or ALT/SGPT, lactate 
dehydrogenase [LDH], uric acid) will be analyzed by the central laboratory.  Refer to Section 6.1. 
9Hematology assessment (eg, red blood cell [RBC] count, complete blood count [CBC], white blood cell [WBC] with differential, he moglobin, hematocrit, nucleated red blood 
cells [nRBC], absolute reticulocyte count, platelet count, mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], me an corpuscular hemoglobin concentration 
[MCHC], and red blood cell distribution width [RDW]) will be tested by the central laboratory.  Refer to Section 6.1.  
10EPO will be assessed centrally.  During the Screening Period, the serum EPO level should be collected on the same day as a plan ned RBC transfusion, prior to the transfusion 
or 7 days after any RBC transfusion due to possible reduction of the serum level related to the hemoglobin level achieved after  the last transfusion. 
11Serum ferritin will be assessed centrally. Sample should be collected within 5 weeks prior to randomization. Sample should be c ollected prior to administration of IP.  
Additional serum ferritin results from previous local laboratory assessments (ie, within the 16 week window immediately prior t o randomization date) should be collected, if 
available in the medical records, and entered into the eCRF.
12During the Treatment Period, MDS Disease Assessment (which includes investigator assessment of clinical benefit and MDS disease status) should be completed by the 
investigator in conjunction with bone marrow/peripheral blood sample collection for cytomorphology and cytogenetics collected at the Week 25 Visit.  For details related to the 
allowed time window related to procedures and assessments refer to Section 6.2.2 .  Based on the outcome of the MDS Disease Assessment, subjects will either be discontinued
from treatment with IP and enter the Posttreatment Follow-Up Period or continue double-blind treatment with IP in the Extension  Phase of the Treatment Period.  Refer to 
Section 6.2.3 for additional details.
13During the Screening Period, bone marrow biopsy AND bone marrow aspirate are required. The screening BMB should be performed wi thin 5 weeks prior to randomization.  
The screening BMA should be collected within the protocol screening window.  After randomization, a bone marrow biopsy is colle cted only when adequate aspirate is not 
attainable.  During the Extension Phase of the Treatment Period: Bone marrow and peripheral blood samples to be collected at Ext ension Cycle 8, Day 1 and Day 1 of every 
eighth Extension Cycle thereafter (ie, Extension Cycle 8, 16, 24+, etc. or approximately every 24 weeks in the event of dose de lays). Bone marrow samples at End of Treatment 
Visit: Perform only if visit is > 90 days from prior bone marrow procedure. Refer to central laboratory manual for additional i nformation related to sample collection
 
 
  
 
.
15On dosing days, local laboratory sample should be collected and Hgb levels assessed prior to each IP administration to ensure do se modification rules are followed as outlined 
in Section 7.2.1.1 , Table 6.  In these circumstances, a split sample should also be collected and sent to the central laboratory for analysis. Sub jects must have blood pressure 
assessed (as detailed in Section 6.1) prior to each IP administration.
16If subject completed Screening EORTC QLQ-C30  questionnaires within 14 days prior to C1D1, it does not have to be repeated at C1 D1. If performed on C1D1, 
both EORTC QLQ-C30  questionnaires should be completed by the subject prior to IP administration.
17Long-Term Posttreatment Follow-up for Overall Survival (OS), Progression to AML, other malignancies/pre-malignancies (please ref er to Section 10.5 for details), and data
collection for subsequent MDS therapies may be conducted by record review (including public records if allowed by local regulati ons) and/or telephone contact with the 
CCIC
CI
CCI
CCI
&(/*(1(35235,(7$5<,1)250$7,21orporatiorporati onon
21
oprioprieeomization.  Remization.  R
rior to transfusor to transfu
lbumin/creatinlbumin/creat
ed. LLocal test ocal te
m the date of ICm the date of I
ll be performel be performe
one within 72one within 7
nd the potentiad the potent
dditional detadditional deta
urea nitrea nitr ogen [og
bililirubin, ASTirubin, AS
] with differenwith differe
ar hemoglobinar hem
SectionSection 6.16.1. 
d on the same on the sam
oglobin level aglobin lev
domization. domization. SS
week windowweek wind
sessment of clessment of c
cytomorpholoytomorpholo
BBased on theased on the
ue doubleue double --blinblin
pirate are requpirate are 
window.window.   AfteAf
ne marrow ane marrow a n
+, etc. or appro etc. or appro
w procedure. w procedure. 
uld be collecteuld be collecte
mstances, a spmstances, a s
or to each IP aor to each IP 
RTCCQLQLQ--C30C30
 questionnaestionna
owow-up for Ovup for O
MDS therapies DS therapies 35(3(31(
/
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 52 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017subject, family, or the subjectâ€™s treating physician.  The investigator must make every effort to obtain information regarding the subjectâ€™s survival status before determining the 
subject is lost to follow-up.
18Post-treatment Follow-up: For subjects who do not complete the Primary Treatment Phase or do not participate in the Extension P hase or subjects who terminate the Extension 
Phase with less than 1-year of ADA monitoring, ADA and PK samples will be collected at EOT and then every 12 weeks for up to on e year from the first dose in the Primary 
Treatment Phase (please refer to Section 6.4and Section 6.5for details).
CCI&(/*(1(35235,(7$5<,1)250$7opriopriee$7,21orporatiorporati onon
21efore determinfore determ
who tero terminate tminate
the first dose he first dose
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 53 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20176. PROCEDURES
Any questions regarding the protocol should be directed to the Celgene Medical Monitor or 
designee. 
All of the protocol required assessments are listed in Section 5, Table 4 , with an â€œXâ€ indicating 
at which visits the assessments are to be performed. All data obtained from these assessments must be recorded in the subjectâ€™s source documentation.  Except for the Week 25 Visit, all study
visits during the Treatment Period (both Primary and Extension Phases) must occur within 
Â± 3 days of the scheduled day.  A 14 day window  is allowed for the Week 25 Visit (refer to 
Section 6.2.2 for details).  Week 25 Visit and Extension Cycle 1 Visit procedures/assessments 
may not need to be repeated if previously performed within Â±7 days of the scheduled visit.
  
End of Treatment Visit procedures/assessments may not need to be repeated if previously 
performed within Â±7 days of EOT visit.  If a subject is discontinued during a regular scheduled 
visit, all EOT procedures should be completed at that visit.  End of Treatment Visit 
procedures/assessments may occur at 42 Day Follow-up assessment if subject is discontinued within Â± 7 days of 42 Day Follow-up assessment.
A window of Â± 14 days is allowed for Posttreatmen t Long-Term Follow-up assessments (ie, OS, 
progression to AML, other malignancies/pre-malignancies, subsequent MDS therapies).  Procedures are described in detail below.
Subjects must have hemoglobin and blood pressure assessed prior to each IP administration. 
Blood pressure values should be confirmed by a mean of two readings obtained approximately 5minutes apart with the subject seated for approximately 10 minutes prior to initial reading. 
Safety laboratory analyses and all laboratory assessments will be performed centrally (except 
otherwise stated in this section) during the Treatment Period.  
Local laboratories are allowed in cases when timely results are needed (eg, randomization, study 
treatment dosing decisions, hematology assessments between clinic visits, adverse event).  In 
these circumstances, a split sample should st ill be co llected and sent to the central laboratory for 
analysis.  With prior sponsor consultation, local la boratories may also be used to determine study 
eligibility if central laboratory results are not availab le (eg, hemolyzed sample, etc.) or if there is 
a discrepancy between local and central labor atory results impacting st udy eligibility.  Local 
laboratory data should be collected in the eCRF if relevant to st udy eligibility determination, 
dose administration, dose modification, or an AE, significant discrepancy between local and 
central laboratory results (from samples coll ected at the same study time point), or when no 
central laboratory results were obtained.  
Refer to the eCRF completion guidelines for additional information related to data entry 
requirements of local laboratories.  
Sample collection, processing, storage, and shipment procedures will be provided in the Study 
Laboratory Manual.
6.1. Screening Period
!Signing of the ICF
CCI&(/*(1(35235,(7$5<,1)250$7,21yy
to o 
ssments sments 
d visit.d visit.     
previously previousl
regular schregular s
ment Visit ment Visit 
subject is dsubject is
mm Fo Fomm llollw-u
ubsequent ubsequent
ssessed priossessed prio
ean oean f ftwtwoo
ximately 10imately 1
yy assessmeassessmeyy
e Treatmee Treatme
ses when times when 
tology assetology ass
mple shouldple shoul
or r cocnsultatnsult
ratoryratory resulreyy
n local and n local an
uld be colld be coll
tion, tion, dose dose 
atoryatory resulresulyy ttll
boratoryratory resresyy
to the eCRto the eCR
uiuirements orements iii
SamSaple cole com
aboraabora
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 54 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!Assessment of Inclusion/Exclusion Criteria For Study Eligibility
Screening evaluations will be performed for all subjects to determine study eligibility. These 
evaluations must be completed within 5 weeks of rando mization (refer to Table of Events,
Section 5, Table 4 for further information). Screening la boratory values must demonstrate 
subject eligibility, but may be repeated wi thin the screening window, if necessary.
Waivers to the protocol will not be granted during the conduct of this trial, under any 
circumstances.
The following assessments/procedures will be performed during the Screening Period as 
specified in the Table of Events, Table 4 :
!Bone Marrow and Peripheral Blood Samples
Screening MDS diagnosis confirmation requires both bone marrow biopsy (BMB), bone marrow 
aspirate (BMA), and peripheral blood samples. Samples may be reviewed locally, but must also
be sent to the central laboratory for analysis.
The screening BMB, BMA, and peripheral bl ood samples should be co llected within the protocol 
screening window or 5 weeks prior to randomization.  If a subject is rescreened (eg, due to 
retesting of another lab), repeat bone marrow samples do not need to be collected contingent that 
initial samples were adequ ate for cytom orphology/cytogeneti c assessment by the central 
laboratory. During the course of the study, wh enever a bone marrow sample is collected, a 
peripheral blood smear is to be prepared.
Sample collection, processing, storage, and shipment procedures will be provided in the studyâ€™s 
Central Laboratory Manual.
!Cytomorphology Assessment
Bone marrow and peripheral blood samples will be prepared locally and sent to the
central laboratory for analysis to c onfirm MDS diagnosis and baseline WHO
(Appendix B ) and/or FAB classification ( Appendix C ) prior to randomization.  
If the central reviewer and local pathologist disagree on the diagnosis of a subject, a 
third reviewer at the central laboratory may be consulted to provide an adjudication assessment. The central laboratory may also request the site to send in samples 
reviewed by the local pathologist for further assessment.
!Cytogenetics Analysis
The central laboratory will conduct cytogenetic analysis throughout the study. The 
central laboratory will provide standardized analysis and reporting for all subjects. 
Bone marrow samples will be sent to the central laboratory for processing and 
cytogenetic analysis prior to randomization.
In the event that cytomorphology/cytogenetic analysis cannot be performed by the central 
laboratory prior to randomization, local cytom orphology/cytogenetic an alysis may suffice for
randomization purposes after consultation with the S ponsor. Every attempt should be made to
send bone marrow and peripheral blood samples to the central laboratory for processing and
analysis prior to the first dose of investigational product. If this does not occur, a central â€œover
CCI&(/*(1(35235,(7$5<,1)250$7,21B), bone maB), bone ma
allyally,butbutmum
llectedllected wiwti
s rescreenedescreened
d to be collto be co
c assessmenc assessm
ne marrow marrow
nt procedurnt procedu
blood blood samsa
ysis ysis to confto c
ABBclassificssifi
wer and locer and loc
the centralthe centr
The central The centr
bybythe lthe lyy ocal
enetics Anaenetics Ana
ecentralcentral lal
centralcentral lablab
Bone mBone m
cycytotoyyy
nnththe evente even
laboratoaborat
ndod
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 55 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017readâ€ of the cytomorphology/cytogenetics re port and photographs will be performed (at a later
date) by the central laboratory.
Results from central laboratory analysis should be used to d etermine baseline IPSS-R category 
(Greenberg, 2012 ; Appendix D ).  
The central laboratory will also assess bone marrow and peripheral blood samples during the 
Treatment Period of the study.
 
Refer to Section 6.11 for additional information and Table 4 for timing of sample collection 
during the study.
!Prior Transfusion History
Transfusion history must be available for at least the 16 weeks immediately preceding and 
including the date of randomization. Transfusion d ata should include the type of transfusion (eg, 
RBC, pl atelets), number of units, reason and d ate of transfusion.  
Transfusion data should also include the pretransfusion Hgb levels that triggered the RBC 
transfusions. 
These Hgb levels can be from local or centr al laboratory measure ments.  For platelet 
transfusions, data should include the platelet value for which thep latelet transfusion was 
administered. These platelet values can be from the central or a local laboratory. 
Documentation of the following criteria is required to meet protocol inclusion criteria and must 
be confirmed prior to randomization:
!Average transfusion requirement of at least 2 units of packed red blood cells (pRBCs) 
per 8 weeks during the 16 weeks immediately preceding randomization.  Only RBC 
transfusions administered due to a pre-transfusion Hgb of â‰¤ 10 g/dL will counted to 
determine eligibility.
!There must also not be any consecutive 56-day period that was RBC transfusion free 
during the 16 weeks immediately preceding randomization.
All RBC transfusion records for at least 16 weeks immediately preceding and including the date 
of randomization s hould be collected (including any transfusio ns at outside local institutions).  
Red blood cell (RBC) transfusions administered for elective surgery will not count towards 
meeting RBC transfusion inclusion cr iteria requirements, but should st ill be rec orded in the 
eCRF.  
The RBC transfusion data during the 16 weeks immediately preceding randomization will be
used to determine the baseline RBC transfusion re quirement for an individual study subject.  
Thus, this information must be collected during the Screening window (prior to randomization). 
!Prior Erythropoiesis-stimulating agent (ESA) Therapies
Type of ESA, dose, frequency, duration, best response, and reason for discontinuation should be 
collected and entered into the eCRF re gardless of date of discontinuation.  
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21lection lection 
ly precedinly precedin
e e tytype of trpe ofyyy
els that trigels that trig
mmeasuremeasure
which thewhich the
centralcentral  or orl
uiredreditto mo meee
ment of at lment of at
6 weeks im weeks i
red due to red due to
y.
o not be anynot be an
6 weeks im6 weeks im
n records frecords f
n shoulshoul d bedb
ll (RBC) tral (RBC) tr
BC transfuC transfu
RBC transRBC tran
usedsedtotodetedete
Thus, thiThus, t$7
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 56 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Eligible subjects must also be refractory or in tolerant to prior ESA treatment, or ineligible for, 
ESA treatment.  See Section 4.2for additional details .
!Demographics and Medical History
The subjectâ€™s date of birth, sex, race and ethnicity will be recorded on the appropriate eCRF.
Relevant medical history (including recent surgical history) and current med ical c onditions, 
including those symptoms related to MDS, must also be recorded on the appropriate eCRF at 
screening. 
History of MDS disease and other prior maligna ncies will also be r ecorded on th e appropriate
eCRF. This may include relevant information related to original MDS diagnosis (eg, date of 
original diagnosis, WHO and/or FAB classification at original diagnosis, prior treatments 
administered) and/or other past malignancies. 
Historic serum ferritin results from previous local laboratory reports (ie, within the 16 week 
window immediately prior to randomization date) will be also collected, if available in the 
medical records, and entered on the appropriate eCRF.
!Concomitant Medications and Procedures 
All prior/concomitant medications taken in the 5 weeks prior to randomization will be recorded 
onthe appropriate eCRF(s).
All prior/concomitant procedures within the 8 weeks prior to randomization will be recorded on 
the appropriate eCRF(s).
Prior G-CSF/GM-CSF and iron chelation ther apy should be recorded o n the appropriate eCRF(s) 
regardless of treatment discontinuation date.
Prior anti-cancer treatments should be rec orded on the appropriate eCRF(s) regardless of 
treatment discontinuation/procedure date.
Record concomitant medications/procedures on ongoing basis until 42 days post last dose of IP
or End of Treatment (EOT), whichever occurs later.  Refer to Section 8for additional details.
!Physical Examination
Information about the physical examination must be present in the subjectâ€™ssource 
documentation.  Significant findings must  be included on the appropriate eCRF.
Refer to Table 4 for timing of physical examinations during the study.
!Eastern Cooperative Oncology Group Performance Status
Performance status will be assessed by the inves tigator during Screening and at other timepoints
indicated on Table 4 using ECOG criteria provided in Appendix G .
!Electrocardiogram
Electrocardiogram (ECG) at screening is performed locally at the study site. ECG w ill be 
performed using the internationally recognized 12-leads. If available, the following ECG parameters will be recorded on the respective e CRF(s): eg, heart rate (HR), PR interval, QRS 
duration, QT, QTc. The investigator will review the results and assess as normal, abnormal - not 
clinically significant, or abnormal - clinicallysignificant, and report the abnormal finding(s) on 
CCI&(/*(1(35235,(7$5<,1)250$7,21ee
of of 
nts nts 
ththe 16 weee 16 w
vailable in vailable in
andomizatdomiza i
r to randomr to random
houlhouldb edb e rere
ded ded on the on the
.
ocedures oncedures 
hever occuhever occ
ationation
ysical examysical e
ficant findiicant findi
orrtimingtiming oo
sterntern CooCoo
nce status e status 
ed on d TablTabl
!!EE
ElectrocaElectroca
rforrfor
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 57 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017the appropriate eCRF. If the ECG is abnormal, the investigator should consult a cardiologist if
deemed appropriate.
Refer to Table 4 for timing of ECGs during the Tr eatment Period of the study.
!Urinalysis
Urinalysis to include microscopic, quantitative analysis of urine. (eg, microalbumin/albumin, 
protein, creatinine, microalbumin/creatinine ratio).  
Microscopic urinalysis will be tested by the central laboratory.  
Refer to Table 4 for timing of urinalysis sample collection during the Treatment Period of the 
study.
!Coombsâ€™ Test
A direct or indir ect Coombsâ€™ test at screening is performed at the locallaboratory if screening 
total bilirubin is â‰¥ 2.0 x ULN.  Refer to Section 4.3.  If positive, a local reticulocyte count may 
be requested.
!Assessment of HIV/Hepatitis B/Hepatitis C status 
If known, local test results confirming HIV, Hepa titis B, Hepatitis C status should not have been 
performed earlier than 4 weeks from the date of ICF signature.  If beyond this window, 
additional local testing may be requested (see Section 4.3).
!Serum Ferritin
Sample should be  collected within 5 week s prior to randomization. 
Serum ferritin analysis is to be performed by the central laboratory. 
Additional serum ferritin results from previous local la boratory assessments (ie, within the 16 
week window immediately prior to randomization date) should be collected, if available in the 
medical records, and entered into the eCRF.
Refer to Table 4 for timing of serum ferritin testing during the study.
!Serum EPO Level
During the Screening Period, the serum EPO level should be collected on the same day as a
planned RBC transfusion, prior to the transfusion or 7 days after any RBC transfusion due to 
possible reduction of the serum level related to th e hemoglobin level achieved after the last 
transfusion. 
Serum EPO analysis is to be performed by the central laboratory.  
Refer to Table 4 for timing of serum EPO leve l testing duringthe study.
!Hematology Panel
Hematology assessment (eg, red blood cell [RBC] count, complete blood count [CBC], white 
blood cell [WBC] with differential, hemoglobin, hematocrit, nucleated red blood cells [nRBC], 
absolute reticulocyte c ount, platelet count, mean corpuscular volume [MCV], mean corpuscular 
hemoglobin [MCH], mean corpuscular hemoglobin concentration [MCHC], and red blood cell 
distribution width [RDW]) will be tested by the central laboratory.  
CCIhe he
oryryiiyyf fscreescre
cululocyocyte cote coyy
is C statusis C status
e.  If beyoe.  If beyo n
o randomizo random
the centralthe central ll
vivious ous lolocalca
ndomizatdomiz ioio
e eeCRF.CRF.
erum ferriterum ferrit
velvel
Period, tPeriod hehe
usiosion, prin, pri oro
n of the sern of the ser
Oanalysis analysis
to to TableTable 44
!!H
HemHem atoato
od
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 58 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017On dosing days, local laboratory sample should be  collected and Hgb levels assessed prior to 
each IP administration to ensure dose modification rules are followed as outlined in Section 
7.2.1.1 , Table 6 .  In these circumstances, a split sample should also be collected and sent to the 
central laboratory for analysis.  
Refer to Table 4 for timing of hematology assessments during the study.  
!Serum Chemistry Panel
Serum chemistry (eg, sodium, potassium, chloride, bicarbonate [if available], calcium, 
magnesium, phosphorus, blood urea nitrogen [BUN], creatinine, creatinine clearance and/or estimated glomerular filtration rate, gluc ose, albumin, total protein, alkaline phosphatase,
direct/indirect total bilirubin, AST/SGOT or ALT/SGPT, lactate dehydrogenase [LDH], uric 
acid) will be analyzed by the central laboratory.  
Refer to Table 4 for timing of serum chemistry assessments during the study. 
!Pregnancy Testing and Counseling 
This protocol defines a FCBP as a sexually mature woman who: 1) has not undergone a 
hysterectomy or bilateral oophorectomy or 2) has not been naturallypostmenopausal
(amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24
consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
A medically supervised serum pregnancy test (condu cted at the central labor atory or locally) is to 
be obtained and verified negative in all female subjects of childbearing potential at screening.  
The investigator will appraise a female subject as a FCBP according to this definition.  Justification must be recorded in the eCRF and the source document. Pregnancy testing is not 
required for non-FCBP subjects.
Serum beta human chorionic gonadotropin ( Î²-hCG) pregnancy test (which must be negative) 
with a minimum sensitivity of 25 mIU/mL will be performed within 5 weeks prior to Dose 1 Day 
1. Urine (or serum) pregnancy test will be performed to assess subject eligibility within 72 hours 
prior to the first administration of IP, if the initial serum pregnancy test did not already occur with 72 hours of dosing (negative results required for IP administration). 
During the Treatment Period urine or serum pregnancy test is allowed. 
For males and FCBP, counseling about pregnancy precautions and the potential risks of fetal 
exposure must be conducted prior to each IP administration or monthly (eg, in the event of dose 
delays).  Refer to Section 10.4 for additional details.
Refer to Table 4 for timing of pregnancy testing and counseling during the study.
!Vital Signs, Height, and Weight
Vital signs, including height (measured at Scr eening only), weight (at Screening and on study 
drug dosing days only), seated blood pressure, temp erature, heart rate, a nd respiratory rate. 
On study drug dosing days, blood pressure must be assessed prior to each IP administration.  
Blood pressure values should be confirmed by mean of two readings obtained approximately 5 
minutes apart with the subject seated for approximately 10 minutes prior to initial reading. 
Refer to Table 4 for timing of vital signs during the study.
CCI&(/*(1(35235,(7$5<,1)250$7,21], , uriurc c 
 not undergnot unde
ypostmenopostmenop
ringgpotentient
cedingeding 2424co
atthheecentrcentr
of childbeof childbe
CBPCBP accorcc
he source de source d
n (Î²n (Î²--hCGhCG ))
mL will bemL will b
willill bblle perfoe per
f IP, if the if IP, if the 
ive results ive result
od urine ord urine or
counselingcounseling
onductedonducted p
o o SectionSection 11
lele44fofor timr tim
Vital SVital S
all signs, inc signs, incll
drug dosingdrug dosing
On studOn stu
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 59 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!Adverse Event Assessment - record on ongoing basis
Refer to Section 10.1.
!Subject Reported Outcomes or Quality of Life or Health Economics (EORTC
QLQ-C30 
Refer to Section 6.12.
!
!Randomization in Integrated Response Technology (IRT)
In addition to demographic in formation, the following information s hould be readily available 
prior to performing the ra ndomization transaction in the IRT system: 
!Baseline IPSS-R risk category ( Greenberg, 2012; Appendix D )
!Average 8-week baseline RBC transfusion requirement.
The first dose of IP should be administered after, but within 3 days of rando mization and can be 
on the same day as randomization.  Refer to the IRT manual for additional information on randomization u tilizing IRT.
!Monitoring for Progression to AML and Other Malignancies/Pre-malignancies
Progression to AML as per WHO classification (V ardiman, 2009) will be monitored and will be 
included as part of the safety assessment throughout the course of the study.  Progression to 
AML should be monitored from time of signing of informed consent through at least 3 years 
after last dose of IP or until death, lost to fo llow-up or withdrawal of consent from the study. 
The occurrence of a new malignancy or pre-malignant lesion will be monitored as an event of 
interest and should be included as part of the assessment of adverse events throughout the course 
of the study (please refer to Section 10.5 for details). Investigators are to report the development 
of any new malignancy or pre-malignant lesion as a serious adverse event, regardless of causal 
relationship to IP (study drug[s] or control), occurring at any time for the duration of the study, 
from the time of signing the ICF for up to and including at least 3 years of long-term follow-up, 
or until death, lost to follow-up, or with drawal of consent for further data collection.
Documentation supporting the diagnosis of progr ession to AML and other malignancies/pre-
malignancies (eg, confirmatory histology or cyto logy results, etc.) may be requested.  
Appropriate information rel ated diagnosis of AML and other malignancies/pre-malignancies 
should be captured on the eCRF and in the subjectâ€™s source documents.  
Refer to Section 10.5 and Section 10.6 for more information regarding reporting requirements.  
6.2. Treatment Period
The subject will begin treatment upon confirmation of eligibility. The subject must start 
treatment within 5 weeks of signing the informed consent form (ICF).  If screening assessments 
are performed within 72 hours of Cycle 1 Day 1 (C1D1), safety laboratory and physical 
examinations need not be repeated at C1D1 with the exception of blood pressure measurement, hematology, serum ferritin, and serum EPO sample collection.  
CCICCI
CCI
&(/*(1(35235,(7$5<,1)250$7,21y available y available
of randorando mizmiz
dditional inditional in
herrMalignMalig
iman, 2009iman, 2009
ut the coursut the cour
of informeof informe
owow--up or wup or w
prepre--mamalignaligna
off the asse the asseff
10.510.5 fofor derd
aalignant leslignant le
[s] or [s] or concontrtrnnn
e ICF for uICF for u
lowlow-up, or p, o
porting the orting the
, confirmat, confirmat
nformatforma ioionn
aptured onaptured on
o o SectionSection 11
.2..2. T
The subThe sub
tm
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 60 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017If subject completed the Screening EORTC QLQ-C30  questionnaires within 2 
weeks of C1D1, it does not have to be repeated at C1D1. If performed on C1D1, both EORTC
QLQ-C30  questionnaires should be completed by the subject prior to IP 
administration.
On dosing days, local laboratory hgb levels should be assessed prior to each IP administration to 
ensure dose modification rules are followed as outlined in Section 7.  In these circumstances, a 
split sample should also be collected and sent to the central laboratory for analysis.  Subjects 
should also have blood pressure assessed (as detailed in Section 6.1) and the clinical site should 
confirm with the subject if any transfusions were received at outside local centers in between 
study visits, prior to each IP administration.
6.2.1. Primary Phase of the Treatment Period: Weeks 1-24
Subjects will receive IP (either luspatercept or matching placebo) on Day 1 of each 21-day 
treatment cycle.
Treatment cycles are 21 days in duration, and will occur as described in Section 7.2.
The following procedures/evaluations will be performed at the frequency specified in the Table 
of Events ( Table 4 ) during the Primary Phase of the Treatment Period. The 
procedures/evaluations should be performed prior to dosing on the visit day, unless otherwise 
specified:  
!IP administration and accountability
!Eastern Cooperative Oncology Group Performance Status (as detailed in Section 6.1)
!Pregnancy Testing and Counselin g (as detailed in Section 6.1)
!PK and ADA sample collectio n (as detailed in Section 6.4and Section 6.5)
!ECG (as detailed in Section 6.1)
!Physical Examination (as detailed in Section 6.1)
!Vital Signs (as detailed in Section 6.1)
!Hematology Panel (as detailed in Section 6.1)
!Serum Chemistry Panel (as detailed in Section 6.1)
!Urinalysis (as detailed in Section 6.1)
!Serum EPO Level (as detailed in Section 6.1)
!Serum Ferritin (as detailed in Section 6.1)
!Transfusion Data Collection and Assessment
During the study, the following will be recorded for all transfusions (including any transfusions 
received at outside institutions in between study visits) the subject received within 16 weeks 
prior to randomization, until 16 weeks after th e last dose of IP or the End of Treatment (EOT) 
visit, whichever occurs later:
âˆ€type of transfusio n (eg, pRBC or platelet)
CCICCI
CCI
&(/*(1(35235,(7$5<,1)250$7,21d d 
n 
ach 21ach 21 --dayd
Sectectioion n7.2
uency specincy speci
riod. The od. The
n the visit dn the vis
Perforerfor mamancenc
(as detailed(as detaile
n (as detailen (as detaile
n 6.16.1))
(as detailed(as detail
tailedtailed in in SeSe
anelanel (as de(asll
hemistryemistry PaPyy
alysis (as dealysis (as d
erumerum  EPOEPOmm
SerumSerumm
!!TraTra
During theDuring the
eceiveeceive
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 61 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017âˆ€number of units
âˆ€reason for transfusion 
âˆ€date of transfusion
âˆ€hemoglobin value for which any RBC trans fusion is given (ie, pretransfusion hgb)
âˆ€platelet v alue for which any p latelet transfusion is given
!Clinical site staff should confirm if any transfusions were received by the subject 
(including any at outside local institutions  in between study visits) prior to each IP 
administration via use of patient diary or other local procedure in place at the investigational site.
!Adverse Event Assessment to be assessed on an ongoing basis. Refer to Section 10.1.
!Monitoring for Progression to AML and other malignancies/pre-malignancies on an 
ongoing basis.  Refer to Section 6.1.
!Concomitant Medications and Procedures - record on ongoing basis. Refer to 
Section 8.  
!Subject Reported Outcomes or Quality of Life (EORTC QLQ-C30 ). (as 
detailed in Section 6.12)
!
6.2.2. MDS Disease Assessment: Week 25 Visit
Assessment of Transfusions, Bone Marrow, and Peripheral BloodThe MDS Disease Assessment consists of the investigatorâ€™s assessment of clinical benefit from 
study drug and status of underlying disease.
The first MDS Disease Assessment should be completed 24 calendar weeks after the date of 
first dose, regardless of dose delays. The calculated due date for the first MDS Disease 
Assessment is defined as C1D1 + 168 days (ie,  24 weeks). The MDS Disease Assessment by the 
investigator should be completed no sooner than 24 calendar weeks (ie, 168 days) after the day
of C1D1 and requires a minimum of 24-weeks of transfusion information for the assessment of 
clinical benefit.  Up to date information related to all transfusions received during the Treatment Period (including those received at outside institutions) must be available prior to completion of
the clinical benefit component of the MDS Disease Assessment.
As central laboratory results from bone marrow and peripheral blood samples (eg, 
cytomorphology, cytogenetics analy sis) are required as part of the MDS Disease Assessment, a 
14-day window is allowed for the Week 25 Visit in order to account for sample co llection and 
turnaround time of results.  
In order for subjects to remain on double-blind treatment beyond the first 24 calendar weeks, the 
following criteria must be confirmed upon the completion of the MDS Disease Assessment by 
the investigator:
CCICCI
CCI
&(/*(1(35235,(7$VisitVisit
and Peripand Perip
f the investithe investi
ease.ase.
tshoulshoul d bed b
aysays. The caThe c
D1 +D1 + 168 d168 d
mpleted no leted no 
minimum minimum
to date infoo date inf
those receithose rece
nefit coefit co mpomp
laboratoryaboratory
rpholrphol ogyogy$5<,1)250$7,21P P 
o Section Section 1
aalignancieignancie
ing basis.ing basis. R
RTCTCQLQQ
,,
ayaywindowwindowyy
rnaround trnaround t
In order n orde
lo7$5
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 62 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!Evidence of clinical benefit (eg, decrease in RBC transfusion requirement compared to 
baseline requirement or hemoglobin increase compared to baseline)
AND
!Absence of disease progression per IWG criteria for altering natural history of MDS 
(Cheson, 2006 ; Appendix E ).
Based on the outcome of the MDS Disease Assessment, subjects will either be discontinued from 
treatment with IP and enter the Posttreatment Follow-up Pe riod or continue double-blind 
treatment with IP in the Extension Phase of the Treatment Period. 
For subjects that meet criteria to continue double-blind treatment in the Extension Phase, the 
duration between the last dose of IP in the Primary Phase and first Extension Phase dose should not be delayed beyond 21 days solely due to awaiting cytomorphology/cytogenetics results 
contingent that the investigator has confirmed  absence of signs of disease progression based on 
review of peripheral blood parameters.  
In circumstances where the subject does receive the first Extension Phase dose prior to 
cytomorphology/cytogenetics resu lts being available, the investigator must complete assessment 
of cytomorphology/cytogenetics results prior to the next IP administr ation.
A bone marrow biopsy is to be collected only when adequate aspirate is not attainable. Whenever 
a bone marrow sample is collected, a peripheral blood smear is to be prepared.  Refer to the
Central Laboratory Manual for additional information.
The following procedures/evaluations will also be performed at the Week 25 Visit:
!
!Subject Reported Outcomes or Quality of Life (EORTC QLQ30 ) (as detailed 
in Section 6.12)
!
!Transfusion Data Collection and Assessment (as detailed in Section 6.1)
!Adverse Event Assessment - record on ongoing basis. Refer to Section 10.1.
!Monitoring for Progression to AML and other malignancies/pre-malignancies on an 
ongoing basis.  Refer to Section 10.5.
!Concomitant Medications and Procedures - rec ord on ongoing basis.  Refer to Section 8.
!Eastern Cooperative Oncology Group Performan ce Status (as detailed in Section 6.1)
!Pregnancy Testing and Counseli ng (as detailed in Section 6.1)
!PK and ADA Samp le Co llection (a s detailed in Section 6.4and Section 6.5)
CCICCI
CCI
CCI
&(/*(1(oon Data Con Data Co
rse Event Ase Event A
Moninitoritoriiing ng
ongoing bongoing 
!!ConcCon
!E( 35235,(7$5<,1)250$7,21m m 
ase, the e, the 
dose shoudose shou
etietics resulcs resul tstl
ogressiogres on bn b
hase dose prhase dose p
tor must cotor must c
nistration.nistration.
e aspirate ie aspirate i
mear is to beear is to b
performedperforme
tcomes or Qtcomes or Q5,35,23552
1(3
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 63 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!Physical Examination (as detailed in Section 6.1)
!Vital Signs (as detailed in Section 6.1)
!Hematology Panel (as detailed in Section 6.1)
!Serum Chemistry Panel (as detailed in Section 6.1)
!Urinalysis (as detailed in Section 6.1)
!Serum EPO Level (as detailed in Section 6.1)
!Serum Ferritin (as detailed in Section 6.1)
6.2.3. Extension Phase of the Treatment Period:  After Week 25 Visit
Subjects who meet criteria to remain on double-blind treatment after completion of the Week 25 
Visit MDS Disease Assessment may continue dosing on Day 1 of each 21-day treatment cy cle in 
the Extension Phase of Treatment Period until the subject experiences unacceptable toxicities, 
disease progression per IWG criteria for altering natural history of MDS ( Cheson, 2006 ; 
Appendix E ), withdrawsconsent, or meets any other discontinuation criteria (Section 11).
Bone marrow aspirate and peripheral blood s amples will be collected  (eg, cytomorphology, 
cytogenetics analysis) and the MDS Disease Assessm ent will be repeated by the investigator at 
Extension Cycle 8, Day 1 and Day 1 of every eighth Extension Cycle thereafter (ie, Extension 
Cycle 8, 16, 24+, etc. or approximately every 24 weeks in the event of dose delays) until the 
subject is discontinued from treatment.  
A bone marrow biopsy is to be collected only when  adequate aspirate is not attainable. Whenever 
a bone marrow sample is collected, a peripheral blood smear is to be prepared.  Refer to the
Central Laboratory Manual for additional information.
In addition, information related to all tran sfusions received during the Treatment Period 
(including those received at outside institutions) should be available prior to completion of each 
MDS Disease Assessment. Clinical site staff should conti nue to confirm if any transfusions were 
received by the subject (including any at outside lo cal institutions in between study visits) prior 
to each IP administration via use of patient diary or other local procedure in place at the 
investigational site.
For subjects to continue double-blind treatment in the Extension Phase of the Treatment Period, 
each MDS Disease Assessment (criteria detailed in Section 6.2.2 ) should confirm continued 
clinical benefit and absence of disease progression per IWG criteria for altering natural history of 
MDS ( Cheson, 2006 ; Appendix E ).
Additional procedures/assessments as outlined in Section 6.2.1 will also continue in the 
Extension Phase.  The frequency of procedures/a ssessments in the Extension Phase may differ 
than the Primary Phase.  Refer to Table 4 for additional information related to required 
assessments/procedures and frequency in the Extension Phase.  
6.3. Dose Delays
On days when subjects return to the investigat ional site for IP administration, but IP is not 
administered (eg, due to protocol  dose modification, delay rules (S ection 7.2.1 ), all required 
CCIof the Weethe Weeff
ytreatmtreatm enten
ceptable toceptable to
(Cheson, 2Cheso
ririteria (teria (i SecSe
cted (eg, cyed (eg, cy
be repeatedbe repea
ion Cycle on Cycle 
in the eventthe eve
en adequaten adequa
al blood smal blood sm
formatioformatio nn
ansfusionsfusio nsn
institutionsnstitutio
al site staffal site sta
ing any at oing any at
a use of paa use of p
nue doubleue doubl
e AssessmAssessm
and absenand abse
onon, 2006, 2006 ;;AA
nal pnal p roceduroced
nsionsion Phasn Phas
an the Priman the Prim
assessmenssessmen
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 64 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017assessments and procedures should be performed, reg ardless if IP is administered. During the 
time period of dose delay, the following assessments/procedures should be pe rformed:
!If dose delay is due to a laboratory or vital signs abnorm ality, the assessment that was the 
reason for the dose delay should be repeated at least on weekly basis.
!If dose delay is due to increased hemoglobin  level, perform hematology at least weekly.
!If dose delay is due to an AE, perform hematology, serum chemistry, and serum ferritin 
at least every 3 weeks thereafter and before next dose administration. 
!Pharmacokinetic (PK)/ADA samples should be collected on first day of dose delay and 
prior to IP administration on day dosing resumes.
!For males and FCBP, pregnancy counseling as detailed in Section 6.1.
Refer to the eCRF completion guidelines for detailed instructions related to eCRF data entry.
6.4. Pharmacokinetics
Blood samples will be collected to analyze luspatercept concentrations in serum in all subjects.  
At each PK time point, approximately 3 mL of blood will be collected and serum prepared as 
described in the study reference guide. Blood samp les for PK will be taken at the following visits 
during the study (also see Table 4 ): 
!Primary Phase of Treatment Period: C1D1 (must be collected before the first dose), 
C1D8, C1D15, C2D1, C4D1, C5D8 and then Day 1 of every other treatment cycle thereafter in the Primary Phase (ie, C6D1 and C8D1, if no dose delays)
!Week 25 Visit (Collect sample only if > 14 days from prior sample collection.)
!Extension Phase of Treatment Period (if applicable): Extension Phase Cycle 4, Day 1 and 
Day 1 of every fourth Extension Phase treatment cycle thereafter (eg, Extension Phase Cycles 4, 8, etc.) for up to one year from the first dose in the Primary Tr eatment Phase. 
!Posttreatment Follow-up: For subjects who do not complete Primary Treatment Phase or 
do not participate in Extension Phase or subjects who terminate the Extension Phase with 
less than 1-year ADA of moni toring, PK samples will be collected at EOT and then every 
12 weeks for up to one year from the first dose in the Primary Treatment Phase.
After the study is unblinded, PK samples may no longer be collected from subjects in the 
placebo arm. In addition, upon unblinding of the study, PK sampling at all Post-Treatment Follow-up visits may continue only if subjectsâ€™ last available ADA is positive and they have not 
reached the maximum of 1-year ADA monitoring. Pharmacokinetic (PK) sampling per 
investigatorâ€™s or sponsorâ€™s discretion is allowed and should be recorded as an unscheduled visit.  
Detailed procedures of PK sample collection, processing, and shipping are provided in the study 
reference guide.
6.5. Anti-Drug Antibody (ADA)
Blood samples will be collected for assessment of anti-drug anti bodies (ADA) against 
luspatercept in serum in all subjects.  The maximum ADA monitoring period will be 1 year from 
CCI&(/*(1(35235,(7$5<,1)250$7,21and nd 
RF data RF data ene
ns in serums in serum
cted and seted and s
ill be takenill be
t be collectt be collec
Day 1 of eDay 1 of e
and C8D1and C8D1
>14 day14 day ss
odod(if (if applapp
n Phase Phase tretre
ne ye year ar fromfr
p: For subjep: For subje
ExtensioExtensio n P
DA DA ofofmo
p to one yp to one y ee
unblinded, nblinded, 
additaddit ioion, un, u
isits mayisits may cocoyy
e maximummaximum
gatorâ€™s or gatorâ€™s or 
etailed procailed proc
reference geference g
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 65 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017the first dose of the Primary Treatment Phase unless justified by safety reasons.  At each ADA 
time point, approximately 3 mL blood will be collected and serum prepared as described in the 
study reference guide. However, during the firs t year of treatment, an additional blood draw is 
not needed for the ADA test, as the ADA test will be conducted utilizing the PK samples obtained at the same visit.  Blood samples for ADA will be taken at the following visits during 
the study (also see Table 4 ): 
!Primary Phase of Treatment Period: C1D1 (must be collected before the first dose), 
C2D1, and then Day 1 of every other treatment cycle thereafter in the Primary Phase (ie, C4D1, C6D1, and C8D1 if no dose delays).
!Week 25 Visit (Collect sample only if > 14 days from prior sample collection)
!Extension Phase of Treatment Period (if applicable): Extension Phase Cycle 4, Day 1 and 
Day 1 of every fourth Extension Phase treatment cycle thereafter (eg, Extension Phase Cycles 4, 8, 12, 16+, etc.) for up to 1 year from the first dose in the Primary Treatment 
Phase.
!Post-treatment Follow-up: For subjects who do not complete the Pr imary Treatment 
Phase or do not participate in the Ex tension Phase or subjects who terminate the 
Extension Phase with less than 1-year  of ADA monitoring, ADA samples will be 
collected at EOT and then every 12 weeks for up to one year from the first dose in the 
Primary Treatment Phase.
After the study is unblinded, ADA samples may no longer be collected from subjects in the 
placebo arm. In addition, upon unblinding of the study, ADA sampling at all Post-Treatment 
Follow-up visits may continue only if the s ubjectâ€™s last available ADA sample is positive and the 
subject has not reached the maximum of  1-year ADA monitoring.  Antidrug anti bodies (ADA)
sampling per investigatorâ€™s or sponsorâ€™s discretion is allowed and should be recorded as an 
unscheduled visit.
Detailed procedures of ADA sample co llection, processing, and shipping are provided in the 
study reference guide.
6.6. Unscheduled Visits
Should it become necessary to repeat an evaluat ion (eg, laboratory tests or vital signs), the results 
of the repeat evaluation should be entered as an additional unscheduled visit in the eCRF.  
Refer to the eCRF completion guidelines for detailed instructions related to eCRF data entry.
6.7. End of Treatment Visit
An end of treatment (EOT) evaluation will be performed for subjects who are withdrawn from 
treatment for any reason as soon as possible af ter the decision to permanently discontinue 
treatment has been made. Evaluations will be performed as specified in the Table 4 .
If a subject is discontinued during a regular scheduled visit, all EOT procedures should be 
completed at that visit. If a procedure had been performed within 7 days of the EOT visit, it does 
not need to be repeated unless clinically indicated pe r investigator discretion (with the exception 
of blood pressure assessment and sample co llection for h ematology, chemistry, and urinalysis).  
CCI&(/*(1(35235,(7$5<,1)250$7,21e, e, 
e 4e 4, Day, Day  11yy
tensiotensio n nPhaPh
imary Treaimary Trea
he ePrimary Primary
tswho termwho te
ngg, ADA sa, ADA sa
ne yne year fear frorfff
nger be colnger be col
tudyudy, ADAADA
â€™sslast avalast ava
ar ar ADA moADA m
scretion is scretion is
e cocollectllectioio
VisitsVisits
ssaryssary  to repto repyy
ioon shouldn should
RF coRF co mpmplel
End of TEnd of 
d d ofof treatm treatff
atmtment fent fororfff
treatmreatm ent hent h
a suas u
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 66 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Bone marrow procedure should only be performed at EOT visit if > 90 days from prior bone 
marrow procedure.  End of Treatment (EOT) Visit procedures/assessments may occur at 42 Day 
Follow-up assessment if subject is discontinued within +/- 7 days of 42 Day Follow-up 
assessment.
The reason for discontinuation will be recorded in the eCRF and in the source document for all 
randomized subjects, regardless of whether they are dosed or not. Reasons for treatment 
discontinuation are provided in Section 11.1.
6.8. Posttreatment Follow-up Period 
6.8.1. Safety Follow-up
All subjects discontinued from protocol-prescribed therapy for any reason will be followed for a 
period of 42 days after the last dose of IP for AE reporting, as well as SAEs made known to the 
Investigator at any time thereafter that ar e suspected of being related to IP.
Females of childbearing potential should avoid becoming pregnant for 12 weeks after the last 
dose of IP and male subjects should avoid fathering a child for 12 weeks after the last dose of IP. 
Refer to Section 10for additional details.
6.8.2. Long-Term Follow-up
Transfusion data collection will continue up until 16 weeks from the date of last dose of IP or 16 
weeks after the End of Treatment Visit (whichever is later).  
For subjects who do not complete the Primary Treatment Phase or do not participate in the 
Extension Phase or subjects who terminate the Extension Phase with less than 1-year of ADA monitoring, ADA and PK samples will be collected at EOT and then every 12 weeks for up to 
one year from the first dose in the Primary Treatment Phase (please refer to Section 6.4and 
Section 6.5).
All subjects discontinued from protocol-prescribed therapy for any reason should be followed for 
progression to AML, other malignancies/pre-malignancies, survival and subsequent MDS 
therapies.
Subjects who discontinue from treatment for any reason will be followed via telephone contact 
by the site for collection of data on survival, cause(s) of death, progression to AML, other 
malignancies/pre-malignancies (please refer to Section 10.5 for details), post-treatment therapy 
(ies) for MDS at the 42-Day and 12-Week Follow-up assessments and then every 3 months after 
the 12 Week Follow-up assessment for at least 3 years after last dose of IP or until death, lost to 
follow-up or withdrawal of consent from the study. Refer to Table of Events, Section 5, Table 4 .
Data regarding subsequent MDS therapies,  determination of AML progression and other 
malignancies/pre-malignancies, (refer to Section 6.1and Section 10.5 for additional details), and 
date and cause of death will be recorded in the eCRF.  The investigator must make every effort 
to obtain information regarding the subjectâ€™s survival status before determining the subject is lost 
to follow-up. If the subject is discontinued from Long-Term Follow-up, the reason for 
discontinuation should be recorded on the End of Study eCRF.
CCIoollollowedwed fof
de known tde know
2 weeks afweek
eks after theks after th
ks from theks from the
ater).  ater).  
atmatment Phaent Pha
ExtensioExtensio n n
ollected at Ellected at 
yyTreatmenTreatmenyy
otocolotoco -prescpres
ignancies/pgnancies/p
e e frofm mtreatr
oon of data n of dat
mamalignancilignanci
t the 42t the 42 -DaD
FoFollollow-w-upup
p or wir withthiiidradra
regarregar ding sding
alignanciesalignancies
date and cdate and c
o obtaio obta
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 67 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Long-term follow-up may be conducted by record review (including public records if allowed by 
local regulations) and/or telephone contact with the subject, family, or the subjectâ€™s treating 
physician.
6.9. Efficacy Assessments
Treatment response will be assessed locally by the investigator in accordance with IWG 2006 
criteria for MDS ( Cheson, 2006 ; Appendix E ) with modifications for the erythroid response 
criteria through transfusion assessments, hemato logy laboratory parameters, peripheral bl ood 
smear, bone marrow aspirates and/or biopsies, and cytogenetics.
Other efficacy assessments will include serum ferritin, concomitant iron chelation therapy use, 
health-r elated qu ality of life, .  
Efficacy data will also be reviewed by an external unblinded DMC and/or external blinded 
Steering Committee as specified time points detailed in each committeesâ€™ respective charters.  
Bone marrow aspirate (or biops y, if adequate aspirate is not attainable) samples for assessing 
treatment response will be collected at the fre quency specified in the Table of Events, S ection 5, 
Table 4 .  Whenever a bone marrow sample is collected, a stained peripheral blood smear is to be 
prepared.
Cytogenetic testing is to be completed whenever a bone marrow aspirate is obtained for 
assessment of cytogenetic response in accordance with IWG 2006 criteria for MDS ( Cheson,
2006 ; Appendix E ).  Bone marrow biopsy can be used for cytogenetics testing if adequate 
aspirate is not attainable (note that specific handling of the biopsy is required for cytogenetics 
testing).
6.10. Safety Assessments
The safety measures assessed are routinely used in clinical studies evaluating the safety of investigational product for hematologic malignan cies. Safety assessments, including (but not 
limited to) physical examination, vital signs, ECG, urinalysis, hematology, serum chemistry, 
pregnancy testing (for FCBP subjects only), AEs, concomitant medications and procedures, and 
transfusion data collection and assessment, will be performed at the frequency specified in Table 4 or more frequently if clinically indicated.
 
 
 
 
 
 
 
  
. 
CCICCI
CCIpypuse, use, 
alal blinded  blinded ll
pectpective chae cha
mples for amples for a
able of Eveable of Ev
eripheral blpheral bl
row aspiratrow aspira
WG 2006 crWG 2006 cr
for cytogenfor cytogen
g of the biop of the bi
nelyelyusedused ini
ogicgicmamalignlig
vital signsvital sign
subjeubjects onlcts on
and assessmnd assess
lylyif clinicclin
(1(*(1*(/*((/*&(/&(&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 68 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017 
 
 
 
 
 
.
6.12. Subject Reported Outcomes or Quality of Life Measurements
The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire 
(EORTC QLQ-C30) ( Aaronson, 1993; Appendix F ) is a valid ated health -related qu ality of life
(HRQoL) measure applicable to subjects with any cancer diagnosis. It is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social 
and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher 
scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. The EORTC QLQ-C30 is available in many languages. This 
instrument takes 10 to 15 minutes to administer. 
  
 
 
  All eligible subjects will complete the EORTC QLQ-C30  at the frequency 
noted in the Table of Events, Section 5, Table 4.
For the C1D1 visit, if the subject completed the Screening Visit EORTC QLQ-C30  
questionnaires within 14 days prior to C1D1, they do not have to be repeated at C1D1. If 
performed on C1D1, both EORTC QLQ-C30  que stionnaires should be completed by 
the subject prior to IP administration.
It is important that every subject comple te all of the EORTC QLQ-C30 assessments 
at every specified time point to minimize the amount of missing data.
CCICCI
CCI
CCI
CCI
CCI
CCI&(/*(1Table of Evble of Ev
1D1 visitD1 visit
onnaires wionnaires wi
formormed on ed on 
hhe subjecte subject
titis imps im5235,(7$5<,1)250$7,21.
ity of Lifety of Life
eentnt of Can of C
FF) i) is a valis a va
any cancer ny cancer
ysicaysica l lfunctfunct
res are tranres are tran
better funcbetter func
ORTC QLQRTC QL
s to admins to admin0$7
25)25,1)
5<
1ligible subjigible subj35235(3 5(31(
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 69 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017 
 
 
 
 
 
.
6.14. Screen Failures 
For all subjects determined as screen failures the following information is to be captured in the 
subjectâ€™s source documents and eCRF page(s): the date informed consent form (ICF) was signed, demographics, the reason subject did not qualify for the study, and the inve stigatorâ€™s signature 
for the eCRF pages. The adverse events experienced by screen failure subjects will be collected 
from the date of signing consent to the day the sub ject is confirmed as a screen failure. Relevant 
information will also be recorded on the Screening Log.
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21s to be capto be 
sent form (Isent form (
the tinvestinves i
failure subjfailure subj
firmed as irmed as a$7$7
50$250
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 70 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20177. DESCRIPTION OF STUDY TREATMENTS
7.1. Description of Investigational Products
Luspatercept will be provided by the Sponsor. Luspatercept for injection is formulated as a 
sterile, preservative-free, lyophilized cake/powde r.  Luspatercept for injection is available in 2 
fill sizes, and when reconstituted, each consists of 50 mg/mL luspatercept in a 10 mM citrate 
buffer-based solution (10 mM citrate, pH 6.5, 9% sucrose, 0.02% polysorbate 80).  The drug 
product is packaged in a 3 mL glass vial in the following f ill sizes:  
!25 mg/vial:  The 25 mg/vial presentation contains 37.5 mg of luspatercept protein.  
After reconstitution with 0.68 mL water for injection (WFI), each single-use vial will deliver at least 0.5 mL of 50 mg/mL luspatercept (25 mg)
!75 mg/vial:  The 75 mg/vial presentati on contains 87.5 mg of luspatercept protein. 
After reconstitution with 1.6 mL WFI, each single-use vial will deliver at least 1.5 mL of 50 mg/mL luspatercept (75 mg)
The recommended storage condition for Luspatercept for Injection (25 mg/vial and 75 mg/vial; 
lyophilized powder formulation) is 2Â°C to 8Â°C. It is recommended that the reconstituted 
luspatercept for injection, at room temperature, be  administered immediately.  However, it may 
be held for up to 10 hours at 2Â°C to 8Â°C.  If not used immediately, the total in-use time of the 
reconstituted luspatercept for injection, from reconstitution to administration, must not exceed 10 
hours.
Samples of luspatercept drug product, held at the recommended storage condition, have been 
shown to be stable through the labeled shelf-life.
Placebo to be used in the study will be sterile normal saline (0.9% sodium chloride for injection) 
subcutaneous.  Sterile, normal s aline s hould be s upplied by the site. The investigational siteâ€™s 
designated individuals will prepare the placebo syringes to match the active syringes. The 
investigator and subject will be blinded. The manufacturerâ€™s directions for storage and handling are to be followed, as are standard clinical practices for ensuring sterility of the placebo.
7.2. Treatment Administration and Schedule
There will be unblinded designated site personnel at each site responsible for preparing the 
investigational product.  Luspatercept or placebo will be administered as a subcutaneous injection to subjects by the study staff at the clinical site and administration will be documented 
in the subjectâ€™s source record.  Subjects must have Hgb, blood pressure and weight assessed 
prior to each IP administration. Clinical site staff should also confirm if any transfusions were 
received by the subject (including a ny at outside local institutions in between study visits) prior 
to each IP administration via use of patient diary or other local procedure in place at the 
investigational site.
Subcutaneous injections will be given in the upper arm, thigh, and/or abdomen. Calculated doses 
requiring reconstituted volume greater than 1.2 mL should be divided into separate similar 
volume injections across separate sites using the same anatomical location but on opposite sides of the body (example left thigh and right thi gh).  The maximum volume per SC injection should 
CCI&(/*(1(35235,(7$5<,1)250$7,21ein.  ein.  
vial will vial will
ercept proteercept prote
liver at lealiver at lea
5 m5 mg/vial ag/vial amm
that the recthat the r
immediateimmediate
ately, the toately, the 
n to adminio admin
ecommendeecommend
e normale normal  sasall
ululddbe suppbe supp
e placebo sye placebo s
nded. The med. The 
rd clinical prd clinical 
Administrdminist
ed designated designat
duct.  ct.  LuspaLusp
ects byects by  the theyy
â€™s source resource r
h IP adminh IP admin
d by the subthe suy
ch IP admich IP adm
vestigatvestigat ioion
SubcutanSubcutan
quiiii
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 71 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017not exceed 1.2 mL.  The maximum total dose pe r administration shoul d not exce ed 168 mg, 
which results in 3.36 mL maximum total volume after reconstitution.
The injection sites can be rotated according to Investigator judgment, and the injections can be 
given in the following order as needed, for example: 1) right upper arm, 2) left upper arm, 3) right upper thigh, 4) left upper thigh.
Eligible subjects will be rando mized at a 2:1 ratio to either:
!Experimental Arm: Luspatercept (ACE-536): Starting dose 1.0 mg/kg subcutaneously 
injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle).  
Luspatercept clinical drug product will be provided by the Sponsor as a lyophilized 
powder.  Luspatercept will be administered after reconstitution as a subcutaneous 
injection to subjects by the study staff at the clinical site.
OR
!Control Arm: Placebo (Volume equivalent to experimental arm) subcutaneously 
injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle).  
Placebo (normal saline) product will be provided by the local investigational site.
7.2.1. Dose Modifications: Dose Titration, Dose Reduction, and Dose Delay
7.2.1.1. Dose Titration Increase
Starting as soon as Cycle 3 Day 1 and assessed by the investigator prior to every subsequent 
treatment cycle, subjects may have the dose level increased in a stepwise manner beyond the 
starting dose of 1.0 mg/kg to 1.33 mg/kg, and up to  a maximum of 1.75 mg/kg, but the maximum 
total dose should not exceed 168 mg, during both the Primary and Extension Phases of the 
Treatment Period if all the following criteria are met:
!Subject has â‰¥ 1 RBC transfusion event (for pretransfusion Hgb of < 9.0 g/dL) during the 
2 most recent prior treatment cycles (~6-weeks).
!The two most recent prior treatment cycles assessed must be at the same dose level.
!Subject must not have met protocol dose delay and/or reduction criteria in the two most 
recent treatment cycles (exception of dose delay required due to influence of RBC transfusions).  Refer to Table 6 , footnote b .
If all criteria above are met, the dose may be increased by 1 dose level.
The dose level should be titrated individually for each subject and must not exceed 1.75 mg/kg.
Starting dose with dose increases and reducti ons are presented below for reference ( Table 5 ).
Table 5: Starting Dose Level with Dose Reductions and Dose Titration
3rdDose 
Reduction
(~25% 
reduction)2ndDose 
Reduction
(~25% 
reduction)1stDose 
Reduction
(~25% 
reduction)Starting Dose 
Level1stDose 
Titration 
Increase2ndDose 
Titration 
Increase
0.45 mg/kg 0.6 mg/kg 0.8 mg/kg 1.0 mg/kg 1.33 mg/kg 1.75 mg/kg
CCI&(33rdrdDD
RedRe&(/*(1(35235,(7$5<,1)250$7,21ly ly 
ilized ized 
aneous neous 
) subcutanesubcutane
dayytreatmtreatyy e
calcaliillnvestnvest ii
ion,on,and Dand D
investinvest igatoigato
ncreased inncreased in
p to a maxim to a maxim
both the Priboth the Pr
ria are met:ia are met:
n event even (fof
nt cycycles (~les (~
ior treatmeor treatme
ave met prove met pr
cycycles (cles (y exe
  Refer toRefer to T
ve are met,ve are met
vel should bvel should 
dose wie withthidh
lele55::
&(&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 72 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20177.2.1.2. Dose Delay and Dose Reduction 
Dose delay and/or reduction or discontinuation may be required due to increased hemoglobin or 
adverse events in either treatment arm (luspatercept or placebo). Table 6 below provides 
guidelines for dose modifications and dose delay.
Celgene or its authorized represe ntative should be notified of dose modification or interruption 
within 24 hours. Dose reduction and dose delays guidelines are detailed in Table 6 below.
Table 6: Dose Modification: Dose Delay, Dose Reduction, and Discontinuation 
Guidelines
Event at the Day of Dosing
(Assessed prior to each IP administration)Action
Any suspected related AE â‰¥ Grade 3a,d Dose delaycuntil resolved to â‰¤Grade 1 or 
baseline, and then reduce dose by 25%
â‰¥ 2 dose reductions suspected related AE aDiscontinue treatment
Î”Hgb â‰¥ 2.0 g/dL compared to pre-dose Hgb of 
previous treatment cycle Reduce dose by 25%bif Î”Hgb not influenced by 
RBC transfusions
Predose Hgb â‰¥11.5 g/dL Dose delay until Hgb â‰¤11.0 g/dL 
â‰¥ 50% increase in white blood cell count (WBC) 
compared to pre-dose WBC of previous treatment 
cycle and above upper limit of normal in the 
absence of an associated condition (eg, infection 
or concomitant corticosteroid use)Dose delay; recheck CBC, including WBC, at least 
weekly during dose delay.
Treatment may be resumed if:WBC values below upper limit of normal
ewithin 2 
weeks
If WBC remains above upper limit of normalefor 
â‰¥ 2 consecutive weeks in absence of an associated 
condition (eg, infection or concomitant 
corticosteroid use); continue dose delay and collect 
bone marrow/peripheral blood samples to assess MDS disease status. 
Treatment may be resumed if:Absence of disease progression per IWG response 
criteria for altering natural history of MDS (Cheson, 2006 )
ANDWBC values return below upper limit of normal
e
Discontinue treatmentfif: 
Disease progression per IWG response criteria for 
altering natural history of MDS ( Cheson, 2006 )
OR
WBC remain above upper limit of normale
CCI&(/*(1(35235,(7$5<y; recheckrecheck5<,1)250$7,21$$$
ade 1 or ade 1 or 
by 25%by 25%50
)2 if Î”Hgbif Î”Hgb nono1)
il Hgb l Hgb â‰¤11<,C
during doseduring do
atment mayatment m
WBC valueWBC valu
weeksweeks
If WBIf WB
â‰¥ 225<
&5
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 73 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 6: Dose Modification: Dose Delay, Dose Reduction, and Discontinuation 
Guidelines (Continued)
aPossibly, probably or definitely related to IP.
bPredose Hgb value not being influenced by RBC transfusion (ie, Hgb result > 14 days after last RBC transfusion 
or within 3 days from next RBC transfusion); Hgb should be rechecked weekly during dose delay.
cIf dose delay is > 12 consecutive weeks, treatment should be discontinued.
dIncludes systolic blood pressure â‰¥160 mmHg and diastolic blood pressure â‰¥100 mmHg.
eUpper limit of normal >10,000 total WBC/ Î¼L or as defined by institutional standards
fPeripheral blood smear should be prepared for central pathology lab assessment. 
gAt the investigatorâ€™s discretion, bone marrow samples may also be collected and analyzed centrally to assess MDS 
disease status (eg, cytomorphology) prior to making decision regarding treatment discontinuation.  The central 
laboratory must also confirm <5% bone marrow blasts prior to resumption of treatment. 
hThe investigator may contact the Medical Monitor prior to making decision regarding treatment discontinuation.
7.2.1.3. Overdose 
Overdose, as defined for this protocol, refers to luspatercept dosing only.  On a per dose basis, an
overdose is defined as the following amount over the protocol-specified dose of luspatercept 
assigned to a given subject, regardless of any associated adverse events or sequelae.  
Subcutaneous 10% over the protocol-specified dose
On a schedule or frequency basis, an overdose is defined as anything more frequent than the 
protocol required schedule or frequency.  Complete data about drug administration, including any overdose, regardless of whether the overdose was accidental or intentional, should be 
reported in the eCRF.  See Section 10.1 for the reporting of adverse events associated with 
overdose.Event at the Day of Dosing
(Assessed prior to each IP administration)Action
Presence of â‰¥ 1% blasts in peripheral blood 
(based on either local or central laboratory 
hematology sample)Dose interruption; immediately prepare peripheral 
blood smearf,gfor cytomorphology assessment by 
central pathology laboratory. 
!If central pathology laboratory 
cytomorphology assessment confirms â‰¥1% blasts in the peripheral blood; 
discontinue treatment
h
!If central pathology laboratory 
cytomorphology assessment determines 
< 1% peripheral blasts are present, repeat 
hematology assessment.  
-If presence of < 1% blasts in 
peripheral blood, treatment can be resumed at next scheduled dosing 
cycle.
-If presence of â‰¥ 1% blasts in 
peripheral blood; discontinue treatment
h
CCI&(/*(1(35235,(7$sion (ie, Hgbsion (ie, Hgb
ould be recheould be rech
should be dishould be d
nd diastolic bnd diastolic b
L or as definor as defin
d for central d for centra
marrow sampmarrow sam
prior to makprior to mak
% b% bone marroone marro
he Medical Me Medical 
se e
fined for thiined for thi
efined as thined as th
o a given sua given su
SubcutaneSubcutane
a schedulea schedul
protocolprotocol rerell
any oveny ov7$5<,1)250$7ms ms 
d; 
tory ry 
ment determment deter
ts are presens are prese
ment.  ment.  
ence of < 1%nce of < 1
pheral blooheral bloo
esumed at numed at n
cycle.cycle.
--If presIf pr
perp
7$$7,21$7
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 74 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20177.3. Method of Treatment Assignment
The treatment assignment (randomization) will occur at the end of the Screening Period, once all 
the required screening procedures have been completed and subject is deemed eligible to 
participate in the study based on assessment of all prot ocol inclusion and exclusion criteria.  This 
study will utilize the IRT for enrollment. 
Designated research personnel at each investigational site will be assigned password protected, 
coded identification numbers which gives them  the authorization to call into IRT to enroll 
subjects.  For drug assignment at each dose start and in the event of any dose reduction, dose 
titration site staff must contact IRT to record the new dose level and obtain the new study 
treatment assignment.
The relationship of the randomization number to the sub ject identification (ID) number will be 
described by a ra ndomizatio n algorithm. The randomization algorithm will be employed by the 
IRT system to assign a subject to a treatment based on the prespecified rules, such us double 
blind study, stratified randomization with randomization ratio active versus placebo on a 2:1; subjects will be placed into the appropriate stratum per the responses/data entered/collected for 
questions collecting stratification and based on the combination of these d ata points, the IRT will 
place the subject in the next available slot within the appropriate stratum for that subject.  TheIRT will be ut ilized to ensure an equal weight central randomization based on randomization 
method according to stratification factors defined in Section 3.1,Study Design. The 
randomization number corres ponds to a particular treatment arm within a stratum. The 
randomization number, by itself, w ill not unblind a user to the subjectâ€™s treatment. The 
randomizatio n number should be coupled with all the unblinded code information, in order the 
subject to become unblinded.
7.4. Packaging and Labeling
The IP will be labeled per local requirements.
7.4.1. Blinding
For this trial, all subjects, study site staff and Celgene Corporation representatives with the 
exception of designated individuals (eg, the pharmacist at the investigational site, the 
bioanalytical laboratory), will remain blinded to  all treatment assignments until all subjects have 
completed the study, or at the time the study is unblinded (per DMC recommendation) and the 
database is locked.
Placebo will not be supplied for luspatercept. The designated site individual (for example the 
pharmacist) at the investigational site will use a syringe (that exactly matches the syringe used 
for reconstituted luspatercept) and sterile normal saline (0.9% sodium chloride for injection) to 
prepare a matching placebo. Thus, the designated site individual at the Investigational site will be unblinded and will give Investigators and their staff luspatercept and placebo in a blinded 
manner.
Randomization, drug dispensing, dose reduction/titration, and drug discontinuation will be 
accomplished by an IRT system. Authorized site personnel must contact the IRT for 
randomization, study drug assignment at the beginning of each cycle, to register dose reductions 
CCI&(/*(1(35235,(7$5<,1)250$7,21mber will bember will b
mplomplo yed byyed by
such us dosuch us do
splacebo oplacebo o
ata entered/ata entere
hese data pse data p
stratum for ratum for
atatioion basen b
3.13.1,,StudyStudy
ent arm wint arm w
er to the suer to the su
he unblindhe unblind
ementsments .
udyudysisiyyte stafte stafii
ndividuals (ndividua
yy), will), wiyyy  rememl
y, or at the tor at the 
d.d.
nnot be suppot be sup
st) at the invat the in
onstinstuted luted li
pare a matcpare a matc
unblinded anblinded a
manner.manner
d
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 75 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017or titrations, and treatment discontinuation. Confirmation of each call w ill be sent to the 
investigational site and Celgene.
For emergency unblinding refer to Section 12.2.
If applicable, include information in this section regarding the physical aspect of blinding related 
to the packaging and labeling.
7.5. Investigational Product Accountability and Disposal 
Accountability for study drug that is administr ated during the course of the study is the 
responsibility of the Investigator or  designee.  Investigational clinical supplies must be received 
by a designated person at the clinical site and kept in a secure and temperature-controlled 
location.  The investigational site must maintain accurate records demonstrating dates and 
amounts of study drug received, to whom it was administered (subject-by-subject accounting), and accounts of any luspatercept accidentally or deliberately destroyed or returned.  Accurate 
recording of all IP administration will be made in the appropriate section of the subjectâ€™s eCRF 
and source documents.  Unless otherwise notified, all vials of study drug, both used and unused, must be saved for drug accountability.  The used v ials may be discarded, per the institutionâ€™s 
standard practice, after drug accountab ility has been comp leted by the monitor.  The Investigator 
must return all unused vials of study drug to the Sponsor at the end of the study, or the study 
drug may be destroyed at the clinical site with th e permission of the Sponsor.  For either 
scenario, the outcome must be documented on the drug accountability log.  The Sponsor will 
provide direction fo r the outcome of all unused vials.
Celgene (or designee) will review with the Inve stigator and relevant site personnel the process 
for investigational product return, disposal, and/or destruction including responsibilities for the 
site versus Celgene (or designee).
7.6. Investigational Product Compliance
Study drug will be administered as a subcutaneous injection at the clinical site by the study staff.  
Monitoring for subject compliance with the treatment regimen is therefore unnecessary.
Accurate recording of all IP administration will be made in the appropriate section of the 
subjectâ€™s eCRF and source documents.
The Investigator or designee is responsible for accounting for all IP that is administered during 
the course of the study.
CCI&(/*(1(35235,(7$5<,1)250$7,21ceived eived 
ed ed 
es and es and 
t accountint accountin
urned.  Accurned.  Acc
f the subjec the subjecff
g, both usedboth u
ded, per theed, per th
ythe mthe m onionitotiii
end of the end of
n on of fthte SpSp
ccountabilicountabili
gator and rgator and r
/or destrucor destru
ct Complct Comp
s a subcutansubcutan
nce with thnce with th
P administradminist
rcecedocumecum
designee is esignee is
studystudy .
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 76 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20178. CONCOMITANT MEDICATIONS AND PROCEDURES
Over the course of this study, additional medications may be required to manage aspects of the 
disease state of the subjects, including side e ffects from trial treatments or disease progression. 
Supportive care, including but not limited to anti-emetic medications, may be administered at the 
discretion of the Investigator. 
All prior/concomitant treatments used from 5 w eeks prior to first dose of IP until 42 days after 
the last dose of IP (or the End of Treatment (EOT) Visit, whichever occurs later) must be 
reported on the eCRF. 
All prior procedures within the 8 weeks prior to randomization will be recorded on the 
appropriate eCRF(s).
Prior G-CSF/GM-CSF and iron chelation ther apy should be recorded o n the appropriate eCRF(s) 
regardless of treatment discontinuation date.
Prior anti-cancer treatments should be r ecorded on the appropriate eCRF(s) regardless of 
treatment discontinuation/procedure date.
If a subject requires treatment with any new medications that are specifically excluded in 
Section 8.2, the subject will be discontinued from treatment and should complete the end of 
treatment visit and enter the posttreatment follow- up period of the study. The Investigator should 
consult the medical monitor regarding any questio ns about whether a new medication or dosage 
of existing medication would require the subject to discontinue from the study. 
For information regarding other drugs that may interact with IP and affect its metabolism, 
pharmacokinetics, or excretion, please see the Investigators Brochure and/or local package insert.
8.1. Permitted Concomitant Medications and Procedures
Granulocyte colony stimulating factors (ie, G-CSF, GM-CSF) are allowed only in cases of neutropenic fever or as clinically indicated per product label.
Concurrent corticosteroids used for medical conditions other than MDS is allowed provided 
subject is on a stable or decreasing dose for â‰¥ 1 week prior to randomization.
Administration of attenuated vaccines (eg, influen za vaccine) is allowed if clinically indicated,
per investigator discretion.  
8.1.1. Iron Chelation Therapy
Subjects who are using iron-chelating therapies at time of randomization should be on a stable or 
decreasing dose for at least 8 weeks.  
Concurrent treatment with iron chelation therapies during the Treatment Period is allowed at the 
discretion of the investigator and is recommended to be used per product label.
8.1.2. RBC Transfusions
Concurrent treatment for anemia with blood transfusions is allowed, at the discretion of the 
Investigator, for low hemoglobin levels, symptoms  associated with ane mia (eg, hemodynamic or 
pulmonary compromise requiring treatment) or com orbidity.
CCI&(/*(g*(1(35235,(7$5<,1)250$7,21priate riate eeCRFCR
) regardlessregardless
ecifically eifically e
should coould co mm
f the studyf the stud
whether a whether a
ontontinue inue frofr
ract wiact w thhi IP hh
vestivestigators gators
Medicationedicatio
(ie, Gie, G -CSFCS
dicated per icated pe
for medicafor medica
easing doseeasing dose
ated vaccinated vacc
etioion.  n.  
Chelation Chelation
o are usingo are using
dose for dose for 
urrent treaturrent tre
cretiretion ofon offf
8.1.2..1.2.
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 77 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017For any RBC transfusions received during the st udy, collect hemoglobin value just prior to 
transfusion.
Each subject will have a â€œpre-trans fusion hemoglobin thresholdâ€ for requiring transfusion during 
the study which will be determined based on transfusion history. Baseline pre-transfusion hemoglobin threshold will be the mean of all documented pre-transfusion hemoglobin values 
during the 16 weeks prior to Dose 1 Day 1. During treatment, if the pre-transfusion hemoglobin 
level is increased by â‰¥ 1 g/dL (at the time of a next anticipated transfusion event) compared to 
the pre-transfusion hemoglobin threshold for that subject, transfusion should be d elayed by a 
minimum of 7 days and/or the number of units transfused should be reduced by 1 or more RBC 
units. Subjects may be transfused at the Investigatorâ€™s discretion for symptoms related to anemia or other requiremen ts (eg, infection).
8.2. Prohibited Concomitant Medications and Procedures
Best supportive care for this study specifically excludes cancer surgery, immunotherapy, 
biologic therapy, radiotherapy, and systemic chemotherapy where the goal is to eradicate or slow the progression of the disease.
The following concomitant medications are specifically excluded during the course of the study:
!Cytotoxic, chemotherapeutic, targeted or investigational agents/therapies
!Azacitidine, decitab ine or other hypomethylating agents
!Lenalidomide, thalidomide and ot her immunomodulating drugs (IMiDs)
!Erythropoietin s timulating agents (ESAs) and other RBC hematopoietic growth factors 
(eg, Interleukin-3).
!Granulocyte colony stimulating factors (ie, G-CSF, GM-CSF), except in cases of 
neutropenic fever in cases of neutropenic fever or as clinically indicated per product label.
!Hydroxyurea
!Androgens, unless to treat hypogonadism
!Oral retinoids (topical retinoids are permitted)
!Arsenic trioxide
!Interferon
8.3. Required Concomitant Medications and Procedures
Not applicable.
CCI&(/*(1(35235,(7$5<,1)250$7,21RBC BC 
o anemia anemia 
munotherapmunothera
alliills to erads to 
during the during the
nal agents/thal agents
agentsagents
modulatmodulat ing
and otherand other
ctors (ie, Gctors (ie, G
eutropenitropeni cc
to treat hyo treat hy py
topical rettopical ret i
oxidexide
ronon
RequirRequi
applicable.applicable
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 78 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20179. STATISTICAL CONSIDERATIONS
9.1. Overview
This is a Phase 3, double-blind, randomized, placeb o-controlled, multicenter study to determine 
the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to 
very low, low, or intermediate MDS with ring sideroblasts who require RBC transfusions. 
The design of the study, including the proposed targeted subject population, study endpoints, and 
statistical plan, is discussed below.
9.2. Study Population Definitions
Study populations to be analyzed are defined as follow: 
Intent-to-treat (ITT): The intent-to-treat (ITT) population will consist of all randomized 
subjects regardless of whether or not the subject received IP. 
Safety: The Safety Population w ill consist of all subjects who were randomized and received at 
least one dose of IP.  Subjects will be included in the treatment group corresponding to the IP they actually received.
Statistical methods to handle missing data will be described in the statist ical analysis plan (SAP).
The SAP will describe any predefined rules for including/excluding any subjects with data from any analyses (eg, time windows, visit by visit analysis, endpoint analysis, protocol violation).
9.3. Sample Size and Power Considerations
A total sample size of 210 (140 in experimental arm [luspatercept (ACE-536)], 70 in control arm [placebo]) will have 90% power to detect the difference between a response rate of 0.30 in the experimental arm (luspatercept [ACE-536]) and a response rate of 0.10 in the control arm 
(placebo).  The sample size calculation is based on one-sided alpha of 0.025, test statistics on 
difference of proportions using pooled estimate of variance and 10% dropout rate. 
9.4. Randomization and Stratification
A 2:1 rando mization w ill be used as this is an orphan disease with a limited number of subjects 
available. Subjects will be randomized to receive luspatercept or placebo at a 2:1 ratio. A 2:1 randomization sch eme would enrich the number of participants exposed to the active treatment 
group ( Dumville, 2006 ). 
Subjects will be randomized to receive luspatercept or placebo at a 2:1 ratio. Randomization will 
be accomplished by an IRT to ensure timely registration and randomization. A stratified 
randomization schedule will be implemented. Randomization w ill be stratified by baseline RBC 
transfusion burden and baseline IPSS-R risk category ( Greenberg, 2012; Appendix D ). 
Stratification will be based on the following factors:
!RBC transfusion burden at baseline
âˆ€â‰¥ 6 RBC units/8 weeks (mean of the two consecutive 8 weeks periods 
immediately prior to randomization)
CCI&(/*(1(35235,(7$5<,1)250$7,21and nd 
randoran mizemize
ndomized ndomized 
up correspoup corres
in the in the statiati
/excludingexcluding
, endpo, endpo intint
derationsderations
ntal arm [ntal arm [ lulu
t the differethe differe
536])536]) and aand
ioon nis bases bas
pooled estpooled est imim
on and Son and S
will be usedill be used
will be randll be ran
cheme woucheme wou
ille, 2006le, 2006 ))
will be randll be rand
ompmplished shed 
dodomizatmizat ioionn
ransfusioransfusio nn
Stratifictratifi
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 79 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017âˆ€< 6 RBC units/8 weeks (mean of the two consecutive 8 weeks periods 
immediately prior to randomization)
!IPSS-R at baseline 
âˆ€Very low, low
âˆ€Intermediate
9.5. Background and Demographic Characteristics
Subjectsâ€™ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency tabulations by dose cohort.  Prior transfusion hi story will be summarized.  Medical history data 
will be summarized using frequency tabulations by the Medical Dictionary for Regulatory 
Activities (MedDRA) system organ class and preferred term.  Myelodysplastic syndrome (MDS)
diagnoses as well as RBC transfusion dependence will be summarized using frequency 
tabulations.
9.6. Subject Disposition
Subject disposition (analysis population allo cation, entered, discontinued, along with pr imary 
reason for discontinuation) will be summarized using frequency and percent for both treatment 
and follow-up phases.  A summary of subjects enrolled by site will be provided. Protocol 
deviations will be summarized using frequency tabulations.
9.7. Efficacy Analysis
9.7.1. Primary Efficacy Analysis
The primary efficacy analysis will be the comparison of the response rates in the two treatment 
arms in ITT population. The primary efficacy endpoint of transfusion independent response is 
defined as the absence of any RBC transfusion during any consecutive 56 day period during the 
Primary Phase of the Treatment Period (first 24 weeks of double-blind treatment) ie, days 1 to 56, days 2 to 57, days 3 to 58, etc.
Subjects discontinued from the Primary Phase of the Treatment Period without achieving at least 
56 days consecutive of RBC transfusion independence will be counted as non-responders. 
For the primary efficacy endpoint, 56-day RBC tran sfusion independence, the response rate will 
be calculated using the number of responders divided by number of subjects in the ITT 
population (responders pl us non-responders). The response rates of the subjects who were 
randomized to luspatercept and the placebo will be calculated. In the primary efficacy analysis, 
the statist ical hypothesis is
2 12 1 0
::
PPHPPH
a #âˆƒ
where1Pdenotes the true response rate in the luspatercept group, and 2Pdenotes the true 
response rate in the placebo group. The number and percentage of subjects in the ITT population 
CCI&(/*(1(35235,(7$5<,1)250$7,21ptpive ive 
uencyuency
istoryistory data datayy
gululatoryatory
syndromsyndrom e
g frequencyg frequenc
scontscont inuedinu
uency and pncy and
by site willby site wi
atatioions.
e the cothe co mpm
aryy efficacyefficacyy
RBC transfuBC transfu
ment Periodment Perio
o 58, etc.o 58, etc
d frod fro m m ththe Pe
veeofof RBC  RBC ff
ryy efficacy efficacyyy
ed using thd using th
on (respon(respon
mized to lumized to 
e statistatiststicalical
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 80 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017who achieve the response will be presented by treatmen t group. The Cochranâ€“Mantelâ€“Haenszel 
(CMH) test will be used to test the difference between the 2 response rates at a 1-sided 
significance level of 0.025 with rando mization factors as strata. 
Additional details will be outlined in the SAP.
9.7.2. Secondary Efficacy Analyses9.7.2.1. Key Secondary Efficacy Analyses
The key secondary endpoint, proportion of subjects achieving RBC-TI with duration â‰¥ 12 weeks, 
will be tested in the same manner as primary efficacy endpoint using the CMH test.
The analyses for the key secondary endpoint will be based on the ITT population. In order to 
perform hypothesis testing on multiple endpoints while controlling the overall Type I error rate, 
a sequential testing approach will be employed where the order of the endpoints to be tested are 
pre-specified. The primary efficacy endpoint will be tested first at the one-sided 0.025 significance level. If superiority of luspatercept is demonstrated for the primary efficacy 
endpoint then the key secondary endpoint will be tested, at a one-sided 0.025 significance level.
Proportion of subjects achieving RBC-TI with duration â‰¥ 12 weeks is the absence of any 
RBC transfusion during any consecutive 84 day period during the Treatment Period (Weeks 1-
24; Weeks 1-48), ie, days 1 to 84, days 2 to 85, days 3 to 86, etc. Subjects discontinued from the 
Treatment Period without achieving at least 84 consecutive days of RBC transfusion independence will be counted as non-responders. 
Full details will be included in the SAP.
9.7.2.2. Additional Secondary Efficacy Analyses
Other secondary variables will be analyzed descriptively, unless otherwise specified, and will be 
based on the ITT population. Kaplan-Meier methods will be used to estimate curves for time to 
event secondary variables. Counts and percentages will be used to describe categorical secondary variables. 
Hemoglobin (Hgb) increase â‰¥ 1.0 g/dL is defined as proportion of subjects with â‰¥ 1.0 g/dL Hgb 
increase compared to baseline that is sustained over any consecutive 56-day period in the 
absence of RBC transfusions.
Total RBC units transfused over 16 weeks is defined as the total number of RBC units 
transfused over a fixed period of 16 weeks (weeks 9-24; weeks 32-48) compared to the total 
number of RBC units transfused in the 16 weeks immediately prior to randomization.
Proportion of subjects achieving RBC-TI with duration â‰¥ 8 weeks (Weeks 1-48) is the 
absence of any RBC transfusion during any consecutive 56-day period during the Treatment 
Period (Weeks 1-48).
Proportion of subjects achieving modified erythroid response (mHI-E) is defined as 
proportion of subjects meeting modified HI-E criteria ( Cheson, 2006 ; Appendix E ) sustained 
over any consecutive 56-day period duri ng the Treatment Peri od. Red blood cell (RBC)
transfusions administered for  a pre-transfusion Hgb of > 9.0 g/dL will count in the RBC 
transfusion response evaluation.
CCI&(/*(1(35235,(7$5<,1)250$7,21weeks, eeks, 
order to order to 
pe I error re I error r
s ts to be testo be te
ded 0.025 ded 0.025
rimaryimary  effiy
d 0.025 si0.025 si gg
weeks ee is theis th
hhe eTreatmTre
, etc. Subjeetc. Subje
ve ve days days off
AnalysesAnalyses
zed descriptzed descr
Meier mMeier m eth
and percennd percen
e e â‰¥ 1.0 g/dâ‰¥ 1.0 g
seline that iseline tha
fusiousions.n
transfusedtransfuse
r a fixed pea fixed p
RBC units tRBC units t
tion of subtion of sub
nce of any nce of any
erieriod (Weeod (Wee
ProportPropor
opo
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 81 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Duration of RBC-TI will be determined only for subjects who achieve RBC TI â‰¥ 8 weeks on 
treatment. Duration of RBC-TI is defined as the longest RBC-TI period during the Treatment 
Period.  Subjects who maintain RBC-TI through the end of the Treatment Period will be 
censored at the date of treatment discontinuation or death, whichever occurs first. 
Time to RBC-TI will be su mmarized only for subjects who achieve RBC TI â‰¥ 8 weeks on 
treatment. It is defined as the time between randomization and the date onset of TI is first 
observed (ie, Day 1 of 56 days without any RBC transfusions). 
Proportion of subjects achieving hematological response to neutrophils (HI-N) is defined as 
proportion of subjects meeting HI-N criteria ( Cheson, 2006 ; Appendix E ) sustained over any 
consecutive 56-day period during the Treatment Period.
Proportion of subjects achieving hematological response to platelets (HI-P) is defined as 
proportion of subjects meeting HI-P criteria ( Cheson, 2006 ; Appendix E ) sustained over any 
consecutive 56-day period during the Treatment Period.
Mean Change in Mean Daily Dose of Iron Chelation Therapy (ICT)
The change in daily dose for each subject is calculated as the difference of post-baseline mean 
daily dose and baseline mean daily dose. Analysis of covariance (ANCOVA) will be used to compare the treatment difference between groups, with the stratification factors and baseline ICT 
value as covariates.
Mean Serum Ferritin Decrease
The change is calculated as the difference of post-baseline mean serum ferritin and baseline 
mean serum ferritin. Analysis of covariance (ANCOVA) will be used to compare the treatment
difference between groups, with the stratification factors and baseline serum ferritin value ascovariates.
Time to progression to AML is defined as the time between randomization and first diagnosis 
of AML as per WHO classification of â‰¥ 20% blasts in peripheral blood or bone marrow.  
Subjects with diagnosis of AML will be considered to have had an event.  Subjects who have not 
progressed to AML at the time of analysis will be censored at the last assessment date which 
does not indicate progression to AML.
Overall survival (OS) is defined as the time b etween rando mization and d eath/censored date.  
Subjects who die, regardless of the cause of death, will be considered to have had an event.  
Subjects who are alive at the time of analysis will be censored at the last assessment date at which the subject was known to be alive. All subjects who were lost to follow-up will also be 
censored at the time of last contact.
Full analysis details will be included in the SAP.
9.8. Safety Analysis
All safety analyses will be performed on the safety population. Full details will be included in 
the SAP. Planned data presentations and analyses include the following:
Adverse events will be coded using MedDRA. Adverse event listings will include the verbatim 
term and the MedDRA preferred term. Treatment-emergent adverse events will be summarized 
CCI&(/*(1(35235,(7$5<,1)250$7,21as s
ny
efined as fined as 
ed over anover an
ce of post-ce of post- bb
ANCOVAANCOVA )
ificatificat ion faf
seline meaneline m
COVACOVA )wilw
on n factors afactors 
d as the timd as the ti
f f â‰¥ 20% blâ‰¥ 20%
will be conswill be co
of analysisof analysis
n to AML.n to AML
s defined as defined
gardlardless of ess o
alive at thealive at the
ect was knoect was k
he time of he time of
lysis detaillysis detai
8. SaSa
All All safesaf
S
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 82 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017by system organ class and preferred term. Treatmen t-emergent adverse events leading to death or 
to discontinuation from treatment, treatment-emerge nt adverse events (TEAEs) classified as 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
(version 4.03) all grades or grade 3/4 TEAEs, related to investigational product, and serious TEAEs will be summarized separately.
Clinical laboratory results will be summarized descriptively by treatment group. Clinically 
significant hematologic and non-hematologic la boratory abnormalities will be listed and 
summarized according to the NCI CTCAE (version 4.03) by treatment group.
Physical examination data and vital sign measurements, including body weight, will be listed for 
each subject at each visit. Descriptive statistics for vital signs, both observed values and changes from baseline, will be summarized by treatment group.
9.9. Other Analysis
Change in health related quality of life questionnaires utilizing EORTC QLQ-C30 
, changes from baseline in overall score and sub-scores will be analyzed and compared between 
treatment groups using repeated measures of An alysis of Variance (ANOVA)/ANCOVA using 
the screening scores as covariates where appropriate.  Various schemes will be assessed for 
missing data imputation.
 
 
 
 
 
9.10. Timing of Analyses
9.10.1. Interim Analysis 
An interim analysis to assess futility w ill be performed when approximately 105 subjects have 
completed the Primary Phase of the Treatment Period (first 24 weeks of double-blind treatment) 
or discontinued before reaching 24 weeks of double-blind treatment (50% information for primary endpoint). There will be no plan to claim luspatercept superiority based on efficacy 
results so the type one error rate remain s at 0.025 one-sided for the final analysis. 
Conditional power for primary endpoint will be calculated assuming the observed trend 
continues for the rest of the data. If it is 10% (corresponding to a fut ility boundary of p-value 
â‰¥0.201 using beta-spending function) or less, with confirmative data for secondary and other 
efficacy endpoints, the DMC may recommend stopping the study for fut ility.
This interim analysis will be performed by an independent statistician not affiliated with the 
study. The sponsor will remain blinded throughout the study. 
CCICCI
CCI
&(/*(1(35235,(7$5<,1)250$7,21ted for ed for 
changes changes
CCQLQQLQ -C3C3
zed ed and comand co
ANOVANOVA )//
hemes willmes wil
alysesalyses
nalysis alysi
s to assess to assess 
Primaryrimary PhaPhayy
ued before rued before r
ndpoint). dpoint). TT
so the tyso the ty pepeyy
ndidititiiional ponal p
continues fontinues f
â‰¥0.201 uâ‰¥0.201
ca7$5(7$,(75,(35,
52
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 83 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20179.10.2. Final Analysis 
Final analysis will be performed when all 210 subjects have completed 48 weeks of treatment or 
discontinued before 48 weeks. 
There is no plan to claim luspatercept superiority based on interim analysis efficacy results, thus 
the type one error rate remains at 0.025 one-sided for the final analysis. 
Additional follow-up analysis for efficacy and safety will be performed when all subjects have 
been followed for at least 3 years from the last dose of IP.
Full details will be included in the SAP.
9.11. Other Topics
 
 
 
 
 
 
 
9.11.2. Data Monitoring Committee 
An external, independent, unblinded DMC will be comprised of experts in MDS not involved in 
ACE-536-MDS-001 protocol, an independent Geriatrician/Hypertension Expert, an independent Statistician, and may include additional ad hoc members. Representatives of the Sponsor will be 
attending the blinded part of the DMC meetings. The Sponsor will not have access to the 
unblinded data during DMC meetings. 
During the course of the study, the DMC will review the unblinded safety data regularly as well 
as safety and efficacy data in accordance with the guidelines for the preplanned analyses and the
procedure pertaining to monitoring of AML progression outlined in the DMC charter.  An independent third party will prepare the reports of aggregate data summaries and individual
subject data listings, as  appropriate, to the DMC members for each scheduled meeting.
The DMC responsibilities, authorities, and procedures will be detailed in the DMC charter, 
which will be endorsed by the DMC prior to the first data review meeting.
Operational details for the DMC w ill be d etailed in the DMC charter.
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21ee e 
d DMC wiDMC w
independeindepend
addiaddititiiiionalonalll
of the DMCf the DM
DMC meetDMC mee i
of the studyof the study
icacyicacy data idatayy
rtaining taining to to 
nt third part third par
data listdata list inging
e DMC respDMC resp
which will bwhich will 
OperatiOperat)21)2,1)<, 15<,5<$5<7$5(7$,(75,(
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 84 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20179.11.3. Steering Committee 
A Steering Committee will be established by charter for this study.  The Steering Committee will
be comprised of Study Investigators, Sponsor representatives, and may include additional ad hoc 
members.  The Steering Committee will review blinded data. The SC will serve in an advisory capacity to the Sponsor.  The SC may advise and recommend to the Sponsor the following (but 
not limited to):
!Changes to the protocol or conduct of the study based upon emerging clinical or 
scientific data from this and/or other studies.
!Procedures to ensure the safety of  subjects and integrity of study data.
!Procedures to meet the overall goals and objectives of the study.
The SC responsibilities, authorities, and procedures will be detailed in the SC charter, which will 
be endorsed by the SC prior to the first data review meeting.
Operational details for the SC will be detailed in a separate SC charter. 
Note: The SC is separate from the DMC.
 
 
 
9.11.5. Subgroup Analysis
Appropriate subgroup analyses by stratification factors and other baseline characteristics for 
clinical activity may be conducted as exploratory analyses.  Full details will be included in the 
SAP.
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21arter, whicharter, whic
oon nfactors factors 
loratoryloratory  anaanyy$5<$57$5
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 85 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201710. ADVERSE EVENTS
10.1. Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study. It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subjectâ€™s health, including 
laboratory test values (as specifi ed by the criteria in Section 10.3), regardless of etiology. Any 
worsening (ie, any clinically significant adverse ch ange in the frequency or intensity of a pre-
existing condition) should be considered an AE .  A diagnosis or syndrome  should be recorded on 
the AE page of the eCRF rather than the indi vidual signs or symptoms of the diagnosis or 
syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be reported on the overdose eCRF. (See Section 7.2.1.2 for the definition of overdose.) Any 
sequela of an accidental or intentional overdose of an investigational product should be reported 
as an AE on the AE eCRF. If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE e CRF. The overdose resulting in the SAE should 
be identified as the cause of the event on the SAE report form and eCRF but should not be 
reported as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for luspatercept overdose. 
Actual treatment shoul d depend on the severity of the clinical situation and the judgment and 
experience of the treating physician.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subjectâ€™s clinical symptoms, laboratory, pathological, radiological or surgical findings , physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent 
until 42 days after the last dose of IP as well as those SAEs made known to the Investigator at 
any time thereafter that are suspected of being related to IP.  Adverse events (AEs) and SAEs 
will be recorded on the AE page of the eCRF and in the subjectâ€™s source documents.  All SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the 
event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.  
10.2. Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to: 
10.2.1. Seriousness 
An SAE is any AE occurring at any dose that:
!Results in death;
CCI&(/*(1(35235,(7$5<,1)250$7,21ed on d on
r 
reported aseported as
n AE shoulAE shou
verdosverdos e.)e.)A
duct shoulduct sh
hen the seqhen the seq
se resulte result ingin
nd nd eeCRF buCRF bu
d as appropas appr
specific anspecific an
hhe clinical e clinical
ng the studyng the study
 the subjec the subjec
findings, phfindings, ph
e InvestiInvesti gatgat
ose of IP asose of IP 
re suspectere suspe
e AE page AE page 
Celgene DCelgene D
le, or ole, or o ththere
rm.  m.  
EvaluEvalu
ualified Invualified Inv
10.2.1.0.2.1.
S
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 86 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate risk 
of death from the AE);
!Requires inpatient hospitalization or prolongation of ex isting hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);
!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions);
!Is a congenital anomaly/birth defect;
!Constitutes an important medical event.
Important medical events are defined as those occ urrences that may not be immediately life-
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:
!a standard procedure for protocol therapy administration.  However, hospitalization or 
prolonge d hospitalization for a complication of therapy administration will be reported as 
an SAE. 
!routine treatment or monitoring of the stud ied indication not associated with any 
deterioration in condition.
!the administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication of such transfusion remains a reportable SAE.
!a procedure for protocol/disease-related investigations (eg, surgery, scans, endoscopy, 
sampling for laboratory tests, bone marrow sampling).  However, hospitalization or 
prolonge d hospitalization for a complication of such procedures remains a reportable
SAE.
!hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
!a procedure that is planned (ie, planned prior to start of treatment on study); must be 
documented in the source document and the eCRF.  Hospitalization or prolonged hospitalization for a complication remains a reportable SAE.
!an elective treatment of or an elective procedure for a pre-existing condition, unrelated to 
the studied indication, that has not worsened from baseline. 
!emergency outpatient treatment or observation that does not result in admission, unless 
fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.
CCI&(/*(1(35235,(7$5<,1)250$7,21yylifelifeyy --
subject or subject or 
ed above.  ed above. 
h an AE shh an AE sh
However, hHowever, 
administraadmin
dication nodication n
nsfusiosfusio n asas
or prolongeor prolonge
le SAE.e SAE.
e-relrelated inated in
s, bone mbone m aa
fofor a comr a com
prolprolongationg
ence of an Ance of an 
e that is plae that is pla
nted in the nted in the
talizatitalizati on fon 
n electlective ive
ththe studie stud
!!ememee
fuf
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 87 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to the IP, action taken regarding the IP, and outcome.
10.2.2. Severity/Intensity
For both AEs and SAEs, the Investigator must assess the severity/ intensity of the event. 
The severity/intensity of AEs will be graded based upon the subjectâ€™s symptoms according to the 
current active minor version of the Common Terminol ogy Criteria for Adverse Events (CTCAE, 
Version 4.0); http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Adverse events that are not defined in the CTCAE should be evaluated for severity/intensity 
according to the following scale:
!Grade 1 = Mild â€“ transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!Grade 2 = Moderate â€“ mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!Grade 3 = Severe â€“ marked limitation in activity, some assistance usually required; 
medical intervention/therapy requi red, hospitalization is possible
!Grade 4 = Life-threatening â€“ extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice care probable
!Grade 5 = Death - the event results in death
The term â€œsevereâ€ is often used to describe th e intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache).  This criterion is notthe same as â€œseriousâ€ which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subjectâ€™s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.
10.2.3. Causality
The Investigator must determine the relationship between the administration of the IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: a causal relationship of the adverse event to IP administration is 
unlikely or remote , or other medications, therapeutic 
interventions, or underlying c onditions provide a sufficient 
explanation for the observed event.
Suspected: there is a reasonable possibility that the administration of IP 
caused the adverse event.  â€˜Reasonable possibilityâ€™ means there 
is evidence to suggest a causal relationship between the IP and 
the adverse event.
CCI&(/*(1(35235,(7$5<,1)250$7,21nsintytyi
no mno m edicaledical
me assistane assis
sistance usstance us
s possibles possib
activittivity,y sis
pypyrequirequiy redrediii
athath
he intensithe intensit
nt itself, hont itself, ho
).  Thi).  Thi s crisc r itii
action ction critcrit
rves as a grves as a
must determust determ
n AE/SAE n AE/SAE
ot suspectesuspecte
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 88 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Causality s hould be a ssessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.
10.2.4. Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
10.2.5. Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or dose reduction of IP, as appropriate) and report if concomitant and/or additional treatments were given for the event. 
10.2.6. Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subjectâ€™s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE).
10.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the study;
!requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing 
condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormality was not a part of a diagnosis or syndrome, then the laborat ory abnormality should be recorded as the AE. 
If possible, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record throm bocytopenia rather than decreased platelets).
10.4. Pregnancy
All pregnancies or suspected pregnancies occurring in either a female subject of childbearing 
potential or partner of childbearing potential of a male subject are immediately reportable events .  
CCI&(/*(1(35235,(7$5<,1)250$7,21ft h e  he 
E, as appliE, as app
nd report if nd report if
Es and SAEs an
e subjectâ€™s subjectâ€™
recovered wecovered
s
to be an Ato be an 
om the studm the stu
ificaticioon/ in/ i
offsignificansignific
or organ toxor organ t
veriterity y gradegrade
umented asumented 
toryoryabnormabnormy
rome shoulrome shou
rt of art of a didiagnag
f possible, tf possible, t
abnormbnorm alal
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 89 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201710.4.1. Females of Childbearing Potential:
Pregnancies and suspected pregnancies (including elevated Î²hCG or positive pregnancy test in a 
female subject of childbearing potential regardless of disease state) occurring while the subject is 
on IP, or within 12 weeks of th e subjectâ€™s last dose of IP, are considered immediately reportable 
events.  Investigational product is to be discontinued immediately. The pregnancy, suspected 
pregnancy, or positive pregnancy test must be reported to Celgene Drug Safety immediately by 
email, phone or facsimile, or other appropriate method, using the Pregnancy Initial Report Form, or approved equivalent form.  
The female subject may be referred to an obstetrician-gynecologist or another appropriate 
healthcar e professional for further evaluation.
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow -up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate method, within 24 hours of the Investigatorâ€™s knowledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant d eath after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
facsimile, or other appropriate method, within 24 hours of the Investigatorâ€™s knowledge of the event using the SAE Report Form, or approved equivalent form.
10.4.2. Male Subjects
If a female partner of a male subject taking IP becomes pregnant, the male subject taking IP 
should notify the Investigator, and the pregnant female partner should be advised to call their 
healthcare provider immediately.  
Males will be advised to use a male latex condom or nonlatex condom NOT made out of natural 
(animal) membrane (for example, polyurethane), during any sexual contact with FCBP prior to 
starting investigational product and continue for 12 weeks following the last dose of IP, even if he has undergone a successful vasectomy.
10.5. Other Malignancies/Pre-malignancies
Events of new malignancy, pre-malignant lesions (excluding benign tumors or benign neoplasia) are to be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form. All SAE criteria (eg, hospitalization) should be marked if applicable, and all 
events must be marked as an â€œImportant Medical Eventâ€ even if no other serious criteria apply; these events must also be documented in the appropriate page(s) of the CRF and subjectâ€™s source 
documents.  Documentation related to the diagnos is of malignancy must be provided at the time 
of reporting as a serious adverse event (eg, any confirmatory histology or cytology results, X-
rays, CT scans, etc.).
CCI&(/*(1(35235,(7$5<,1)250$7,21nd mnd m ust ust m
hher normer norm aa
d equivalend equivalen
, , ththe Investe Inves
me meets ane meets a
acsimsimile, orile, or
vent nusing ing
uld be repould be repo
28 day28 day s thas tha
be reportebe report
 hours of thhours of t
d equivalend equivalen
taking IP btaking IP
d the pregnd the preg
lyy.  .  
se a a mamale lal
r example, r example
nal productal produc
a successfua successfu
Other MaOther Ma
of new malof new ma
o be reporteo be repor
vent byvent by ffyacsacsfff
equivalenquivalen
vents vents
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 90 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Malignancies or cancerous tumors are lesions capable of invading into adjacent tissues, and may 
be capable of spreading to distant tissues. A benign tumor has none of those properties.
Malignancy or cancer is characterized by anaplasia, invasiveness, and metastasis.  For the 
Myelodysplastic Syndrome (MDS) studies, these al so include progression to high/very high risk 
of MDS (per IPSS-R; Greenberg, 2012 ); myeloproliferation (eg, clinically significant increases 
in blasts), progression to AML, etc.
Premalignant or precancerous lesions refer to a state of disordered m orphology of cells  that is 
associated with an increased risk of cancer. If left untreated, these conditions may lead to cancer. 
Such conditions are usually either dysplasia or benign neoplasia (and the dividing line between 
those is sometimes blurry). Sometimes the term "precancer" is used to describe carcinoma in situ, which is a noninvasive cancer that has not progressed to an aggressive, invasive stage. Not 
all carcinoma in situ w ill progress to invasive disease.
Premalignant lesions are morphologically at ypical tissue which appears abnormal under 
microscopic examination, and in which cancer is more likely to occur than in its apparently 
normal counterpart.
10.6. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by facsimile, 
or other appropriate method (eg, via email), using the SAE Report Form, or approved equivalent form.  This instruction pertains to initial SAE reports as well as any follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study (from the time the subject  signs informed consent until 42 days after the last dose of IP) or any 
SAE made known to the Investigator at any time thereafter that are suspected of being related to 
IP.  Serious adverse events occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary 
of hospital records and other relevant documents .  If a subject died and an autopsy has been 
performed, copies of the autopsy report and d eath certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data should be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event. The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.
10.6.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by phone.
CCIcer. er
ween ween 
ma in in 
stage. Notstage. Not
rmal under mal under
in its apparin its appa
pletpletioion of an o
RF. RF. All SAAll 
s knowled knowle
e SAE Repoe SAE Repo
orts as well rts as well 
data on thedata on the
rdless of reldless of re
d consent ud consen
at anyat any titme
ing prior tong prior to
e a detailede a detaile
r relr relevant evant
autopsyautopsy reyy
e becoe beco me am
, or approvor approv
d byd by llyyocalocal ll
ard/Ethics Card/Ethics 
d foollollow-w-u
mmatatioion on fn on f
10.6.1.0.6.1.
Queriueriee
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 91 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201710.7. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to luspatercept based on the Investigator Brochure.
In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.
In addition, any report of progression to high risk MDS or AML if the case is in the luspatercept 
arm, upon unblinding regardless of causality, will be re ported as an expedited safety report to the 
regulatory authorities, as requested.
Celgene or its authorized representative sh all notify the Investigator of the following 
information:
!Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (ie, SUSAR);
!Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pe rtinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 14.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety  contact information, pleas e refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pr egnancy Report Form Completion Guidelines.
CCI&(/*(1(35235,(7$5<,1)250$7,21dance ance
products foroducts fo
s.s.
n the luspatn the lusp
ed safeted safet y y rer
of the fof the fo llollo
P in this stuin this s
);
ls that suggs that sugg
agenicitagenici y,y,t
gator shall ator shal
significant rignificant r
pertpertinent sinen
IRB/EC.  IRB/EC
t Informatt Informa
ontact intact nfofi
delines or toelines or t
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 92 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201711. DISCONTINUATIONS
11.1. Treatment Discontinuation
Subjects will have an End of Treatment (EOT) vi sit at the time of IP discontinuation.  All 
subjects who received at least one dose of IP will be followed for at least 3 years post last dose of 
IP. 
The following events are considered sufficient reasons for discontinuing a subject from the 
investigational products:
!Lack of Efficacy 
!Adverse Event
!Withdrawal by subject
!Death
!Lost to follow-up
!Pregnancy
!Protocol violation
!Study terminated by Sponsor
!Disease Progression as per IWG criteria for altering natural history of MDS ( Cheson, 
2006 ;Appendix E )
âˆ€For subjects with 5-10% blasts, a 2ndbone marrow sample should be collected 
within 4 weeks for clinical assessment (e g, cytom orphology, cytogenetics) to 
confirm progression before disc ontinuing subjects from treatment. 
!Other (to be specified on the eCRF)
âˆ€Including treatment discontinuation guida nce related to dose modification 
Table 6 .
The reason for discontinuation of tr eatment should be rec orded in the eCRF and in the source 
documents.
The decision to discontinue a subject from treatment remains the responsibility of the treating 
physician, which will not be delayed or refused by the Sponsor.  However, prior to discontinuing a subject, the Investigator may contact the Medical Monitor and forward appropriate supporting 
documents for review and discussion.
11.2. Study Discontinuation
Subjects who discontinue from treatment for any reason will be followed via telephone contact by the site or subject site visit for collection of data on survival, cause(s) of death, progression to 
AML, other malignancies/pre-malignancies, post-treatment therapy(ies) for MDS at the 42-Day and 12-Week Follow-up assessments and then every 3 months after the 12-Week Follow-up 
assessment for at least 3 years after last dose of IP or until death, lost to follow-up or withdrawal 
of consent from the study.
CCI&(/*(1(35235,(7$5<,1)250$7,21alaltering nering nl
a 22ndndbone bone
sessment (sessment (
e disconte discont inin
the the eeCRF)CRF
nt discontnt discont ini
ation ofon of  tref
contcontinue ainue a
h will not bh will not b
e Investe Invest igatigat
s ffor revior revifff ewew
2.2. StuStu
Subjects wSubjects w
by the sy the 
ML
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 93 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Every attempt should be made to contact subjects during follow-up unless subjects discontinue
from the study. Every attempt should be ma de to collect all data on discontinued subjects.
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
!Screen failure
!Adverse event
!Withdrawal by subject
!Death
!Lost to follow-up
!Protocol deviation
!Study terminated by Sponsor
!Other (to be specified on the eCRF)
The reason for study discontinuation should be recorded on the End of Study eCRF and in the 
source documents.
CCI&(/*(1(35235,(7$5<,1)250$7,21of Studyf Study ey
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 94 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201712. EMERGENCY PROCEDURES
12.1. Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the prot ocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page). This global 
Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are 
responsible for obtaining your call-back information and contacting the on-call Celgene/contract 
research organization Medical Monitor, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls. 
12.2. Emergency Identification of Investigational Products
The blind must not be broken during the course of the study unless in the opinion of the Investigator, it is absolutely necessary to safely treat the subject.  If it is medically imperative to 
know what IP the subject is receiving, IP should be temporarily discontinued if, in the opinion of the Investigator, continuing IP can negatively affect the outcome of the subjectâ€™s treatment.
The decision to break the blind in emergency situations remains the responsibility of the treating 
physician, which will not be delayed or refused by the Sponsor.  However, the Investigator may contact the Medical Monitor prior to breaking the blind to discuss unblinding, mainly in the 
interest of the subject. 
The Investigator should ensure that the code is broken only in accordance with the protocol. The 
Investigator should promptly notify the Medical Monitor of the emergency unblinding and the 
reason for breaking the blind, which should be clearly documented by the Investigator in the 
subjectâ€™s source documentation.
Emergency unblinding should only be performed by  the Investigator through the IRT by using an 
emergency unblinding personal identification number (PIN), and the Investigator should call IRT
for unblinded dose information.
CCI&(/*(1(35235,(7$5<,1)250$7,21be e 
on 
ves are ves are 
ene/contracene/contrac
bbe used if ye used if 
r designee fdesignee f
ProductsProduct
unless in theunless in t
ubject.  If itect.  If i
porarily disporarily d
the outcomthe outco
uations reuations r m
ed by the Sped by the S
ing the blinng the bli
the code ishe code i
tify the Meify the Me
which shouwhich sho
ation.ion.
g shoulshou d onon
ng personag persona
se informate informat
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 95 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201713. REGULATORY CONSIDERATIONS
13.1. Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ens ure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International Council for
Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study w ill receive approval from an IRB/EC prior to 
commencement. The Investigator will conduct all aspects of this study in accordance with 
applicable national, state, and local laws of the pertinent regulatory authorities.
13.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the local regulations.  Celgene staff or an authorized representative will evaluate and approve all Investigators who in turn will select their staff.
The Investigator should ensure that all persons a ssisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions, including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
form (ICF) and are screened for entry into the st udy.  Subjects who fail screening must have the 
reason(s) recorded in the subjectâ€™s source documents.
The Investigator, or a designated member of the Investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data verification.  The Investigator must ensure timely and accurate completion of eCRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by Celgene on public registry websites) is considered Celgene confidential 
information.  Only information that is previously disclosed by Celgene on a public registry 
website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment and IB information is not to be made publicly 
available (for example on the Investigatorâ€™s or their institutionâ€™s website) without express written 
approval from Celgene.  Information proposed  for posting on the Investigatorâ€™s or their 
institutionâ€™s website must be submitted to Celgene for review and approval, providing at least 5 business days for review.
At the time results of this study are made available to the public, Celgene will provide 
Investigators with a summary of the results that is written for the lay pe rson. The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the 
subject.
CCI&(/*(1(35235,(7$5<,1)250$7,21Practice anPractice 
luate and aluate and a
dyy are adeqare adeqyy
y--related drelated d
. The InvesThe I
persons to persons to 
of all subjeof all sub
dydy.  Subjec.  Subje
ments.ments.
of the Invesf the Inve
e queries anqueries 
tal charts, aal charts
st ensure timst ensure 
the protocothe protoc
elgene on pgene on 
mmataion than th
y disclosedy disclose
CelCelgene prgene pr
xample on xample o
mm CelCelmm genegene
nâ€™s websitewebsite
ss days forss days for
 the time re the time r
Investnvest igatigat
esponsespon
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 96 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201713.3. Subject Information and Informed Consent
The Investigator must obtain informed consent of a subject and/or a subjectâ€™s legal representative 
prior to any study related procedures.
Documentation that informed cons ent occurred prior to the study subjectâ€™s entry into the study 
and of the informed consent process should be recorded in the study subjectâ€™s source documents including the date.  The original ICF signed and dated by the study subject and by the person 
consenting the study subject prior to the study subjectâ€™s entry into the study, must be maintained 
in the Investigatorâ€™s study files and a copy given to  the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the infor med consent, the ICF must be revised.  Study 
subjects participating in the study when the amended protocol is implemented must be re-
consented with the revised version of the ICF.  The revised ICF signed and dated by the study subject and by the person consenting the study s ubject must be maintained in the Investigatorâ€™s 
study files and a copy given to the study subject.
13.4. Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (w hichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require  a waiver or authorization separate from the 
subjectâ€™s signed ICF, it is the responsibility of the Investigator to obtain such permission in writing from the appropriate i ndividual.
13.5. Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
13.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol , ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
Investigational product (IP) product can only be supplied to an Investigator by Celgene or its 
authorized representative after documentation on all ethical and legal requirements for starting 
CCI&(/*(1(35235,(7$5<,1)250$7,21ol is ol is
Study Study 
re-
the studythe study
Investnvest igatoigato
privacyivacy ananydd
ost stringenst stringen
necessary, necessa
cords relevcords relev
iver or authver or au
InvestInve igatoiga
st be approvt be app
endments wndments 
ned beforened before
mm the IRB/E the IRBmm
tlle and ameand 
re do not ree do not re
poses.poses.
nstitutionnstitution
anand Appd App
e the start oe the start o
submitted tubmitted t
dates of issdates of iss
sought. ought
al
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 97 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017the study has been received by Celgene or its authorized representative. This documentation 
must also include a list of the members of the IRB/EC and their occupation and qualifications. If 
the IRB/EC will not disclose the names, occupations and qualifications of the committee 
members, it should be asked to issue a statement confirming that the composition of the committee is in accordance with GCP. For example, the IRB General Assurance Number may be 
accepted as a substitute for this list. Formal appro val by the IRB/EC should mention the protocol 
title, number, amendment number (if applicable), study site (or region or area of jurisdiction, as 
applicable), and any other documents reviewed. It must mention the date on which the decision 
was made and must be officially signed by a committee member. Before the first subject is 
enrolled in the study, all ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all co mmunication with the IRB /EC and, if applicable, 
between a Coordinating Investigator and the IRB /EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
13.7. Ongoing Information for Institutional Review Board/ Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:
!Information on serious or unexpected adverse events as soon as possible; 
!Periodic reports on the progress of the study;
!Deviations from the protocol or anything th at may involve added risk to subjects.
13.8. Termination of the Study
Celgene reserves the right to terminate this st udy prematurely at any time for reasonable medical 
or administrative reasons. Any premature discontinuation will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
The Sponsor may consider closing this trial when data supporting key endpoints and objectives 
of the study have been analyzed.  In the case where there are subjects still being administered the 
investigational product, and it is the opinion of the Investigator(s) that these subjects continue to 
receive benefit from treatment, the Sponsor may c hoose to initiate an open-label, roll-over or 
extension study under a separate protocol to allow these subjects continued access to luspatercept 
following their participation in this study ACE-536-MDS-001.
CCI&(/*(1(35235,(7$5<,1)250$7,21otocol ocol 
aluated to aluated to 
also be revalso be rev
and, if appand, if app
o applies toapplie
r, if applicar, if applic
be reviewee revi
nal Revienal Revie
vestigator mestigator 
ed advered adver sese
s of the stus of the stu
colcol or any or anyl thy
of the Stuof the S
ht to terminht to term
sons. Anyons. Any py
requiremerequireme
mayayconsidconsidy
yhhyave beenave been
ational pronal pro
ve benefit fve benefit
tensionsion stun stu
foollolwing wing 
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 98 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment;
!GCP noncompliance;
!Inaccurate or incomplete data collection;
!Falsification of records;
!Failure to adhere to the study protocol.
CCI&(/*(1(35235,(7$5<,1)250$7,21
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 99 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201714. DATA HANDLING AND RECORDKEEPING 
14.1. Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigat ional product are complete, accurate, filed and 
retained.  Examples of source documents include: hospital records; clinic and office charts; 
laboratory notes; memoranda; subjectâ€™s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and re ports; and records kept at the pharmacy, and 
the laboratories, as well as copies of eCRFs or CD-ROM.
14.2. Data Management
Data will be collected via eCRF and entered into the clinical database per Celgene standard operating procedures (SOPs). This data w ill be electronically verified through use of 
programmed edit checks specified by the clinical team.  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary.  Resolutions 
to these issues will be reflected in the database.  An audit trail within the system will track all changes made to the data.
14.3. Record Retention
Essential documents must be retained by the Investigator according to the period of time outlined in the clinical trial agreement. The Investigator must retain these documents for the time period described above or according to local laws or requirements, whichever is longer. Essential 
documents include, but are not limited to, the following:
!Signed ICFs for all subjects;
!Subject identification code list, screening log (if applicable), and enrollment log;
!Record of all communications between the Investigator and the IRB/EC;
!Composition of the IRB/EC;
!Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);
!List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significan t study-related duties, together with their roles in the 
study, curriculum vitae, and their signatures;
!Copies of CRFs (if paper) and of documentation of corrections for all subjects;
!IP accountability records;
!Record of any body fluids or tissue samples retained;
!All other source documents (subject records, hospital records, laboratory records, etc.); 
!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
CCI&(/*(1(35235,(7$5<,1)250$7,21s s 
, and and 
gene ene standastand
gh use of gh use of 
n the data wthe da
, if necessa, if necessa
in the systein the sys
ator accordiator accord
st retain thest retain th
quirementsquirements
follofollo wingwing
st, screeninst, screen
titions betwons betw
IRB/EC;RB/EC;
mmumm nicaticat
e(s);(s);
ubub--investinvest igig
igator has igator has 
dyy, curri, curri cucu
CopiCop essofof
!IP acIP ac
!R
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 100 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to r etain them for a specified period.  
The Investigator must obtain approval in writi ng from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene for permission to make alternative arrangements. Details of these arrangements should be 
documented. 
All study documents should be made available if required by relevant health authorities. 
Investigator or institution should take measures to prevent accidental or premature destruction of 
these documents.
CCIof of 
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 101 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201715. QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully moni tored by Celgene or its authorized representative 
for compliance with applicable government regula tions with respect to current GCP and SOPs.
15.1. Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  All aspects of the study are reviewed  with the Investigator and the staff at a study 
initiation visit and/or at an Investigatorsâ€™ Meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protocol , eCRFs, procedures for obtaining informed 
consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring will include on-site visits with the Investigat or and his/her staff as  well as any appropriate 
communications by mail, email, fax, or telephone.  During monitoring visits, the facilities, 
investigational product storage area, eCRFs, subjectâ€™s source documents, and all other study documentation will be inspected/reviewed by the Ce lgene representative in  accordance with the 
Study Monitoring Plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the eCR Fs or via queries by the Investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
15.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Pract ice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/ECs, regulatory  authorities (eg, Food and Drug Administration 
[FDA], European Medicines Agency [EMA ], Health Canada) and company authorized 
representatives.  The Investigator should make ever y effort to be available for the audits and/or 
inspections.  If the Investigator is contacted by any regulatory authority regarding an inspection, 
he/she should contact Celgene immediately.
CCI&(/*(1(35235,(7$5<,1)250$7,21a 
d d 
will will 
e e 
facilitcilities, ies, 
all other stul other s
accordanceaccordanc
t iis a dis a di recrecii
ocumentatioumentati
/her staff.  /her sta
s by the s by the Inv
nts, adherents, adhe
ecording beecording b
ecific mecific m onion
cedures, a Gcedures, a G
atives of thatives of th
ne SOPs toe SOPs to
to permit dto permi
s and applis and ap
by IRB/ECby IRB/EC
Medicines AMedicines A
The InvestThe Inves
If the Invesf the Inves
ulld contactd contact
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 102 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201716. PUBLICATIONS
As described in Section 13.2, all protocol and amendment-related information, with the 
exception of the information provided by Celgene on public registry websites, is considered 
Celgene confidential information and is not to be used in any publications.  Celgene protocol-
related information proposed for use in a publication must be submitted to Celgene for review and approval, and should not be utilized in a publication without express written approval from 
Celgene, or as described in the Clinical Trial Agreement.  
Celgene will ensure Celgene-sponsored studies are considered for publication in the scientific 
literature in a peer-reviewed journal, irrespective of the results.  At a minimum, this applies to 
results from all Phase 3 clinical studies, and any other study results of significant medical 
importance.  This also includes results relating to investigational medicines whose development programs have been discontinued.
Study results may also be presented at one or more medical congresses, and may be used for 
scientific exchange and teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication 
on health authority study registry websites, as  required by local health authority regulations.  
 
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21es to s to 
al 
evelopmenevelopmen
maymay byye usedused
resulresul ts mts ml
es, as well aes, as we
h authorityh authority
<, 15<$5<7$5
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 103 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201717. REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European 
Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for 
use in international clinical trials in  oncology. J Natl Cancer Inst 1993;85(5):365-76.
AdÃ¨s L, Itzykson R, Fenaux P. Myel odysplastic syndromes . Lancet 2014:383(9936):2239-52.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borwitz MJ, Le Beau MM, et al.  The 2016 revision 
to the World Health Organization (WHO) classification of myeloid neoplasms and acute 
leukemia. Blood 2016;127(20):2391-405. 
Attie KM, Allison MJ, McClure T, Boyd IE, Wilson DM, Pearsall AE, et al. A phase 1 study of 
ACE-536, a regulator of erythroid differentiatio n, in healthy volunteers. Am J Hematol 2014; 
89(7):766-70.
Balducci L. Anemia, fatigue and aging. Transfus Clin Biol 2010:17(5-6):375-81.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for 
the classification of the myelodysplast ic syndromes. Br J Haematol 1982;51(2):189â€“99.
Broudy VC, Lin N, Brice M, Nakamoto  B, Papayannopoulou T. Erythropoietin r eceptor 
characteristics on primary human eryt hroid cells. Blood 1991;77(12):2583-90.
Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, et al.  Pathology and 
genetics of tumors of hematopoietic and lymphoid tissues.  In: Jaffe ES, Harris NL, Stein H, 
Vardiman JW, editors.  World Health Organization classificatio n of tumors. Lyon (France): 
IARC Press; 2001:63-73.
Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, et al. Myelodysplastic 
syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, 
Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon, France: IARC Press; 2008:88-93.
Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, QiarrÃ© MC, et al. Health, economic, 
and quality-of-life effects of eryth ropoietin and granulocyte colony-stimulating f actor for the 
treatment of myelodysplastic s yndromes: a randomized, controlled trial. Blood 2004;104(2):321-
7.
Catenacci DV, Schiller GJ. Myelodysplastic syndromes: a comprehensive review. Blood Rev 
2005;19(6):301-19.
Chan LS, Shapiro R, Buckstein R, Lin Y, Callum J, Chodirker L, et al. Initial transfusion 
intensity predicts survival in myelodysplastic syndrome. Leuk Lymphoma 2014;55(10):2296-300.
Cheson BD, Greenberg PL, Bennett JM, Lowenbe rg B, Wijermans PW, Nimer SD, et al. Clinical 
application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108(2):419-25.  
Conte S, Katayama S, Vesterlund L, Karimi M, Dimitriou M, et al. Aberrant splicing of genes 
involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. Br J Haematol. 2015 Aug 10.
CCI&(/*(1(35235,(7$5<,1)250$7,21studystudy ofofyy
tol 2014; ol 2014; 
81.1.
HR, R, et al. et a PrP
82;5182;51 (2)(2):18:1
ryythyropoiropoih ete
77(12)(12):2583
 VardimanVardiman
s.  .  In: JaffeIn: Jaf
assificatassificat io
MM, PorwiMM, Porwi
dlow SH, Clow SH, C
WHO ClaWHO Cla
FrFrance: IAance
S, HemeryS, Hemer
ryththyropoiropoihhh etei
ic syndroc syndro mm
ler GJ. Myer GJ. My
9.
apiro R, Bupiro R, Bu
redicts survedicts surv
eson BD, Gson BD, G
applicatpplicat ioionn
cririteria iteriaii
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 104 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017del Rey M, Benito R, Fontanillo C, Campos-La borie FJ, Janusz K, et al. Deregulation of genes 
related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. PLoS 
One. 2015 May 8; 10(5):e0126555.
Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, et al. Disruption of 
SF3B1 results in deregulated expression and splicing of key genes and pathways in 
myelodysplastic syndrome hematopoietic stem  and progenitor cells. Leukemia. 2015 May; 
29(5): 1092-103.
Dreyfus F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. 
Blood Rev 2008;22(Suppl 2):S29-34.
Dumville JC, Hahn S, Miles JN, Togerson DJ. The use of unequal randomization ratios in 
clinical trials: a review. Contemp Clin Trials 2006;27(1):1-12.
Fenaux, P, Rose, C. Impact of iron overload in myelodysplastic syndromes. Blood Rev 2009;23 
(Suppl 1):S15-9.
Fenaux, P, AdÃ¨s, L. How we treat lo wer risk myelodysplastic syndrome. Blood 
2013;121(21):4280-6.
Fenaux, P, Haase D, Sanz GF, Santini V, Buske C. Myelodysplastic syndromes: ESMO Clinical 
Practice Guidelines for diagnosis, treatment  and follow-up. Ann Oncol 2014;25(suppl 3): iii57-
iii69.
Germing U1, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, et al, Survival, 
prognostic factors and rates of leukemic transfor mation in 381 untreated patients with MDS and 
del(5q): a multicenter study. Leukemia 2012;26(6):1286-92.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring 
system for evaluating prognosis in my elodysplastic syndromes . Blood 1997;89(6):2079-88.
Erratum in: Blood 1998;91(3):1100.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, SolÃ© F, et al. Revised 
international prognostic scoring system for myelodysplastic syndromes. Blood 
2012;120(12):2454-65.
Guidelines for the diagnosis and treatment of Myelodysplastic syndromes and chronic 
Myelomonocytic Le ukemia, Nordic MDS group, Issue 7, 6th update, 1 Feb 2014.
Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF. From stem cell to red cell: regulation 
of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood 2011;118(24):6258-68.
HellstrÃ¶m-Lindberg E. Efficacy  of erythropoietin in the myelodysplastic syndromes: a meta-
analysis of 205 patients from 17 studies. Br J Haematol 1995;89(1):67-71.
HellstrÃ¶m-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A 
validated decision model for treating the anaemia of myelodysplastic syndromes with 
erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J 
Haematol 2003;120(6):1037-46.
HellstrÃ¶m-Lindberg E, van de Loosdrecht A. Eryt hropoiesis-stimulating agents and other growth 
factors in low-risk MDS. Best Pract Res Clin Haemaol 2013;26(4):401-10.
CCI&(/*(1(35235,(7$5<,1)250$7,21s. 
s in s in
ood Rev 20od Rev 2
 BlBlood ood
stic syndromc syndrom
n Oncon Onco l 20
A, CermakA, Cermak
ion in 381 uion in 38
6):1286):128 -92.92
MorelMorel  P, P, llS
dysplastysplast ic syic s
J, Sanz G, , Sanz G
systemsystem ffmmor orfff
osis and treasis and 
kemia, Nordemia, Nor
Wong P, Zhaong P, Zh
is at multis at mul ip
118118(24)(24):62:62
m-LindberLindber
ysis of 205 psis of 205
HellstrHellstr Ã¶m-Ã¶m-LL
validatedvalidated
yththyrhh
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 105 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of 
life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J 
Haematol 2003;121(3):270-4.
Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS 
reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J 
Hematol 2008;83(10):765-70.
List AF. Iron overload in myelodysplastic syndromes: diagnosis and management. Cancer 
Control 2010;17(1):Suppl 2-8.
Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors 
and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005;23(30):7594-603.
Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. 
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118(24):6239-46.
Malcovati L, Cazzola M. Refractory anemia with ring sideroblasts. Best Prac Res Clin Haematol 
2013:26(4):377â€“85.
MassaguÃ© J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
Messa E, Cilloni D, Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv 
Hematol 2010;2010:756289.
Mufti GJ, Bennet JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and 
classification of myelodysplastic syndrome: International Working Group on Morphology of 
myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008;93(11):1712-17.
NCCN Clinical Practice guidelines in Oncology  (NCCN guidelines) Myelodysplastic syndromes 
version 2.2015.
Noel P, Solberg LA Jr. Myel odysplastic syndromes. P athogenesis, diagnosis and treatment. Crit 
Rev Oncol Hematol 1992;12(3):193-215.
Obeng E, et al. Mutant Splicing Factor 3b Subunit 1 (SF3B1) Causes Dysregulated 
Erythropoiesis and a S tem Cell Disadvantage Abstract 828, ASH 2014.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and 
response criteria of the Eastern Cooperative On cology Group. Am J Clin Oncol 1982;5(6):649-
55.
 
 
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic 
SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365(15):1384-95.
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21ffactors actors fff
a: A basis a: A basis
utto Cutto C ,,et a
-46.-46.
est Prac Reest Prac Re
m 1998;67:7m 1998;6
yelodysplasyelodyspla
nn Inn I, BrunBrun
ernational Wernational W
onsensus prnsensus pr
oblastsoblasts .HaHa
OncoOnco lologyy
dysplastiysplasti c syc sy
2(3):1932(3):193 -21
Splicing FaSplicing F
Stem Cell Stem Cel
ch RH, Torch RH, Tor
ria of the Ea of the E
PapaemPapaem
B(/*(/*&(/
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 106 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Papaemmanuil E, Gertsung, M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and 
biological implications of driver mutations in myelodysplastic syndromes. Blood 
2013;122(22):3616-27.
Pellagatti A, Boultwood J. The molecular pathoge nesis of the myelodysplastic syndromes. Eur J 
Haematol 2015;95:3-15
Platzbecker U, Hofbauer LC, Ehninger G, HÃ¶lig  K. The clinical, quality of life, and economic 
consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 2012;36(5):525-36.
Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion 
dependency on survival and leukemic evolutio n in patients with myelodysplastic syndrome 
[abstract]. Blood 2008;112(11):640.
Santini, V. Clinical Use of Erythropoietic Stimulating Agents in Myelodysplastic Syndromes.  
Oncologist 2011;16(suppl 3):35â€“42.
Santini V. Schemenau J, Levis A, Balleari E, Sapena R, AdÃ¨s L, et al. Can the revised IPSS 
predict response to erythropoietic-stimulating agents in patients with classical IPSS low or 
intermediate-1 MDS? Blood 2013;122(13):2286-8.
Schanz J, TÃ¼chler H, SolÃ© F, Mallo M, LuÃ±o E,  Cervera J, et al. New comprehensive cytogenetic 
scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid 
leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30(8):820-9.
Steensma DP, Gattermann N. When is iron overl oad deleterious, and when and how should iron 
chelation therapy be administer ed in myelodysplastic syndromes? Best Pract Res Clin Haematol 
2013;26(4):431-44.
Thomas ML. Strategies for achieving transfusion independence in myelodysplastic syndromes. 
Eur J Oncol Nurs 2007;11(2):151-8.
Vardiman JW, Thiele J, Arber DA, Brunning RD , Borowitz MJ, Porwit A, et al. The 2008
revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute 
myeloid leukemia: rationale and important changes. Blood 2009;114(5):937-51.
Visconte V, Selleri C, Maciejewski JP, Tiu RV. Molecular pathogenesis of myelodysplastic 
syndromes. Transl Med UniSa 2014;4(8):19-30.
Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev
2013;27(5):243-59.
CCI&(/*(1(35235,(7$5<,1)250$7,21roome m
ic Syndromic Syndr
an the revisn the r
classical IPclassical IP
. . NewNew com
DS) and oliDS) and oli
ase merge. se merg
ad delad de eteriter
splastic synplastic syn
ransfusioansfusio n ni
A,A,BrunninBrunnin
OrganizatOrganizat ioi
le and impoand imp
MaciejewsMaciejews
Med UniSaed UniSa
nhares Y, Gnhares Y
243243-59.-59.
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 107 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 201718. APPENDICES
APPENDIX A: Table of Abbreviations
Table 7: Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term Explanation
ActRIIB Activin receptor type IIB
ADA Antidrug antibodies
AE Adverse event
ALT Alanine aminotransferase 
AML Acute myeloid leukemia
ANCOVA Analysis of covariance
ANOVA Analysis of variance 
AST Aspartate aminotransferase 
AUC Area under the curve
Î²-hCG Î²-subunit of human chorionic gonadotropin
BM Bone ma rrow
BMA Bone ma rrow aspirate
BMP Bone morphogenetic protein 
BSC Best supportive care
CBC Complete blood count
CXDX Cycle X Day X
Cmax Maximum plasma concentration of drug
CMH Cochranâ€“Mantelâ€“Haenszel
CMML Chronic myelomonocytic leukemia
CRF Case report form
CTCAE Common Terminology Criteria for Adverse Events
DMC Data Monitoring Committee
EC Ethics Committee
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic case report form
CCI&(/*(1(35CochranCochr â€“n35235,(7$5<,1)250$7,21777$7$7$7$70$5025)21),1<nadotropinnadotropin5<$57$
c protein  protein (7
carecare5,lood countlood cou35X Day XX Day X23aximum plasaximum pla52M35(ChronChr(((31(CC1(1((1((1*(/*CGCG(/ECOGECOG&(&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 108 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 7: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
EEA European Economic Area
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire 
EOT End of treatment
EPO Erythropoietin
ESA Erythropoiesis- stimulating agents
FAB French-American-British
FCBP Female of childbearing potential
FDA Food and Drug Administration
GCP Good Clinical Practice
G-CSF Granulocyte colony-stimulating factor
GDF Growth Differentiation Factor 
GM-CSF Granulocyte-macrophage colony-stimulating factor
Hgb Hemoglobin
HI-E Hematological improvement-erythroid
HI-N Hematological improvement-neutrophils
HI-P Hematological improvement-platelets
HIV Human Immunodeficiency Virus 
HMA Hypomethylating agents
HR Hazard ratio
HRQoL Health-related quality of life 
IB Investigatorâ€™s Brochure
ICF Informed c onsent form
ICH International Council for Harmonisation
ICT Iron chelation therapy
IMiDs Immune-modulatory drugs (a proprietary series of drugs with 
immunomodulatory and other properties)
IND Investigational New Drug
Int Intermediate
IP Investigational Product
IPSS International Prognostic Scoring System
CCI&(/*(1(3523methylating amethylating235,(7$5<,1)250$7,21777$7$7$7$70$5025)21),1<stimulatingstimulating5<$5mentment -erytythroh7$
ovementovement --nene(7
improvemenmproveme5,munodeficiemunodef3523zard ratiozard ratio52HHeaealthlth-rel35(InvesInv(((31(II1(1((1((1*(/*
INDN&(&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 109 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 7: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
IPSS-R International Prognostic Scoring System-Revised
IRB Institutional Review Board
IRT Integrated Response Technology
ITT Intent to treat
IWG International Working Group
IWGMDS International Working Group on Morphology of Myelodysplastic Syndrome
MDS Myelodysplastic syndromes
MedDRA Medical Dictionary for Regulatory Activities
NCCN National Comprehensive Cancer Network
NCI National Cancer Institute
OS Overall survival
PK Pharmacokinetics
pRBC Packed red blood cell
Q3W Every 3 weeks
QoL Quality-of-life
RA Refractory anemia
RAEB Refractory anemia with excess blasts
RAEB-T Refractory anemia with excess blasts in transformation
RARS Refractory anemia with ring sideroblasts
RBC Red blood cell 
RBC-TI Red blood cell transfusion independence 
RCMD-RS Refractory cytopenia with multilineage dysplasia with ringed sideroblasts
SAE Serious adverse event
SAP Statistical analysis plan
SC Steering Committee
SF3B1 splicing factor 3B subunit 1
SGOT Serum glutamic oxaloacetic transaminase 
SGPT Serum glutamic pyruvic transaminase
SOP Standard operating procedure
SUSAR Susp ected unexpected serious adverse reaction
CCI&GPTGPT&(/*(1(35235,(7$5<,1)250$7,21777$7$7$7$7tic Syndromtic Syndrom0$5025)21),1
5<$57$(7,(
emia with exemia with5
y anemia wiy anemia 23actory ctory anemianem2
Red blood ceed blood5
Red blood b3(RRefef(((1(1(1((1((1*(
B1B1/*
SGOTSGO&(&
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 110 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Table 7: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
TD Transfusion dependent
TEAE Treatment- emergent adverse event
TGF Transforming growth factor
TI Transfusion independence
ULN Upper limit of normal
US United States
USP United States Pharmacopeia
WFI Water for injection
WHO World Health Organization
CCI&(/*(1(35235,(7$5<,1)250$7,21777$7$7$7$70$5025)21)
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 111 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017APPENDIX B: Myelodysplastic Syndromes World HealthOrganization
Classification System (2016)
Peripheral blood and BM findings and cytogenetics of myelodysplastic syndromes (MDS)
Name Dysplastic
lineagesCytopeniasaRing sideroblasts as 
% of marrow 
erythroid elementsBone marrow (BM)
and peripheral 
blood (PB) blastsCytogenetics by
Conventional karyotype 
analysis
MDS with single 
lineage dysplasia 
(MDS-SLD)1 1 or 2 <15% / <5%bBM <5%, PB <1%, 
no Auer rodsAny, unless fulfills all criteria 
for MDS with isolated del(5q)
MDS with multilineage dysplasia 
(MDS-MLD) 2 or 3 1-3 <15% / <5% b BM <5%, PB <1%, 
no Auer rodsAny, unless fulfills all criteria 
for MDS with isolated del(5q)
MDS with ring 
sideroblasts
(MDS-RS)
MDS-RS with 
single lineage dysplasia 
(MDS-RS-SLD) 
MDS-RS with
multilineage 
dysplasia
(MDS-RS-MLD)1
2 or 3 1 or 2
1-3â‰¥15% / â‰¥5%
b
â‰¥15% / â‰¥5%bBM <5%, PB <1%, 
no Auer rods
BM <5%, PB <1%,
No Auer rodsAny, unless fulfills all criteria 
for MDS with isolated del(5q)
Any, unless fulfills all criteria 
for MDS with isolated del(5q)
MDS with isolated del(5q)1-3 1-2 None or any BM <5%, PB <1%, 
no Auer rodsdel(5q) alone or with 1
additional abnormality except -
7 or del(7q)
MDS with excess 
blasts (MDSEB)
MDS-EB-1  
MDS-EB-20-3
0-31-3
1-3None or any
None or anyBM 5-9% or PB 2-
4%, no Auer rods
BM 10-19% or PB 5-
19% or Auer rodsAny
Any
MDS, unclassifiable 
(MDS-U)
!with 1% blood 
blasts
!with single lineage
dysplasia and
pancytopenia
!based on defining
cytogeneticabnormality1-3
1
01-3
3
1-3None or any
None or any
<15%
dBM <5%, PB=1%c, 
no Auer rods
BM <5%, PB <1%, 
no Auer rods
BM <5%, PB <1%, 
no Auer rodsAny
Any
MDS-defining abnormality
Refractory cytopenia 
of childhood1-3 1-3 None BM <5%, PB <2% Any
aCytopenias defined as haemoglobin <10 g/dL, platelet count <100 x 109/L, and absolute neutrophil count <1.8 x 109/L; rarely, 
MDS may present with mild anaemia or thrombocytopenia above these levels. PB monocytes must be <1 x 109/L
bIf SF3B1 mutation is present.
c1% PB blasts must be recorded on at least two separate occasions.
dCases with â‰¥15% ring sideroblasts by definition have significant erythroid dysplasia, and are classified as MDS-RS-SLD
CCI&(/*(ee
iaia
n definingefining
geneticgene
bnormalitybnormality*(1(35235,(7$5<,1)250$7,215q)5q)7, all criteria all criteria 
lated del(5q)ed del(5$777
%, PB <1%,%, PB <
Auer rodsAuer rAnAny,y, unless unless
for MDSfor M50
7$1
BM <5M 
no Ano7$7$7$7$
33None or anyNone or any
None None5,(
52
1-31-3
135
*((
Refractory cytRefractory cyt
of childhooof childhoo(/&&Cytoptopy
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 112 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Sources: Arber DA, Orazi A, Hasserjian R, Thiele J, Borwitz MJ, Le Beau MM, et al.  The 2016 revision to the World Health 
Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405.
CCI
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 113 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017APPENDIX C: French-American-British (FAB) Myelodysplastic Syndromes
(MDS) Classification System
MDS SubtypePeripheral 
Blasts (%)Bone 
Marrow 
Blasts (%)AML 
TransformationMedian 
Survival 
(months)MDS 
Diagnoses 
(%)
Refractory anemia (RA) â‰¤1 <5 10-20 30-65 10-40
Refractory anemia with 
ringed sideroblasts 
(RARS)â‰¤1 <5 10-35 34-83 10-35
Refractory anemia with 
excess blasts (RAEB)<5 5-20 >50 8-18 25-30
Refractory anemia with 
excess blasts in transformation (RAEB-T)â‰¥5 21-29 60-100 4-11 10-30
Chronic myelomonocytic 
leukemia (CMML)<5 â‰¤20 >40 15-32 10-20
Key: AML = acute myelogenous leukemia; RA = refractory anemia; RARS = refractory anemia with ringed 
sideroblasts; RAEB = refractory anemia with excess blasts ; RAEB-T = refractory anemia with excess blasts in 
transformation; CMML = chronic myelomonocytic leukemia.
Data from Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the 
classification of the myelodysplastic sy ndromes. Br J Haematol 1982;51(2):189â€“99.
CCI&(/*(1(35235,(7$5<,1)250$7,21777$70-350-3$7$7
25$7
8225252525
4-114-111)
<,40405<<<
$<
mia; RARS =mia; RARS =
RAEBRAEB --T = rT = 
emiamia.
in G, Galton G, Galton 
J HaematolJ Haematol
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 114 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017APPENDIX D: International Prognostic Scoring System Score - Revised
IPSS-R Cytogenetic Risk Groups*,**
Cytogenetic Prognostic 
SubgroupsCytogenetic Abnormalities
Very good -Y, del(11q)
Good Normal, del(5q), del(12p), del(20q), double including del(5q)
Intermediate del(7q), +8, +19, i(17q), any other single or double independent clones
Poor -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities
Very poor Complex: >3 abnormalities
IPSS-R Prognostic Score Values*
Prognostic Variable 0 0.5 1 1.5 2 3 4
Cytogenetics Very 
Good- Good - Intermediate Poor Very Poor
BM Blasts (%) â‰¤2 - >2 - <5 - 5 - 10 >10 -
Hemoglobin (g/dL) â‰¥10 - 8 - <10 <8 - - -
Platelets (x 109/L) â‰¥100 50 - <100 <50 - - - -
ANC (x 109/L) â‰¥0.8 <0.8 - - - - -
IPSS-R Prognostic Risk Categories/Scores*
Risk Category Risk Score
Very Low â‰¤1.5
Low >1.5 - 3
Intermediate >3 - 4.5
High >4.5 - 6
Very High >6
CCI&(/*Veryery*(1(35235,(7$5<,1)250$7,21$7$7$7$7 clonesclones0$$$
3 abnormali3 abnormali5025)2
22,1<-- Internte<5<<
$5<<5<5 --$$$57$8 -8 -<10<7$7$7$7$
0 <50<50(75<0.80.8555,35555
ories/Scoreories/Scor53333(3((((
diatediat1(
HighHigh(1
HHyyigig*
(/
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 115 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017IPSS-R: Prognostic Risk Category Clinical Outcomes*
No. pts Very Low Low Intermediate High Very High
Subjects (%) 7012 19% 38% 20% 13% 10%
Survival*** - 8.8 5.3 3.0 1.6 0.8
AML/25%***,^ - NR 10.8 3.2 1.4 0.7
*Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, SolÃ© F, et al. Revised international prognostic 
scoring system for myelodysplastic syndromes. Blood 2012;120(12):2454-65.
***Medians, years.^ Median time to 25% AML evolution.Schanz J, TÃ¼chler H, SolÃ© F, Mallo M, LuÃ±o E, Cervera  J, et al. New comprehensive cytogenetic scoring system for 
primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an 
international database merge. J Clin Oncol 2012;30(8):820-9.
CCI777
ing system foing system fo
derived fromderived from
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 116 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017APPENDIX E: International Working Group Response Criteria for 
MyelodysplasticSyndromes
Altering Natural History of MDS According to IWG Criteria for MDS ( Cheson,2006 )
Category Response Criteria (responses must last at least 4 weeks)
Complete Remission (CR) Bone marrow: â‰¤ 5% myeloblasts with normal maturation of all cell linesaPersistent dysplasia 
will be noteda,b
Peripheral bloodc 
- Hgb â‰¥ 11 g/dL
- Platelets â‰¥ 100 X 109/L
- Neutrophils â‰¥ 1.0 X 109/LbBlasts 0%
Partial Remission (PR) All CR criteria if abnormal before treatment except:
- Bone marrow blasts decreased by â‰¥ 50% over pre-treatment but still > 5%
- Cellularity and morphology not relevant
Marrow CRbBone marrow: â‰¤ 5% myeloblasts and decrease by â‰¥ 50% over pre-treatmentb
Peripheral blood:  if HI responses, they will be noted in addition to marrow CRb.
Stable Disease (SD) Failure to achieve at least PR, but no evidence of progression for > 8 wks
Failure Death during treatment or disease progression characterized by worsening of cytopenias,
increase in percentage of bone marrow blasts, or progression to a more advanced MDS FABsubtype than pre-treatment.
Relapse After CR or PR At least 1 of the following:
- Return to pre-treatment bone marrow blast percentage
- Decrement of â‰¥ 50% from maximum remission/response levels in granulocytes or 
plateletsc
- Reduction in Hgb concentration by â‰¥ 1.5 g/dL or transfusion dependence
Cytogenetic Res ponse Complete:
- Disappearance of the chromosomal abnormality without appearance of new ones
Partial:
- At least 50% reduction of the chromosomal abnormality
Disease Progression For subjects with:
- Less than 5% blasts: â‰¥ 50% increase in blasts to > 5% blasts
- 5%-10% blasts: â‰¥ 50% increase to > 10% blasts
- 10%-20% blasts: â‰¥ 50% increase to > 20% blasts
- 20%-30% blastsd:â‰¥ 50% increase to > 30% blasts 
Any of the following:
-â‰¥ 50% decrease from maximum remission/response in granulocytes or plateletsc
- Reduction in Hgb by â‰¥ 2g / d L
- Transfusion dependence
Survival Endpoints:
- Overall: death from any cause
- Event free: failure or death from any cause
- PFS: disease progression or death from MDS
- DFS: time to relapse
- Cause-specific death: death related to MDS
KEY: CR = complete remission; FAB = French-American-Britis h; Hgb = hemoglobin; HI = hematologic improvement; IWG = 
International Working Group; MDS = myelodysplastic syndromes; PR = partial remission; PFS= progression-free survival; DFS= disease-free survival.
aDysplastic changes should consider the normal range of dysplastic changes (modification).
bModification to IWG (2000) response criteria.
cCriteria not applicable for ACE-536-MDS-001 patient population.  
CCI&(/*(1(3523with:ith
Less than 5%Less than 5%
5%-5%-10%10%
-- 10%-0%235,(7$5<,1)250$7,21$7
still > 5%ill > 5%50
treatmentreatmentbt
n to marrowto mar C2
on for > 8on for > 8 wkwk1) rizedri by worsby wor
ogression to a ogression to a,1
marrow blast prrow blast
maximum remmaximum rem
ncentration bycentration by5<
eeofofthehechromchrom
t 50% reducti0% reducti(
2
- 20
AnAny yof th23
1(
*(
&&Y: CY: C
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 117 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017d20 â€“ 30% blasts is considered AML according to WHO classification ( Vardiman, 2009 ).
Notes: Deletions to IWG criteria are not shown. To convert hemoglobin from grams per deciliter to grams per liter, multiply 
grams per deciliter by 10.
Source: Cheson, BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and 
proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108 
(2):419-25.
CCI&(/*(1(35235,(7$5<,1)250$7,21
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 118 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017Appendix E: International Working Group Response Criteria for 
MyelodysplasticSyndromes (Continued)
Hematologic Improvement According to IWG Criteria ( Cheson, 2006 )
Hematologic ImprovementaResponse criteria (responses must last at least 8 week)b
Erythroid Response (HI-E) (pre-
treatment, <11 g/dL)- Hemoglobin increase by â‰¥ 1.5 g/dL
- Relevant Reduction in units of RBC transfusions by an absolute number of at least 4 
RBC transfusions/8 wk compared with the pretreatment transfusion number in the 
previous 8 wk
Platelet Response (HI-P)
(pre-treatment, <100 X 109/L)- Absolute increase of â‰¥ 30 X 109/L for subjects starting with > 20 X 109/Lplatelets
- Increase from < 20 X 109/L to > 20 X 109/L and by at least 100%b
Neutrophil Response (HI-N) (pre-
treatment, <1.0 X 109/L)- At least 100% increase and an absolute increase > 0.5 X 109/Lb
Progression or Relapse After HIc At least 1 of the following:
- At least 50% decrease from maximum respons e levels in granulocytes or platelets
- Reduction in Hgb by â‰¥ 1.5 g/dL
- Transfusion dependence
KEY: HI-E = hematologic improvement erythroid response; HI-N = hematologic improvement neutrophil response; HI-P = 
hematologic improvement platelet response; IWG = International Working Group; RBC = red blood cell.
aPretreatment counts averages of at least 2 measurements (not influenced by transfusions, ie, no RBC transfusions for 2 weeks and no platelet transfusions for 1 week) â‰¥ 1 week apart (modification).
bModification to IWG (2000) response criteria.
cIn the absence of another explanation, such as acute infection, repeated courses of chemotherapy (modification), 
gastrointestinal bleeding, hemolysis, and so forth. It is recommended that the 2 kinds of erythroid and platelet responses be reported overall as well as by the individual response pattern.
Note: Deletions to the IWG criteria are not shown. To convert hemoglobin levels from grams per deciliter to grams per liter, 
multiply grams per deciliter by 10.
Source: Cheson, BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and
proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108
(2):419-25.
CCI&(/*(1(35235,(7$5<,1)250$7,21$7lateletsatelets$7$7$7
50
nngranulocytegranul25
<, 1mprovement nmproveme
oup; RBC = reoup; RBC = r
transfusions, transfusions, 
ated courses oated courses 
nded that the nded that the
ert hemoglobiert hemoglobi
Lowenberg B, wenberg B, 
Working GrouWorking Gr
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 119 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017APPENDIX F: European Organization for Research and Treatment of 
Cancer Quality-of-Life Questionnaire (Version 3.0)
CCI&(/*(1(35235,(7$5<,1)250$7,21

EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 120 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017APPENDIX F: European Organization for Research and Treatment of 
Cancer Quality-of-Life Questionnaire (Version 3.0) (continued)
CCI&(/*(1(35235,(7$5<,1)250$7,21

EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 121 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017APPENDIX G: Eastern Cooperative Oncology Group (ECOG) Performance 
Status
Eastern Cooperative Oncology Group (ECOG) Performance Status
Grade ECOG
0 Fully active, able to carry on all pre-d isease performance without restriction.
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, eg, light house work, office work.
2 Ambulatory and capable of all selfcare but unable to carry out any work activities.  Up and about more than 50% of waking hours.
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4 Completely disabled.  Cannot carry on any selfcare.  Totally confined to bed or chair.
5 Dead.
Source:  Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response 
criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-55.
CCI&(/*(1(35235,(7$5<,1)25chair.ha250$7,21$7about out $7$7$7
hours.ours.5025)21)al. Toxicity al. Toxicity
):649649-55.55
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 122 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21
1(35235,(7$5<,1)250$7,2
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 123 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21
&(/*(1(35235,(7$5<,1)250$7,2
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 124 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017
CCICCI
21
&(/*(1(35235,(7$5<,1)250$7,2
EDMS Doc. Number:Luspatercept (ACE-536)
Protocol ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 125 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21
&(/*(1(35235,(7$5<,1)250$7,2
EDMS Doc. Number:
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH
7LWOH'DWH7XHVGD\0D\30(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
CCIPPD
PPD
&(/*(1(35235,(7$5<,1)250$7,21
EDMS Doc. Number:Luspatercept (ACE-536)
Summary of Changes ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 20171. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!Removal of â€œprogression to acute myeloid leukemia (AML) or high/very high risk 
category MDS per IPSS-Râ€ from the dose modification and treatment discontinuation criteria as per Steering Committee request 
Update to the protocol to remove â€œProgressi on to acute myeloid leukemia (AML) or high/very 
high risk category MDS per International Prognos tic Scoring System â€“ Revised (IPSS-R)â€ from 
the dose modification and treatment discontinuati on criteria to avoid redundancy as â€œprogression 
to AML and high/very high risk category MDS per IPSS-Râ€ is covered by the criteria for disease 
progression per International Working Group (IWG) (Cheson, 2006) used in the protocol.
Revised sections: Protocol Summary; Section 1.3.2, Rationale for the Study; Figure 2: Overall 
Study Design (footnotes); Section 3, Overall Study Design; Section 6, Section 6.2.2; Section 
6.2.3; Procedures; Section 7.2.1.2, Table 6 Dose Modification: Dose Delay, Dose Reduction and 
Discontinuation Guidelines; Section 11.1, Treatment Discontinuation
!Clarification on the anti-drug antibodies (ADA) and pharmacokinetic (PK) sample 
collection in the Follow-up period to maintain the blinding of the study 
Update to the protocol to include ADA sampling for all subjects in the Follow-up period rather 
than only when tested positive at the End of Treatment (EOT) visit as an available ADA 
antibody status for a subject potentially unblinds the Sponsor and/or the clinical site to a 
subjectâ€™s assigned treatment arm.
Revised sections: Protocol Summary; Table 3 Study Endpoints; Section 3; Table 4: Table of 
Events; Section 6.4; Section 6.5; Section 6.8.2
!Clarification on the timing and allowed time window for the Week 25 Visit 
Update to the protocol to clarify the timing of the Week 25 visit procedures and myelodysplastic 
syndromes (MDS) disease assessments.
Revised sections: Protocol Su mmary; Table 3: Study Endpoints; Section 3; Section 6; Section 
6.2.2; Table 4: Table of Events
!Modified protocol criteria related to dose modifications (Dose Delay, Dose 
Reduction and Discontinuation) measures related to potential cases of leukocytosis 
Updates to the protocol language  
to further strengthen dose modif ication and tr eatment stopping guidance
related to potential cases of leukocytosis as well as  to monitor progression to high/very high risk 
MDS or AML as events of interest throughout the study and to report these events to regulatory 
agencies, as requested. 
Revised section: Protocol Summary; Section 3.1; Section 3.2; Section 6.1; Section 6.2.2; Section 
6.8.2; Table 6: Dose Modification: Dose Dela y, Dose Reduction, and Discontinuation 
Guidelines; Section 9.11.2; Section 10.5; Section 10.7.
CCICCI
d to to potentipotenti
DS S or AMLor AML
agenciesgencies ,,aa
ReviseRevise*(1(35235,(7$5<,1)250$7,21y
froom m 
ogressiogressi onon
a fa for dior diff seasea
protocol.otocol.
Figure 2:Figure 2 OO
iion 6on 6.2.2; 22 ;
elay, Dose Rlay, Dos
pharmacokpharmaco
blinding ofblinding 
ubjects in thubjects in t
t ((EOTEOT ))visvis
e Sponsor ae Sponsor
3 Study3 Study EnEnyy
6.8.26.8.2
and alloweand allo
the the timing oiming
ssments.sments.
 Summaryummary
EventsEve
protocol crrotocol cr
on and Dison and Di
he protocohe protoco
/*(
EDMS Doc. Number:Luspatercept (ACE-536)
Summary of Changes ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-536-MDS-001 Amendment 2.0 Final: 09 May 2017!Extended the Posttreatment Follow-up Period from â€œat least 2 yearsâ€ to â€œat least 3 
yearsâ€ from the date of last dose of investigational product (IP)
Updates to the protocol language based on feedback received from  
 to reflect the collection of all cases of cancers occurring in subjects for at least 3 years 
after the last investigational product is taken.
Revised section: Protocol Summary; Table 3: Study Endpoints; Sectio n 3.1; Section 3.2; Figure
2: Overall Study Design; Table 4: Table of Events; Section 6.1; Section 6.2; Section 6.8.2; 
Section 9.10.2; Section 11.1; Section 11.2
The amendment also includes several other minor clarifications and corrections:
!Administrative change to the Medical Monitor/ Emergency Contact Information 
(Cover page).
!Correction in Table 3 (Study Endpoints) to reflect the correct timeframes 
corresponding with a 16-week peri od. 
!Clarification in Section 4.2 (Inclusion criterion 5) regarding required wash out period 
for both prior erythropoiesis stimulating agents (ESA) and granulocyte colony stimulating factor (G-CSF) treatment.
!Clarification in Section 4.2 (Inclusion criterion 8) regarding the requirement to use 
contraception in females of childbearing potential if they are sexually active.
!Clarification in Section 4.3 (Exclusion criterion 5) regarding the sequence of 
assessments evaluated excluding iron deficiency.
!Clarification in Section 4.3 (Exclusion criterion 20); Table 4 (Table of Events)
including footnotes; and Section 6.1 regarding timing of local testing confirming the 
Human Immunodeficiency Virus (HIV), Hepatitis B, and/or Hepatitis C status.
!Clarification in Section 6 regarding the exceptional use of local laboratories to 
determine study eligibility after sponsor c onsultation (eg, hemolyzed sample etc.).  
!Clarification in Section 7.2 regarding the IP administration of volumes greater than 
1.2 mL and the maximum total dose per ad ministration that should not be exceeded.
!Clarification in Section 8.1.1 that iron-c helating therapy at time of randomization 
should be on a stable or decreasing dose for at least 8 weeks.
!   
!Clarification in Appendix E regarding criteri a related to the definition of disease 
progression not applicable for the ACE-536-MDS-001 patient population. 
!Administrative changes (eg, consistency of acronym use throughout the document per 
Celgene Style Guide, spelling, grammat ical e rror corrections, etc.) were also made 
throughout the document.
CCICCI
CCI
&(/*(ClClarificatrificat
progrerogre
!!AdA(1(35235,(7$5<,1)250$7,21mation mation 
frames frames 
g required wrequired
nd granulgranu o
) regarding) regarding
ntial if thetial if the y
erierion 5) reon 5) re
deficiency.deficiency
siosion crin criteriteriii
n 6.1 regard6.1 regar
Virus (HIV)irus (HIV
6 regardingregardin
bilitbility y afafter terfff
ection 7.2 rection 7.2 r
e maximumaximum
oon nin Sectiin Sec
be on a stabe on a sta
*(1
EDMS Doc. Number:Luspatercept (ACE-536)
Summary of Changes ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-536-MDS-001 Amendment 1.0 Final: 21 Sep 20161. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!Modified protocol criteria related to contraception measures to align with definition 
of â€œhighly effective contraception measuresâ€ as per Clinical Trial Facilitation Group(CTFG) guidelines
Updates to the protocol language regarding contraception and pregnancy testing for females of 
child bearing potential (FCBP) to align with definition of â€œhighly effective contraception measuresâ€ as per Clinical Trial Facilitation Group (CTFG) guidelines were requested  
 
 
Revised sections: Section 1.2.2.1, Potential Risks of Human Use; Section 4.2, Inclusion Criteria
8 and 9
!Added monitoring of other malignancies/pre-malignancies as â€œimportant medical 
eventsâ€
 
 the Scientific 
Steering Committee (SSC) recommended monitoring of other malignancies/pre-malignancies
during the Treatment Period and for the duration of the Long-term Follow-up Period as â€œimportant medical events.â€ Designation as an â€œimportant medical eventâ€ will require sites to 
report events of other malignancies/pre-malignancies under the same guidelines as a serious 
adverse event.  These additional measures will further strengthen safety monitoring throughout the course of the study. 
New section: Section 10.5, Other Malignancies/Pre-malignancies
Revised sections: Protocol Summary; Section 3.2, Study Duration for Patients; Section 5, Table 
4 Table of Events; Section 6, Procedures; Section 6.1, Screening Period; Section 6.2.1, Primary 
Phase of Treatment Period: Weeks 1-24; Section 6.2.2, MDS Disease Assessment: Week 25 Visit; Section 6.8.2, Long-term Follow-up; Section 11.2, Study Discontinuation
!Added site guidance regarding collection of transfusion data
As additional assurance that all transfusio n data is collected throughout the course of the study
(including transfusions that may have occurred in between study visits at local institutions), 
specific guidance for sites has been included in the protocol amendment.  
 
CCICCI
CCI
CCI
CCI &(/*(1(310.5, 0.5, OtOherer
ProtocolProtocol  SuSull
nts; Sectionnts; Section
atment Peratment Pe
tioo
&n 6.8.2, n 6.8.2, 
AAddddeded
s addis addi titiiionaon
(iincludinncludin
ecifiecifi5235,(oonitnitoring ooring o
duration of uration of 
on as an â€œimon as an â€œi
/prepre-malignmalig
mmeasures weasures w7$5<,1; ;Secteion 4n4
malignancialignanci250$7,21n n 
rouproup
males of males of 
eption eption 
esteestedd
250)25)21)CCI
(7$5,(7
35235
EDMS Doc. Number:Luspatercept (ACE-536)
Summary of Changes ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-536-MDS-001 Amendment 1.0 Final: 21 Sep 2016Revised sections: Section 5, Table 4 Table of Ev ents; Section 6.1, Screening Period; Section 6.2, 
Treatment Period; Section 6.2.1, Primary Phase of Treatment Period: Weeks 1-24; Section 6.2.3, 
Extension Phase of the Treatment Period: After Week 25 Visit; Section 7.2, Treatment 
Administration and Schedule
!
 
 
!Included dose modification and treatment discontinuation criteria regarding 
leukocyte increase and disease progression as per International Working Group(IWG) criteria (Cheson, 2006)
Additional dose modification and treatment discontinuation rules to account for potential cases 
of leukocytosis and inclusion of disease progression per IWG criteria as treatment 
discontinuation criteria have been in corporated in the protocol amendment based upon  
.
Revised sections: Protocol Summary; Sect ion 1.3.2, Rationale for the Study; Figure 2 
(footnotes); Section 3, Overall Study Design; S ection 6, Procedures; Section 4.2, Inclusion 
Criterion 3; Section 7.2.1.2, Table 6 Dose Modification: Dose Delay, Dose Reduction and Discontinuation Guidelines; Section 11.1, Treatment Discontinuation
!Accounted for update of World Health Organization (WHO) classification system
(Arber 2016) and included French-American-Brit ish (FAB) classification system for 
baseline MDS diagnosis 
As ring sideroblast positive disease is a key attribute of the studyâ€™s patient population additional 
language was added to the protocol taking into consideration the recent update to the WHO
classification criteria (Arber, 2016), which further expanded the definition of ring sideroblast positive disease to also include patients with â‰¥ 5% ring sideroblasts and confirmation of SF3B1 
mutation along with patients who sol ely meet the previously established â‰¥ 15% threshold.  In 
addition, the Scientific Steering Committee (SSC) agreed to this modification and also 
recommended use of the French-American-British (FAB) classification system in addition to the 
WHO classification system to determine eligibility related to baseline MDS diagnosis. 
Revised sections: Section 1.1.1.2, Ring Sideroblas ts; Section 3.1, Study Design, Section 4.2, 
Inclusion Criterion 3; Section 6.1 Screening Period
!Extended collection of transfusion data after treatment discontinuation
The duration of transfusion data collection has been extended to 16 weeks after last dose of IP or 
End of Treatment visit (whichever is later)
CCICCI
CCI
CCI&(/*(1(35235,(7$22, , RationalRational
ectction 6ion 6 , Pr, P
odificatioodificatio nn
 TreatmentTreatmen
orld Healthorld He
dFrenchFrench A
is s 
disease is disease i
he protocolhe protoc
(Arber(Arber ,202
also includalso includ
wiwiththiii pati patih en
SciSciententific ific 
nded eduse ofuse of
classificatlassificat ioio
vised sectised sect ioi
Inclusionclusio n Cn C
!!50$7,21$7
5050250
$5<,1)25eria eria regarre
onal Worknal Wor
es to accous to a
G criteria G criteria aa
tocolocol amenamenll
7$5
EDMS Doc. Number:Luspatercept (ACE-536)
Summary of Changes ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 5 ACE-536-MDS-001 Amendment 1.0 Final: 21 Sep 2016 based on their assessment of another Celgen e clinical study. This additional transfusion 
data  should aid in the characterizatio n of the luspatercept risk-benefit profile.
Revised sections:  Protocol Summary; Section 3.1, Study Design and Figure 2: Overall Study 
Design; Section 5, Table 4 Table of Events; S ection 6.2.1, Primary Phase of Treatment Period: 
Weeks 1-24; Section 6.8.2, Long-term Follow-up
!Included upper pre-transfusion Hgb threshold of 10 g/dL to protocol eligibility 
criterion related to requirement of transfusions
With the older demographic in myelodysplastic syndromes (MDS), patients often develop 
overlapping comorbidities.  When erythrocyte production is affected in MDS, patients frequently 
present with signs and symptoms of anemia including pallor, tachycardia, hypotension, fatigue, 
headache and exercise intolerance, or with signs and symptoms of worsening of an underlying condition such as angina pectoris, heart failure, or a pulmonary disorder. Patients with such co-
morbidities may have more symptoms at a hi gher baseline Hgb level than patient who do not 
have such co-morbidities. Due to this fact, some practitioners choose to transfuse their older MDS patients with multiple co-morbidities at a higher Hgb level of 10 g/dL than they would 
younger and/or more fit patients.  This was disc ussed and agreed to with the Scientific Steering 
Committee (SSC).  
It is important to note that subjects may still receive transfusions at a lower Hgb threshold during 
the Treatment Period if clinically indicated at the inve stigators discretion as outlined in Protocol 
Section 8.1.2.  Additional language has been added to Section 8.1.2 as per SSC recommendation to provide further clarification on ensuring consisten cy in transfusion practices in regard to pre-
transfusion Hgb threshold after study entry.
Revised sections:  Section 4.2, Inclusion Criter ion 6; Section 6.1, Screening Period; Section 
8.1.2, RBC Transfusions
!Added language to allow for the participation of patients with > 2.0 upper limit of 
normal (ULN) serum bilirubin if in the presence of diagnosed or known Gilbert syndrome.
Gilbert syndrome, also known as Gilbert-Meulengracht syndrome, is a benign hereditary
condition characterized by intermittent unconjugated hyperbilirubinemia in the absence ofhepatocellular disease or hemolysis (Fretzay az, 2012). Patients with Gilbert syndrome are
asymptomatic and typically have otherwise normal liver serum chemistries (VanWagner, 2015). 
This is a benign condition that does not othe rwise affect normal liver function and should not 
exclude patients from the trial.
Revised section: Section 4.3, Exclusion Criterion 14
!Revised eligibility criteria to exclude patients with significant cardiac dysfunction 
based on known local ECHO/MUGA results
To further ensure patients with significant cardiac dysfunction are not enrolled into study, the 
Scientific Steering Committee (SSC) recommended that patients with known ejection fraction < 
35% be excluded (based upon local ECHO or MUGA performed within 6 months of randomization d ate).
Revised sections:  Section 4.3, Exclusion Criterion 19
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21equentquent ly ly 
n, fatigue, fatigue, 
underlyingunderlying
with suchwith such
ientnt who doho d
nsfuse theinsfuse thei
g/dL than thdL than
with the Sciith the Sc
ons at a lowons at a lo
tors discretrs discre
ection 8.ection 8. 1.12
cy in transfcy in tran
ririonon66; Sec; Sec
the particie partici
ubinbinif in tif in
wn as Gilberwn as Gilber
y intermittey intermitte
or hemoor hem lysly
yppically haically ha
conditcondit ioion thn th
tssfrom thefrom th
ecttioin: Secn: Sec
Revised Revised
basedbased
To furtheTo furthe
cicientent
EDMS Doc. Number:Luspatercept (ACE-536)
Summary of Changes ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 6 ACE-536-MDS-001 Amendment 1.0 Final: 21 Sep 2016!Revised eligibility criteria to allow use of experimental agents prior to 
randomization
As the MDS population is an older demographic, ma ny patients have overlapping comorbidities 
that may require treatment, which may include i nvestigational agents.  Contingent that the last 
dose of the investigational agent is at least 5 weeks from date of rando mization (or 5 times the 
half-life, if half-life is known), these patients should not be excluded.
Revised sections : Section 4.3, Excl usion Criteria 1 and 8
!Revised eligibility criteria to allow enrollm ent of patients who received a prior sub-
therapeutic course of hypomethylating agent or lenalidomide 
As the investigational use of active therapy (eg, hypomethylating agents, lenalidomide) is 
common in the clinical setting in certain countries (eg, US) for lower risk, non del5q, MDS patients who are erythropoiesis-stimulating agent (ESA) refractory; patients who may have 
received sub-therapeutic courses of these agents  and discontinued due to intolerance should not 
be excluded from the protocol.  The Scientif ic Steering Committee recommended the following 
maximum durations of prior treatment with these agents to ensure only patients receiving sub-
therapeutic courses are enrolled.  
Lenalidomide = no more than 1 calendar week of treatmentHypomethylating agents = no more than 2 doses 
Revised section: Section 4.3, Exclusion Criterion 1 
!Decreased the ESA/G-CSF/GM-CSF washout window to 4 weeks from date of 
randomization
In order to ensure that the required ESA/growth factor washout period can be completed within 
protocol 5-week screening window, the Scientific Steering Committee (SSC) recommended 
decreasing the washout period to 4 weeks to avoid unnecessary screen failures.
Revised section: Section 4.2, Inclusion Criterion 5
!Updated applicable protocol sections to a lign with Investigatorâ€™s Brochure (IB) 
Edition 8 (IB update occurring in parallel)
Revised sections: Section 1.2, Compound Bac kground; Section 1.2.1.1, Toxicology Studies; 
1.2.2.1, Potential Risks of Human Use; Section 1.3.1, Study Rationale and Purpose
!Added information related to benefit/risk and added section titled Overall Benefit 
Risk Assessment to the protocol
 information 
related to benefit/risk and an overall benefit risk assessment has been included in the protocol to allow the investigator to review the information a nd form his/her opinion of the benefit/risks to 
the patient in the current clinical trial.
New section:  Section 1.2.2.2, Overall Benefit Risk AssessmentRevised sections:  Section 1.2.2.1, Potential Risks of Human Use; 
CCICCI
&(/*(1(35235,(7$5<,1)250$7,21ubub-
de) de) is is 
5q,q,MDS MDS 
ho mayo may hhyyav
olerance sholerance s
mmended thmended th
y patpatieientnts res 
shout windhout wind
owth factorwth factor
ScientScient ific Sific S
eeks to avoeeks to avo
sioon Crin Cri teriterii
rotocol otocol secsec
te occurrine occurr
n 1.2n 1 ,CoCom
sks of Humks of Hum
nformationnformatio
Assessmenssessmen
d to benefit/d to benefit/
ow the invew the inve
hhe patie pati ent ient 
New seNew se/*(
EDMS Doc. Number: Luspatercept (ACE-536)
Summary of Changes ACE-536-MDS-001 Celgene Corporation
Confidential and Propri etary 7 ACE-536-MDS-001 Amendment 1.0 Final: 21 Sep 2016The amendment also includes several other minor clarifications and corrections:
!Update to sponsor medical monitor contact information on protocol page 2.
!Update to sponsor therapeutic area head title on protocol page 3.Additional 
supportive information added to Section 1.3.1 Study Rationale  Clarification in 
Protocol Summary that bone marrow aspirate (or biopsy) for assessment of MDS disease is both efficacy and safety assessmentClarification in Section 4.3 regarding 
history of other malignancies (Exclusion criterion 15)Clarification in Section 4.3
(Exclusion criterion 20); Section 5, Table 4 Table of Events; and Section 6.1, Screening Period regarding assessment of known history of Human 
Immunodeficiency Virus (HIV), Hepatitis B, and/or Hepatitis C active infection.  
Clarification in Section 4.3 (Exclusion criterion 22) regarding exclusion of 
vulnerable patients.  
.Clarification in Section 6.1 regarding bone marrow sample co llection
requirements to determine study eligibility  
Update to Section 7.1 with 
current information regarding investigational product (IP) stab ility data Clarification 
in Section 7.1 regarding supply of placebo C larification in Section 7.3 regarding 
randomization processUpdate to Section 7.4 to account for differences in local 
regulations between countries regarding packing and labeling of investigational product (IP)Clarification in Section 8.1 on allowance of attenuated vaccines (eg,
influenza vaccine) as concomitant medication if clinically indicatedClarification in 
Section 8.1.2 regarding pre-transfusion hemoglobin (Hgb) threshold reco mmendation 
during the Treatment PeriodSection 17 was updated to include additional ci tations 
added during this protocol amendment.Administrative changes (eg, consistency of 
acronym use throughout document per Celgene Style Guide, spelling, grammat ical 
error corrections, etc.) were also made throughout document
Supportive Literature Used in the Summary of Changes 
Arber DA, Orazi A, Hasserjian R, Thiele J, Borwitz MJ, Le Beau MM, et al.  The 2016 revision 
to the World Health Organization (WHO) classification of myeloid neoplasms and acute 
leukemia. Blood 2016;127(20):2391-405. 
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical 
application and proposal for modification of the International Working Group (IWG) response 
criteria in myelodysplasia. Blood 2006;108(2):419-25.
Fretzayaz A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. Eur J Pediatric 
2012;171(1):11-5.
VanWagner LB, Green RM. Evaluating elevated bilirubin levels in asymptomatic adults. JAMA 
2015;3; 313(5):516-7.CCI
CCI
CCI
CCI&(/*(1(35235,(7$5<,1)etotoSectionSection
PP)sttabilitabilit y
on in Secton in Sect i
count for dcount for 
ng and labeng and labe
llowance ollowance o
attioion nif clinfc
n hemoglon hemoglo b
n 17 was up17 was up
dment.dment. AdAdm
ument per Cment per C
e e also madalso mad
he he SummaSumm
52an R, an R, ThiThieleel
izatzatioion (Wn( W
127(20):23927(20):23
berg PL, Berg PL, Be
proposal foproposal fo
elodysplasiodysplas
A, MoustaA, Mousta
71(1):1171(1):11 -55
anWagner LanWagner L
2015;2015 3; 313; 31)2cocollectlectioionn250$7,21tionn.  . 
clusiolusio n of n of
25
1)2